Coronavirus (COVID-19) Infection in Pregnancy

Information for healthcare professionals

Version 14.3: Published Tuesday 11 January
Quick reference summary of acute COVID-19 management in pregnancy or up to six weeks postpartum (see section 6 for further detail)

Most common symptoms: Cough, Fever, Dyspnoea, Myalgia
Risk factors for severe disease: Obesity, Age >35, Pre-existing comorbidity, BAME

Initial assessment - does the patient fit the following criteria?
SpO2 ≥94%, RR ≤20 breath/min and low clinical concern

Yes
Can be managed in the community
Advis to stay well hydrated and mobile
Give safety net advice
Complete VTE risk assessment in line with RCOG Green-top Guidelines No. 37a and 37b risk assessment tool.

No
Admission to hospital required with appropriate isolation
Severity of disease

Assessment
Is the patient:
<28 weeks’ gestation with a score ≥4
OR
≥28 weeks’ gestation with a score ≥3
OR
postpartum with a score ≥2

No

Yes

Prophylactic low molecular weight heparin not required at present
Prophylaxis should be offered in line with risk assessment tool

Mild disease
Patients not requiring oxygen and no evidence of COVID-19 pneumonia

Moderate disease
Patients with COVID-19 pneumonia who need oxygen

Severe disease
Patients with COVID-19 pneumonia requiring mechanical ventilation or CPAP

Prophylactic dose low molecular weight heparin during admission and 10 days post discharge (longer duration should be considered if persistent morbidity/limited mobility suspected)

VTE prophylaxis

Approach to clinical management (adapted with permission from M Nana and C Nelson-Piercy)

- All women should receive MDT input.
- Prompt escalation of care is imperative in a deteriorating patient.
- Use supplementary oxygen where required to maintain saturations >94%.
- Withhold aspirin prescribed for pre-eclampsia prophylaxis for the duration of infection.
- Aim neutral fluid balance.
- Women requiring oxygen should receive steroids with PPI cover:
  - Steroids not required for preterm delivery: Prednisolone 40mg OD PO or hydrocortisone 80mg IV BD.
  - Steroids required for preterm delivery: Dexamethasone 12mg x2 IM 24 hours apart, then continue prednisolone.
- Use Tocilizumab or Sarilumab in women with CRP > 75 or admitted to ICU.
- Monoclonal antibodies should be considered in women who are hospitalized with symptomatic infection who do not have SARS-CoV-2 antibodies.
- Remdesivir should only be considered for those who are not improving, or who are deteriorating.
- Invermectin should only be considered within the context of a clinical trial.
- Molnupiravir is not recommended in pregnancy until further studies has established its effectiveness and safety.
- Azithromycin, hydroxychloroquine and lopinavir/ritonavir have been shown to be ineffective and should not be used.
## Contents

- **Executive summary** 4–8
- **Summary of updates** 9–10

1. **Purpose and scope** 11–25
2. **COVID-19 vaccination in pregnancy** 26–35
3. **Antenatal care during the COVID-19 pandemic** 36–46
4. **Venous thromboembolism prevention** 47–49
5. **Labour and birth during the COVID-19 pandemic** 50–60
6. **Managing clinical deterioration during the COVID-19 pandemic** 61–72
7. **Postnatal care** 73–78
8. **Acknowledgements** 79–80

9. **Appendix I: Summary of previous updates** 81–96
10. **Appendix II: Development methods of this guidance** 97
11. **Appendix III: Summary of key studies on maternal and pregnancy outcomes** 98–107
12. **Appendix IV: Example of a telephone triage tool for symptomatic women with suspected or confirmed COVID-19** 108
13. **Appendix V: Example of a maternity escalation plan for women with suspected or confirmed COVID-19** 109
14. **Appendix VI: Maternal structured checklist – for pregnant and/or postpartum women with confirmed or suspected COVID-19** 110–114
15. **References** 115–134
Executive summary
Executive summary

COVID-19 and pregnancy

- Pregnant women appear no more or less likely to contract SARS-CoV-2 than the general population, and more than two-thirds of identified pregnant women have no symptoms. The most common symptoms of COVID-19 in pregnant women are cough and fever.

- There is growing evidence that pregnant women may be at increased risk of severe illness from COVID-19 compared with non-pregnant women, particularly in the third trimester. The overall risk of death remains very low.

- Risk factors associated both with being infected and hospitalised with COVID-19 include ethnic minority backgrounds, having a BMI above 25 kg/m^2, having a pre-pregnancy co-morbidity, (e.g. diabetes or hypertension), a maternal age of 35 years or older, living in increased socioeconomic deprivation and working in healthcare or other public-facing occupations.

- The delta variant seems to be associated with more severe disease: 1:10 symptomatic women admitted to hospital with alpha variant needed admission to intensive care whereas this is 1:7 for symptomatic women with the delta variant.

- The omicron variant may be associated with less severe disease than the delta variant, but it is more infectious, and it is still likely to be associated with adverse maternal and neonatal outcomes, especially in pregnant women who are unvaccinated.

- There is no reported increase in congenital anomalies incidence because of COVID-19 infection. Vertical transmission is uncommon.

- Maternal COVID-19 infection is associated with an approximately doubled risk of stillbirth and may be associated with an increased incidence of small-for-gestational-age babies. The preterm birth rate in women with symptomatic COVID-19 appears to be two to three times higher than the background rate; these are primarily iatrogenic preterm births.

- Higher rates of perinatal mental health disorders have been reported during the pandemic, including anxiety and depression.

Vaccination

- Vaccination in pregnancy against COVID-19 is strongly recommended and should be offered at the same time as the rest of the population based on age and clinical risk.
• More than 275,000 women in the UK and USA have had a COVID-19 vaccine in pregnancy with no concerning safety signals. There is excellent real-world evidence of vaccine efficacy with 98% of women admitted to hospital and getting severe infection having not had the vaccine.

• Those who have had two doses and a booster (or three doses) of vaccine are 88% less likely to be admitted to hospital with the omicron variant than those who have not been vaccinated.

• COVID-19 vaccines can be given at any time in pregnancy, or postpartum (including after an uncomplicated instrumental birth or caesarean section), and preference is to offer the Pfizer-BioNTech or Moderna vaccines.

• Pregnant women receiving a COVID-19 vaccine show similar patterns of reporting for common minor adverse effects to non-pregnant people. The rare syndrome of vaccine-induced thrombosis and thrombocytopenia (VITT) has been reported after the Oxford-AstraZeneca and the Janssen vaccines. It is an idiosyncratic reaction not associated with any of the usual venous thromboembolism risk factors. There is no evidence that pregnant or postpartum women are at higher risk of VITT.

• Breastfeeding women can receive a COVID-19 vaccine without having to stop breastfeeding. There is no evidence to suggest that COVID-19 vaccines affect fertility. Women planning a pregnancy or fertility treatment can receive a COVID-19 vaccine and do not need to delay conception.

Antenatal care

• The National Institute for Health and Care Excellence recommended schedule of antenatal care should be offered in full wherever possible.

• Healthcare providers should be aware of the increased risk of domestic abuse in pregnancy, which has escalated during the pandemic.

• There is evidence that the pandemic has resulted in a greater level of anxiety and other mental health problems in pregnant women compared to the overall population. Women should be asked about their mental health at every contact.

Venous thromboembolism

• All pregnant women admitted with confirmed or suspected COVID-19 should be offered prophylactic low molecular weight heparin, unless birth is expected within 12 hours or there is significant risk of haemorrhage. The dose may need to be individualised for women with severe complications of COVID-19.

• All pregnant women who have been hospitalised and have had confirmed COVID-19, or those up to 6 weeks postpartum, should be offered thromboprophylaxis for 10 days following hospital discharge. A longer duration of thromboprophylaxis should be considered for women with persistent morbidity.
Labour and birth

• In women with symptomatic COVID-19, there may be an increased risk of fetal compromise in active labour and caesarean birth. Women with symptomatic suspected or confirmed COVID-19 should be advised to labour and give birth in an obstetric unit with continuous electronic fetal monitoring. This is not required for asymptomatic infection.

• Senior obstetric and medical input for a woman with severe or critical COVID-19 should be sought, particularly for decision making about birth.

• The level of personal protective equipment (PPE) required by healthcare professionals caring for a woman with COVID-19 who is undergoing a caesarean birth should be determined by the risk of her requiring intubation for a general anaesthetic.

• Water birth is not contraindicated for women who are asymptomatic of COVID-19, providing adequate PPE can be worn by those providing care. Women with symptomatic COVID-19 should not labour or birth in water.

Clinical deterioration

• Chest imaging is essential for the evaluation of an unwell woman with COVID-19. It should be performed when indicated, and not delayed because of radiation exposure concerns.

• A woman’s care should be escalated urgently if signs of decompensation develop. These signs include: increasing oxygen requirements or fraction of inspired oxygen (FiO₂) above 35%, increasing respiratory rate above 25 breaths/minutes or a rapidly rising respiratory rate despite oxygen therapy, a reduction in urine output, acute kidney injury or drowsiness.

• For unwell pregnant women in the third trimester, an individualised assessment should be undertaken by a multidisciplinary team to decide if maternal stabilisation is required before delivery can be undertaken safely. Following this, decisions concerning emergency caesarean birth or induction of labour should be prioritised, either to facilitate maternal resuscitation (including the need for prone positioning) or because of concerns regarding fetal health.

• COVID-19 can be associated with thrombocytopenia. When aspirin has been prescribed as prophylaxis for pre-eclampsia or previous small-for-gestational-age baby it should be discontinued for the duration of the infection as this may increase the bleeding risk in women with thrombocytopenia.

• Oxygen should be titrated to ensure saturations of 94–98% using escalation through nasal cannula, face mask, venturi mask, non-rebreather mask, non-invasive positive airway pressure (e.g. continuous positive airway pressure [CPAP]).
intubation and Intermittent positive-pressure ventilation (IPPV), and extracorporeal membrane oxygenation (ECMO) as appropriate.

- Caution should be applied to fluid balance and intravenous (IV) fluid management. Hourly fluid input/output charts should be recorded in women with moderate to severe symptoms of COVID-19, aiming to maintain a neutral fluid balance in labour. When required, boluses in volumes of 250–500 ml may be employed.

- Corticosteroid therapy should be given for 10 days or up to discharge, whichever is sooner, for women who are unwell with COVID-19 and requiring oxygen or ventilatory support. If steroids are not indicated for fetal lung maturity, treatment should be with oral prednisolone 40 mg once a day, or IV hydrocortisone 80 mg twice daily, for 10 days or until discharge, whichever is sooner. If steroids are indicated for fetal lung maturity, prescribe intramuscular dexamethasone 12 mg x2 (24 hours apart), then oral prednisolone 40 mg once a day, or IV hydrocortisone 80 mg twice daily, to complete a total of 10 days or until discharge, whichever is sooner. IV methylprednisolone is an alternative especially for intensive care units more familiar with this preparation.

- Tocilizumab (interleukin-6 receptor antagonist) has been shown to improve outcomes, including survival, in hospitalised patients with hypoxia and evidence of systemic inflammation (C-reactive protein at or above 75 mg/l).

- Strongly consider treatment with monoclonal antibodies in pregnant and breast feeding women if they are unwell with COVID-19 infection in community and hospital settings, especially if they are unvaccinated.

- Remdesivir should be avoided in pregnancy and breast feeding unless clinicians believe the benefits of treatment outweigh the risks to the individual. Hydroxychloroquine, lopinavir/ritonavir and azithromycin should not be used as they are ineffective for treating COVID-19 infection.

- Molnupiravir is not recommended in pregnancy until further studies have established its effectiveness and safety.

**Postnatal care**

- National guidelines for routine postnatal care should be followed.

- Women should be informed that COVID-19 infection is not a contraindication to breastfeeding.
## COVID-19 Infection and Pregnancy guideline

### Summary of updates

<table>
<thead>
<tr>
<th>Version</th>
<th>Date</th>
<th>Summary of changes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>14.0</strong></td>
<td><strong>30/07/2021</strong></td>
<td><strong>Throughout</strong> Comprehensive editorial review resulting in rewording and minor changes, some of which made to align with new RCOG style guidance.</td>
</tr>
<tr>
<td><strong>14.0</strong></td>
<td><strong>30/07/2021</strong></td>
<td><strong>Throughout</strong> New evidence added to most sections to support or update existing conclusions or advice.</td>
</tr>
<tr>
<td><strong>14.0</strong></td>
<td><strong>30/07/2021</strong></td>
<td><strong>New Quick reference summary</strong> of acute COVID-19 management in pregnancy</td>
</tr>
<tr>
<td><strong>14.0</strong></td>
<td><strong>30/07/2021</strong></td>
<td><strong>New Executive summary</strong> added, replacing Appendix II in v13.</td>
</tr>
<tr>
<td><strong>14.0</strong></td>
<td><strong>30/07/2021</strong></td>
<td><strong>Sections 1.2, 1.4.2 and 1.5</strong> update of epidemiology and risk factors including evidence about severity of disease in pregnancy with the delta variant.</td>
</tr>
<tr>
<td><strong>14.0</strong></td>
<td><strong>30/07/2021</strong></td>
<td><strong>New Section 2</strong> COVID-19 Vaccination in pregnancy added, replacing section 1.4 in v13 (Vaccination against COVID-19). Inclusion of vaccination guidance, addition of Janssen vaccine, recommendation for vaccine at all stages of pregnancy and an increased emphasis on the importance of vaccination overall given the increased safety and efficacy data.</td>
</tr>
<tr>
<td><strong>14.0</strong></td>
<td><strong>30/07/2021</strong></td>
<td><strong>Section 6</strong> overall update, including addition of monoclonal antibodies, emphasis on ECMO and proning, and advice about remdesivir; safety netting and saturation monitoring.</td>
</tr>
<tr>
<td><strong>14.0</strong></td>
<td><strong>30/07/2021</strong></td>
<td><strong>Appendix III, Table 1</strong> updated with new studies. <strong>Table 2</strong> (summary of key studies relevant for the effect of COVID-19 on maternal outcomes) added, along with meta-analyses of studies.</td>
</tr>
<tr>
<td><strong>14.1</strong></td>
<td><strong>25/10/2021</strong></td>
<td><strong>Minor updates</strong> were made as follows:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• <strong>Quick reference summary</strong>: information about ivermectin added</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• <strong>Table of contents</strong>: Hyperlinks to sections added</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• <strong>Section 2.1</strong>: Reference updated in key findings</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• <strong>Section 6.3</strong>: new evidence added on the use of sarilumab and ivermectin</td>
</tr>
</tbody>
</table>
14.2 | Minor updates were made as follows:
• **Quick reference summary:** replaced by flowchart
• **Section 2:** Minor updates of vaccination safety data
• **Section 6:** Clarification of Ronapreve dose to 2.4g, restoration of dexamethasone dose to 12mg intramuscular ×2 (24 hours apart), advice not to use Molupiravir outside a trial setting and on neonatal BCG after maternal administration of Tocolizumab.
• **Section 7:** Update of postnatal neonatal guidance in line with BAPM
• **Addition of Appendix IV.**

14.3 | 06/01/2022 | Minor updates were made as follows:
• **Section 2:** Minor updates on omicron vaccine efficacy.
• **Section 6:** Recognition that monoclonal antibody advice is changing rapidly, with external links for clarification. Clarification of recommended steroid preparations, with addition of methylprednisolone if preferred.
• **Section 7:** Aligning with BAPM isolation advice.
1. Purpose and scope
1. Purpose and scope

This document aims to provide guidance to healthcare professionals who care for pregnant women during the COVID-19 pandemic. It is not intended to replace existing clinical guidelines, but to act as a supplement with additional advice on how to implement standard practice during this time.

The advice in this document is provided as a resource for UK healthcare professionals based on a combination of available evidence, good practice and expert consensus opinion. The guidance may also be relevant to other healthcare systems but may need to be adapted for the local environment. The priorities are:

(i) The reduction of transmission of SARS-CoV-2 to pregnant women, their family members and healthcare workers.

(ii) The provision of safe, personalised and woman-centred care during pregnancy, birth and the early postnatal period, during the COVID-19 pandemic.

(iii) The provision of safe, personalised and woman-centred care to pregnant and postnatal women with suspected or confirmed COVID-19.

This guidance is under regular review and updated as new information and evidence emerges. Owing to the changing prevalence of COVID-19 infections in the UK, changes in care should be proportionate to the background prevalence at a given time. Decision-making around care and discussions about risks and benefits will depend on the background prevalence of the COVID-19 viral infection and the vaccination status of the woman. Updated advice and information will be published in the Coronavirus (COVID-19), pregnancy and women’s health section of the Royal College of Obstetricians and Gynaecologists (RCOG) website.

Information for pregnant women and their families is available in question and answer format, with accompanying videos in some cases, on the RCOG and Royal College of Midwives (RCM) COVID-19 hubs.

This guidance uses the terms ‘woman’ or ‘mother’ throughout, and ‘female’ where this has been specifically stated in the published study. These should be taken to include people who do not identify as women but are pregnant or have given birth.

1.1 Identification and assessment of evidence

This guidance has been developed by a multidisciplinary group using the best available evidence retrieved by fortnightly literature reviews undertaken by a member of the RCOG Library team.
Owing to the relatively recent emergence of COVID-19 and the rapidly evolving nature of the pandemic, highest quality evidence is lacking. Using a conventional grading system for guideline development, such as SIGN, many of the studies would be classed as level 3 or 4 (non-analytical studies, e.g. case series/reports), with a few studies being classed as level 2 (systematic reviews of cohort studies). Much of the advice based on this evidence would therefore be graded D, and in some cases, graded as good practice points based on expert opinion. Furthermore, where randomised trials have been undertaken, such as to investigate therapeutic interventions in severe COVID-19, most of the trial participants were not pregnant. Healthcare providers, women and their families are advised to be aware of the low-quality evidence on which the advice is given when using this guidance to assist decision making.

For a more detailed description of the methods used to develop this guidance please see Appendix II.

1.2 Epidemiology

SARS-CoV-2 is the strain of coronavirus which causes COVID-19. It was first identified in Wuhan City, China, towards the end of 2019. Other human coronavirus (HCoV) infections include HCoV 229E, NL63, OC43 and HKU1, which usually cause mild to moderate upper respiratory tract illnesses like the common cold, Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV).

The diagnosis of COVID-19 can be made based on symptoms and known exposure, or simply from a positive test for SARS-CoV-2 even in the absence of any symptoms. COVID-19 can therefore be symptomatic or asymptomatic.

As with all viruses, mutations can occur leading to the development of new strains. To date five of the new strains of the COVID-19 virus are of concern and have been termed the alpha, beta, gamma, delta and omicron variants. These variants have significant characteristics which may include increased transmissibility or more severe disease. As of November 2021, the delta variant remains the most prevalent variant in the UK. The delta variant seems to be associated with more severe disease; 1:10 symptomatic women admitted to hospital with alpha variant needed admission to intensive care whereas this is 1:7 for symptomatic women with the delta variant.

The omicron variant was first reported in the UK in November 2021. Owing to numerous mutations involving the spike protein, this variant has developed increased transmissibility compared with the delta variant, rapidly becoming the predominant variant in many countries. While associated with a reduced risk of hospitalisation, the increased transmissibility does not exclude the potential for greater hospital admission numbers than previous waves of the pandemic.
The World Health Organization (WHO) publishes a weekly international situation report with an additional Situation Dashboard to provide information for individual countries. The total number of confirmed cases in the UK is published by the Department of Health and Social Care (DHSC), and is available in a visual dashboard.

For the most up-to-date advice please refer to health protection agency websites: for England, Wales, Scotland and Northern Ireland. Public Health England (PHE) and Public Health Scotland (PHS) have been cited throughout this document; specific guidance from the other areas of the UK will be updated as they become available.

### 1.3 Transmission

Most global cases of COVID-19 have evidence of human-to-human transmission. This virus can be readily isolated from respiratory droplets or secretions, faeces and fomites (objects). Transmission of the virus is known to occur most often through close contact with an infected person or, probably uncommonly, from contaminated surfaces. With regard to vertical transmission (transmission from woman to her baby antenatally or intrapartum), evidence now suggests that if vertical transmission does occur, it is uncommon.\(^4\) If it does occur, it appears to not be affected by mode of birth, delayed cord clamping, skin-to-skin contact, method of feeding or whether the woman and baby stay together (rooming in).\(^4\)–\(^9\)

There is, however, evidence of transplacental transmission of antibodies against COVID-19 following maternal infection. Several studies,\(^187\)–\(^190\) have demonstrated the presence of immunoglobulin G (IgG) umbilical cord blood samples suggesting that passive immunity might be transferred to the neonate. IgG levels in cord blood have been reported to be higher with longer intervals between maternal infection and delivery.\(^187\)–\(^190\) The duration of IgG antibody presence and whether this truly confers passive immunity is unknown.\(^187\),\(^190\)

### 1.4 Effect of COVID-19 on pregnant women

#### 1.4.1 Symptoms of COVID-19 in pregnant women

**Key findings**

- Pregnant women do not appear more likely to contract the infection than the general population.
- The majority of pregnant women who are infected with SARS-CoV-2 are asymptomatic.
- Most symptomatic women experience only mild or moderate cold/flu-like symptoms.
- The main symptoms of COVID-19 are cough, fever, sore throat, dyspnoea, myalgia, loss of sense of taste and diarrhoea.
Pregnant women do not appear more likely to contract the infection than the general population.\textsuperscript{10}

The majority of pregnant women who are infected with SARS-CoV-2 will be asymptomatic: the PregCOV-19 Living Systematic Review\textsuperscript{149} reporting on universal screening in pregnancy found an estimated 73\% (95\% CI 62–82) of women were asymptomatic, while another study\textsuperscript{11} from the USA reported that 86\% of women who were admitted in labour and who tested positive for SARS-CoV-2 were asymptomatic.

Most symptomatic women experience only mild or moderate cold/flu-like symptoms.\textsuperscript{12} The PregCOV-19 systematic review\textsuperscript{149} has so far included over 64,000 pregnant women worldwide with suspected or confirmed COVID-19 (reported prior to 29 November 2020). In this review the overall rate of COVID-19 diagnosis in pregnant and recently pregnant women attending or admitted to hospital for any reason was 10\%. The most common symptoms of COVID-19 in pregnant women were cough (41\%) and fever (40\%). Less frequent symptoms were dyspnoea (14\%), myalgia (15\%), loss of sense of taste (11\%) and diarrhoea (6\%). Pregnant women with COVID-19 were less likely to have fever or myalgia than non-pregnant women of the same age. The PRIORITY (Pregnancy CoRonavirus Outcomes RegIsTry) study,\textsuperscript{13} an ongoing prospective cohort study of pregnant women from the USA, found the most prevalent first symptoms in infected women were cough (20\%), sore throat (16\%), myalgia (12\%) and fever (12\%). In this group of 594 symptomatic women, one-quarter had persistent symptoms 8 or more weeks after onset.

At present, it is unclear whether pregnancy will impact on the proportion of women who develop prolonged signs and symptoms after an acute SARS-CoV-2 infection, (so-called ‘long COVID’ or post COVID-19 condition). NICE has produced a rapid guideline outlining the care of individuals who develop long-term effects of COVID-19.\textsuperscript{14,149}

The omicron variant may be associated with less severe disease than the delta variant, but it is more infectious, and it is still likely to be associated with adverse maternal and neonatal outcomes, especially in pregnant women who are unvaccinated.

1.4.2 Severe illness with COVID-19 in pregnant women

**Key findings**

- More than two-thirds of pregnant women with COVID-19 are asymptomatic.
- Compared with non-pregnant women with COVID-19, pregnant women with COVID-19:
  - Have higher rates of intensive care unit (ICU) admissions; this may reflect a lower threshold for admission to ICU, rather than more severe disease.
  - Have higher needs for ventilation and extracorporeal membrane oxygenation (ECMO).
1.4.2.1 Frequency of severe illness in pregnant women

COVID-19 ranges from asymptomatic infection, through to mild disease (no evidence of pneumonia or hypoxia), moderate disease (viral pneumonia), severe disease (severe pneumonia, e.g. with $\text{SpO}_2$ below 90% on room air) and critical disease (Acute Respiratory Distress Syndrome [ARDS], sepsis, septic shock, or complications such pulmonary embolism or acute coronary syndrome).

Severe illness, such as that requiring ICU admission, is relatively uncommon in women of reproductive age, but can occur. During the initial wave of the pandemic, there were case reports and case series of women with severe COVID-19 infection at the time of birth who received ventilation and ECMO, and of maternal death. In the PregCOV-19 Living Systematic Review Consortium analysis, 0.02% (95% Cl 0.00–0.42%) of pregnant women with confirmed COVID-19 were recorded as having died of any cause, and 0.2% (95% Cl 0.0–0.7%) of pregnant women with COVID-19 required ECMO. A large USA study published in January 2021 compared outcomes for pregnant women with and without COVID-19 from April–November 2020, drawing the information retrospectively from a database that covers about 20% of the American population. Data were available for 406,446 women hospitalised for childbirth, 6380 (1.6%) of whom had COVID-19. In-hospital maternal death was rare, but rates were significantly higher for women with COVID-19 (141/100,000 women, 95% CI 65–268) than for women without COVID-19 (5/100,000 women, 95% CI 3.1–7.7).

A study was published in February 2021 with the results from two large COVID-19 registries. The PAN-COVID registry recorded suspected or confirmed COVID-19 at any stage in pregnancy (in the UK and ten other countries), and the AAP SONPM registry recorded maternal COVID-19 around the time of birth (from 14 days before to 3 days after birth). Maternal mortality was uncommon in both registries: it occurred in 3/651 (0.46%) of women with confirmed COVID-19 in the PAN-COVID registry, and in 5/2398 women with COVID-19 (0.21%) in the AAP SONPM registry. For the UK data (PAN-COVID), the mortality rate may be inflated by under-reporting of women with asymptomatic or mild COVID-19 in pregnancy. The authors of this study have postulated that only 10% of maternal COVID-19 infections were detected as cases, and the true infection fatality rate would therefore be ten times lower (i.e. 0.046%, which is close to the estimate of 0.03% for men and women aged 15–44 years in the UK REACT2 study). Nonetheless, these maternal mortality rates are higher than previously recorded maternal mortality rates in these populations – for example, the maternal deaths from the AAP SONPM registry equate to a perinatal maternal mortality rate of 167/100,000 (for women who have COVID-19 around pregnancy).
the time of birth), compared with a pre-COVID rate of 17.3/100 000 in the USA. Moreover, COVID-19 was listed as the cause of death for all the maternal deaths in these registries where cause of death was known.

The UK Obstetric Surveillance System (UKOSS) published its first report on pregnant women admitted to hospital with confirmed COVID-19 in the UK on 8 June 2020, and an updated report was published 5 May 2021. This second report covers the period from 1 March–31 August 2020. During that time, 1148 hospitalised women had COVID-19 in pregnancy. Most (63%) of women were symptomatic with COVID-19; however, this includes many women from the initial wave of the pandemic, when testing was only performed for symptomatic individuals. As testing for SARS-CoV-2 has become more routinely offered on admission to labour ward, the proportion of asymptomatic women is likely to have increased. Of the 1148 hospitalised pregnant women, 63 (5%) required critical care. During this time, eight women with symptomatic COVID-19 died in hospital. Two of the deaths were not related to COVID-19, and six deaths were, giving a maternal mortality rate of 2.2 hospitalised women per 100 000 maternities (95% CI 0.9–4.3). MBRRACE-UK Confidential Enquiries into Maternal Deaths published their second report on SARS-CoV-2 related maternal deaths that occurred between 1 June 2020 and 31 March 2021. MBRRACE methodology reviews the deaths of women that occur during pregnancy and up to 6 weeks after pregnancy, and the deaths of women that occur 6 weeks to 1 year after pregnancy. The estimated SARS-CoV-2 associated maternal mortality rate for this MBRRACE rapid review period is 2.4 per 100 000 (95% CI 1.3–4.0).

Severe illness appears to be more common in later pregnancy. In the UKOSS study, most women were hospitalised in the third trimester or peripartum (bearing in mind that admission at term to give birth will contribute to this distribution). Symptomatic COVID-19 was principally diagnosed in the third trimester: 83% of symptomatic women were diagnosed at or beyond 28 weeks, with 52% diagnosed at or beyond 37 weeks. The reason for hospital admission was known for a subset of pregnant women in the UKOSS study. For asymptomatic women, the reason for admission was principally to give birth (68%). For symptomatic women, the reasons for admission were roughly a third for symptomatic COVID-19, a third to give birth, and a third for other reasons.

The UK Intensive Care National Audit and Research Centre (ICNARC) has released two reports of patients admitted to intensive care with COVID-19. The first report covered the start of 2020 up until 31 August 2020. During that time, a total of 70 women who were either currently or recently (within 6 weeks) pregnant were admitted to intensive care, representing 8.9% of all the 785 pregnant and non-pregnant women admitted aged 16–49 years. The second ICNARC report included the period from 1 September 2020–31 May 2021. During this period, a further 320 women who were either currently or recently (within 6 weeks) pregnant were admitted to intensive care, corresponding to 13.9% of the 2309 women admitted aged 16–49 years. For context, the conception rate in the UK in 2018 was 75.4/1000 women aged 15–44 years, suggesting that the percentage of women pregnant at any one time in the UK is less than 7.5%. It is important to note that the threshold for admitting a pregnant woman to intensive care is likely to be lower than for a non-pregnant woman: a higher rate of
intensive care admission for pregnant women does not therefore necessarily mean a higher burden of severe disease.

A preprint publication written as a collaboration between the International Severe Acute Respiratory and Emerging Infection Coronavirus (ISARIC4C), Clinical characteristic consortium, UKOSS and the Covid-19 Clinical Information Network (Co-CIN) was presented to the Scientific Advisory Group for Emergencies on 25 March 2021. The three sources of data used for this analysis were ISARIC4C/CO-CIN, UKOSS and MBRRACE-UK Confidential Enquiry into Maternal Deaths. Between 1 March 2020 and 28 February 2021, 5479 pregnant women with confirmed SARS-CoV-2 infection were admitted across the UK. Maternal deaths in this period were also included in the study. Data so far suggest that maternal mortality has increased during the pandemic. UK maternal mortality is estimated to be 20% higher than in previous recent years (12/100 000 maternities compared to 10/100 000) the rise in maternal death is not all attributed to COVID-19. Twenty-four women with SARS-CoV-2 infection were reported to MBRRACE-UK; 20 during pregnancy or in the immediate postpartum period (up to 6 weeks postnatal) and four during the extended postpartum period (up to 1 year). Nineteen deaths were because of COVID-related respiratory or thrombotic disease. Of note, in the same time period, the Office for National Statistics reported 319 deaths of women aged 20–39 in England and Wales with COVID-19 mentioned on the death certificate.

1.4.2.2 Data from studies comparing severity of COVID-19 in pregnant and non-pregnant women

It was not clear early in the pandemic whether pregnancy itself was a risk factor for severe illness from COVID-19. There is now growing evidence that pregnant women may be at increased risk of severe illness from COVID-19 compared with non-pregnant women, particularly in the third trimester. The most consistent signal of increased severity of COVID-19 in pregnancy is an increase in ICU admissions for pregnant women. However, ICU admission rates must be interpreted with caution, as the threshold for ICU admission for a pregnant woman may be lower than for a non-pregnant woman. Moreover, there are currently no robust data from the UK comparing pregnant and non-pregnant women with COVID-19. Part of the UKOSS/ISARIC/CO-CIN investigation compared pregnant women with males and non-pregnant females aged 20–39 years. To summarise pregnant females were less likely to require oxygen, non-invasive and invasive ventilation, were less likely to be admitted to ICU and were more likely to be discharged alive, rather than die or be admitted to ongoing care compared with males and non-pregnant females. The studies in this section are from countries with different healthcare systems, populations and different baseline maternal risks, and should therefore be interpreted with caution from a UK perspective.

Intensive care admission is likely to be more common in pregnant women with COVID-19 than in non-pregnant women with COVID-19 of the same age. The PregCOV-19 Living Systematic Review Consortium analysis concluded that pregnant women are more likely than non-pregnant women to be admitted to intensive care (OR 2.13, 95% CI 1.53–2.95) and require invasive ventilation (OR 2.95, 95% CI 2.28–2.94). This finding was based overwhelmingly on a single study published by the US Centers for Disease Control and Prevention (CDC); in this study two major limitations of the results were acknowledged. The first was that admissions for indications related to pregnancy and those for COVID-19 could
not be distinguished. The second was that pregnancy status was missing for three-quarters of the women of reproductive age; a pregnancy rate of 9% was identified – higher than the expected 5%. This could account for significant bias in the results.

Since the last update of that systematic review, a small number of studies from the USA and Mexico have also pointed to increased illness severity from COVID-19 in pregnant women compared to non-pregnant women. The US CDC published an updated study\textsuperscript{158} in November 2020, based on surveillance of COVID-19 cases in the USA from January–October 2020. This study addressed some of the limitations of their earlier work quoted above, although missing data might still have led to bias (e.g. pregnancy status was missing for more than half the cases reported to the CDC). This report compared pregnant women with symptomatic COVID-19 (n = 23 434) to non-pregnant women of reproductive age with symptomatic COVID-19 (n = 386 028). The pregnancy rate in this study was 5.7%, close to the expected value, and by focussing on symptomatic women, this study was less likely to be biased by women being admitted principally for obstetric reasons. This large study found that pregnant women were more likely to be admitted to ICU (adjusted risk ratio [aRR] 3.0, 95% CI 2.6–3.4), to receive invasive ventilation (aRR 2.9, 95% CI 2.2–3.8), ECMO (aRR 2.4, 95% CI 1.5–4.0), and to die (1.5/1000 versus 1.2/1000 cases; aRR 1.7, 95% CI 1.2–2.4).

A large case–control study\textsuperscript{155} from Mexico compared 5183 pregnant women with symptomatic COVID-19 with 5183 matched non-pregnant controls. The data were taken from a prospective cohort of people of any age with clinically suspected SARS-CoV-2 infection who were admitted to one of 475 monitoring hospitals in Mexico. This data therefore suffers from some of the same limitations as the CDC data above, with some outcomes missing for large numbers of individuals. For example, information on ICU admission was only available for one-fifth of pregnant women. Pregnant women had higher odds of death (OR 1.84, 95% CI 1.30–2.61), pneumonia (OR 1.99, 95% CI 1.81–2.19) and ICU admission (OR 2.25, 95% CI 1.86–2.71), but similar odds of intubation (OR 0.93, 95% CI 0.70–1.25).

A smaller study\textsuperscript{151} from the New York area also found higher ICU admission rates for pregnant women with COVID-19: 38 pregnant women admitted to hospital with severe or critical COVID-19 were compared to 94 non-pregnant women with severe or critical COVID-19. Pregnant women were only included in this study if they were admitted for treatment of COVID-19 (and not for any obstetric reason). Pregnant women were more likely to be admitted to ICU (39.5% versus 17.0%, \(P < 0.01\); adjusted OR 5.2, 95% CI 1.5–17.5). This was despite the fact that the control group had higher rates of comorbidities (hypertension, diabetes, obesity) and was slightly older. A similar study\textsuperscript{150} from France during the initial wave of the pandemic compared the clinical outcomes of 83 pregnant women (above 20 weeks of gestation) with COVID-19 to 107 non-pregnant women with COVID-19, after matching the two groups using a propensity score. Pregnant women were at higher risk for ICU admission than non-pregnant women (11.08% versus 2.38%, \(P = 0.024\)), for needing hospital admission because of COVID-19 respiratory decompensation (58.21% versus 17.4%), for the need for oxygen therapy (36.04% versus 17.24%, \(P = 0.006\)), and for endotracheal intubation (10.16% versus 1.67%, \(P = 0.022\)).
Another study from the US, published in January 2021, compared 22 pregnant women with symptomatic COVID-19 to 240 non-pregnant controls. This study found that pregnant women were more likely than non-pregnant controls to have severe COVID-19, based on two different measures of disease severity (adjusted relative risk [RR] for severe COVID-19 was 3.59 [95% CI 1.49–7.01] for one measure of severity, and 5.65 [95% CI 1.36–17.31] for the other measure of severity). Finally, a study from the Washington State COVID-19 in Pregnancy Collaborative, published at the end of January 2021, found a higher mortality rate for pregnant women with COVID-19 than for non-pregnant controls. This study analysed data on 240 women who tested positive for COVID-19 in pregnancy. Of these, 24 women (10%) were admitted to hospital specifically for COVID-19-related respiratory concerns; this is approximately three times the hospitalisation rate with COVID-19 compared to all adults aged 20–39 years in Washington state (RR 3.5, 95% CI 2.3–5.3). There were three maternal deaths directly attributed to COVID-19, giving a maternal mortality rate of 1250/100 000 pregnancies (95% CI 257–3653) and a COVID-19 case fatality in pregnancy that was 13.6 times (95% CI 2.7–43.6) higher than for all adults aged 20–39 years. This study also highlighted the increased risk of severe COVID-19 in the third trimester: of the 24 women who were admitted unwell with COVID-19, the median gestation was $32^{+4}$ weeks of gestation (interquartile range [IQR] $26–36^{+1}$ weeks of gestation).

Taken together, these studies point to a possibly increased risk of severe disease from COVID-19 for pregnant women compared to non-pregnant women with COVID-19. However, the most consistent finding was of increased ICU admission rates for pregnant women, and this may in part be explained by a lower threshold for ICU admission in pregnancy in general.

Studies on the risk of severe disease from COVID-19 in pregnancy are summarised in Appendix IV, Table 2.

The care of pregnant women with severe COVID-19 is covered in section 6 of this guidance.

1.5 Risk factors for hospital admission with COVID-19 infection in pregnancy

### Key findings

- Risk factors that appear to be associated both with being infected and being admitted to hospital with COVID-19 include:
  - Black, Asian or other minority ethnic background.
  - having a BMI of 30 kg/m$^2$ or more.
  - pre-pregnancy co-morbidity, such as pre-existing diabetes and chronic hypertension.
  - maternal age 35 years or older.$^{98,149}$
In the PregCOV-19 Living Systematic Review, the maternal risk factors associated with severe COVID-19 were: age 35 years and older, OR 1.83 (95% CI 1.27–2.63); for BMI 30 kg/m$^2$ and above, OR 2.37 (95% CI 1.83–3.07); for chronic hypertension, OR 2.0 (95% CI 1.14–3.48); and for pre-existing diabetes, OR 2.12 (95% CI 1.62–2.78).

The UKOSS/ISARIC/CO-CIN study in the UK described the characteristics of 5479 pregnant women with confirmed SARS-CoV-2. The estimated incidence of pregnant women admitted to hospital with SARS-CoV-2 aged 35 and older was 8.93/1000 maternities (95% CI 8.49–9.39), pregnant women with a BMI above 30 kg/m$^2$ 10.18/1000 maternities (95% CI 9.70–10.68) and pregnant women of Black, Asian or other minority ethnic background 18.06/1000 maternities (95% CI 17.12–19.04), 18.83/1000 maternities (95% CI 17.36–20.42) and 8.17/1000 maternities (95% CI 7.35–9.07) respectively.

The association between Black, Asian and minority ethnic background and severe COVID-19 in pregnancy echoes findings from before the pandemic which showed women of Black, Asian and minority ethnic background had higher morbidity and mortality in pregnancy than white women. For example, the MBRRACE-UK report of the Confidential Enquiry into Maternal Death and Morbidity 2016–2018 showed there remains a more than four-fold difference in mortality rates among women from Black ethnic backgrounds and an almost two-fold difference among women from Asian backgrounds compared to white women.

The association between Black, Asian and minority ethnic background and severe COVID-19 or death from COVID-19 is not confined to pregnant women. In the UK, 13% of the total population identify as being from a Black, Asian and minority ethnic background, but 30% of all individuals admitted to UK critical care for COVID-19 were from Black, Asian and minority ethnic backgrounds, and individuals from Black, Asian and minority ethnic backgrounds were more likely to die from COVID-19. In the case of COVID-19, it has been postulated that this association may be related to health inequalities or socioeconomic factors; however, further research is needed.

Another possible contributing factor to the observed association between severe illness and Black, Asian and minority ethnic background is vitamin D deficiency. UK advice recommends vitamin D supplementation to all pregnant women and individuals of Black, Asian and minority ethnic background, regardless of the COVID-19 pandemic.
1.6 Effect of COVID-19 on pregnancy

Key findings

- Symptomatic maternal COVID-19 is associated with an increased likelihood of iatrogenic preterm birth.
- COVID-19 may be associated with an increased incidence of small-for-gestational-age babies.
- It seems likely that neonatal morbidity for babies born to mothers with COVID-19 infection is linked to preterm birth rather than the COVID-19 infection itself.
- While stillbirth remains a rare outcome, maternal COVID-19 infection is associated with an increased risk of stillbirth.

Preterm birth is associated with perinatal mortality, but also with long-term morbidity. It is the single biggest cause of neonatal morbidity and mortality in the UK, with about 7% of babies in the UK born preterm. The preterm birth rate in women with symptomatic COVID-19 appears to be two to three times higher than this background rate. The PregCOV-19 Living Systematic Review estimated the risk of preterm birth at approximately 17%. Most of these preterm births (94%) were iatrogenic. In the initial UKOSS study, the median gestational age at birth was 38 weeks of gestation (IQR 36–39 weeks of gestation). Of the women who gave birth, 27% had preterm births: 47% of these were iatrogenic for maternal compromise and 15% were iatrogenic for fetal compromise. The updated UKOSS study confirmed that preterm birth was more likely for women with COVID-19: 19% of women with symptomatic COVID-19 and 9% of women with asymptomatic COVID-19 gave birth before 37 weeks of gestation. Compared with a historical cohort of pregnant women without SARS-CoV-2, pregnant women with symptomatic COVID-19 were more likely to give birth before 32 weeks of gestation (adjusted OR [aOR] 3.98, 95% CI 1.48–10.70) and before 37 weeks of gestation (aOR 1.87, 95% CI 1.23–2.85). Newer studies confirm the increased risk of preterm birth with symptomatic maternal COVID-19 infection. The care of women at risk of iatrogenic preterm birth is addressed in section 5.2. Pregnant women with asymptomatic COVID-19 were not, however, at increased risk of preterm birth.

The results of two large COVID-19 in pregnancy registries found the number of small-for-gestational age neonates was comparable to historical and contemporaneous UK and USA data; however, growth restriction is considered a theoretical possibility in pregnancies complicated by COVID-19 as two-thirds of pregnancies with SARS were affected by fetal growth restriction (FGR). Furthermore, a published systematic review of 42 studies reported an increased risk of low birth weight (OR 1.89 95% CI 1.14–3.12) associated with maternal COVID-19 infection, and a large multinational study also reported a higher low birth weight rate (RR 1.58 95% CI 1.29–1.94) among women with COVID-19 infection. This newer evidence adds to the previously theorised risks that maternal COVID-19 infection poses to fetal growth as seen in pregnancies with SARS.
For babies born to women with COVID-19, the overall outcomes are positive, with over 95% of newborns included in the PregCOV-19 Living Systematic Review\(^{49}\) reported as being born in good condition. A large study\(^{5}\) from the USA also reported reassuring neonatal outcomes during the pandemic. Of 1481 births overall, 116 (8%) women (giving birth to 120 neonates) tested positive for SARS-CoV-2. All 120 neonates were tested at 24 hours of life and none were positive for SARS-CoV-2. Of 79 neonates who had a repeat SARS-CoV-2 polymerase chain reaction test at age 5–7 days (66% follow-up rate), all tested negative; 72 neonates were also tested at 14 days old and again, none were positive. None of the neonates had signs of COVID-19. A national level cohort study in Sweden\(^{222}\) reported small increases in measures of neonatal morbidity for neonates born to mothers with COVID-19 infection, including admission to neonatal unit and respiratory distress syndrome, but no differences in neonatal length of stay or mortality. In the updated UKOSS study,\(^{18}\) 19% of babies born in the UK to women with symptomatic SARS-CoV-2 infection, were admitted to the neonatal unit. These admissions may, in part, represent the policy of the maternity unit rather than concerns about wellbeing of the neonate.

However, a national level study in England\(^{170}\) also reported no difference in measures of neonatal morbidity including admission to neonatal unit or readmission when restricting the analysis to babies born at term. This is indicative that reports of neonatal morbidity for babies born to mothers with COVID-19 infection is likely to be linked to morbidity associated with preterm birth.

Despite over 100 million confirmed COVID-19 infections worldwide, there has been no reported increase in the incidence of congenital anomalies.

Findings from an earlier publication of the PregCOV-19 Living Systematic Review were that stillbirth and neonatal death rates were not raised for women with COVID-19. The updated review,\(^{49}\) however, reported that compared with pregnant and recently pregnant women without the disease, pregnant women with COVID-19 were at higher risk of stillbirth (OR 2.84, 95% CI 1.25–6.45). It is important to note that the overall number of stillbirths was small. The updated UKOSS report\(^{18}\) found no significant difference in the risk of stillbirth or neonatal death for any symptom status of SARS-CoV-2 infection compared to the historical cohort of pregnant women over a 6-month period. Although the number of stillbirths or neonatal deaths that occurred in the groups of pregnant women with symptomatic (n = 5) or asymptomatic (n = 4) SARS-CoV-2 were higher than the historical cohort (n = 2), this difference did not reach statistical significance.

More recently published studies and systematic reviews have reported an increased risk of stillbirth associated with maternal COVID-19 infection.\(^{180,170,219}\) A large study in England,\(^{170}\) reported a statistically significant two-fold increase in stillbirth for women with a laboratory confirmed SARS-CoV-2 infection at the time of birth (OR 2.21 95% CI 1.58–3.11). This study was unable to differentiate between severity of COVID-19 disease in the cohort, and was not able to quantify risk of stillbirth based on historical COVID-19 infection at any other time during pregnancy. In addition, a multinational study\(^{180}\) covering 18 countries also reported a two-fold increase in a composite measure of severe perinatal morbidity and mortality, which included intrauterine fetal death, and an increase in risk of this measure as severity of
COVID-19 symptoms increased. A systematic review of 42 studies also reported a two-fold increase in stillbirth (OR 2.11) associated with maternal COVID-19 infection. While substantial evidence for causality of the observed increased stillbirth risk is lacking, studies have suggested impairment of placental function from COVID-19 infection as a plausible mechanism, and therefore the fetal wellbeing of women with COVID-19 infection should be cared for accordingly (see section 3.4). A nationwide study in the USA reported no increase in the risk of fetal loss prior to 20 weeks of gestation because of COVID-19 infection. However, further evidence on COVID-19 infection in early pregnancy is currently lacking.

Maternal COVID-19 is also associated with an increased rate of caesarean birth. From the initial UKOSS study, 59% of women had caesarean births; approximately half of these were because of maternal or fetal compromise. The remainder were for obstetric reasons (e.g. progress in labour; previous caesarean birth) or maternal request (6%). Of the women having a caesarean birth, 20% required general anaesthesia (GA). Approximately two-thirds of the women who had GA were intubated for maternal respiratory compromise, and the remaining third was to facilitate urgent birth. The updated UKOSS data confirmed this trend, with a 49% caesarean birth rate for women with symptomatic COVID-19 versus 29% for a historical control group from 2018 (before COVID-19).

1.7 Effect of service modifications during the COVID-19 pandemic on maternal and perinatal experience and outcomes

Key findings

During the first wave of the COVID-19 pandemic in 2020, changes were made to the provision of maternity services with the aim of reducing nosocomial transmission. This included reduced antenatal and postnatal appointments, adopting of remote consultation methods, restricted access to midwifery-led birth settings or home birth, and changed methods of screening for FGR and gestational diabetes. These service changes impacted on the experience of women and their families, potentially increasing barriers to care and exacerbating adverse mental health outcomes. The full consequences of these changes have yet to be determined.

During the first wave of the COVID-19 pandemic in 2020, changes were made to the provision of maternity services with the aim of reducing nosocomial transmission, the unintended consequences of which have yet to be determined.

In the UK, two survey studies have demonstrated that during April 2020, the majority of units reduced antenatal and postnatal appointments, adopted remote consultation methods, restricted access to midwifery-led birth settings or home birth, and changed methods of screening for FGR and gestational diabetes. These service changes impacted on the experience of women and their families. An online questionnaire survey of 1451 pregnant or recently pregnant women in the UK found that the majority felt there were barriers to accessing maternity care while anxieties were expressed about changes to antenatal, intrapartum and postnatal services.
Meta-analyses and systematic reviews\textsuperscript{35,36} have found higher rates of perinatal mental health disorders during the pandemic, including anxiety and depression. Some of these impacts may be attributed to modifications to maternity services. The MBRRACE-UK rapid report\textsuperscript{21} highlighted two instances where women died by suicide, where referrals to perinatal mental health teams were refused or delayed because of restrictions related to COVID-19.
2. COVID-19 vaccination in pregnancy
2. COVID-19 vaccination in pregnancy

This section aims to summarise, in a format useful for maternity care, the evidence presented in existing COVID-19 vaccination guidance from the PHE/DHSC Green Book\(^\text{191}\) as well as leaflets and information from PHE and the NHS.

2.1 Background on COVID-19 vaccines available in the UK

**Key findings**

COVID-19 vaccine background (in non-pregnant population):

- The phase 3 trials of the four currently-approved vaccines assessed protection against COVID-19 after two doses in three, and after a single dose in one.
- The Pfizer-BioNTech vaccine has an efficacy of 95% (95% CI 90.0–97.9%) against symptomatic COVID-19.\(^\text{192}\)
- The Oxford-AstraZeneca vaccine has an efficacy of 66.7% (95% CI 57.4–74.0%) against symptomatic COVID-19.\(^\text{193}\)
- The Moderna vaccine has an efficacy of 94.1% (95% CI 89.3–96.8%).\(^\text{194}\)
- The Janssen vaccine has an efficacy of 66.1% (95% CI 55.0–74.8%).\(^\text{196}\)
- Real-world monitoring has confirmed that one dose of the Pfizer-BioNTech or Oxford-AstraZeneca vaccines confers about 60% protection against symptomatic COVID-19.\(^\text{191}\)
- Vaccination with two doses of the Pfizer-BioNTech or Oxford-AstraZeneca vaccines are effective against symptomatic disease secondary to infection by the delta variant.\(^\text{185,186}\)
- Those who have had two doses and a booster (or three doses) of vaccine (combined data on Pfizer, Oxford-AstraZeneca and Moderna) are 88% less likely to be admitted to hospital with the omicron variant than those who have not been vaccinated.\(^\text{249}\)

2.1.1 Available vaccines in the UK and their mechanisms of action

As of June 2021, four COVID-19 vaccines are approved for use in the UK: the Pfizer-BioNTech vaccine, the Oxford-AstraZeneca vaccine, the Moderna vaccine and the Janssen vaccine. The MHRA approved the Pfizer-BioNTech vaccine in the UK on 2 December 2020, the Oxford-AstraZeneca vaccine on 30 December 2020, the Moderna vaccine on 8 January 2021 and the Janssen vaccine on 28 May 2021.
The Pfizer-BioNTech and Moderna vaccines are messenger RNA (mRNA) vaccines in which mRNA encoding SARS-CoV-2 spike protein is introduced into the person when they are vaccinated via a lipid nanoparticle coat. The mRNA does not go into the nucleus of the host cell, so it remains separate from the host DNA. The host cell produces the spike protein, as for the Oxford-AstraZeneca and Janssen vaccines below, and this protein elicits a protective immune response. The mRNA from the vaccine is broken down by the host cell within a few days.191

The Oxford-AstraZeneca and Janssen vaccines are viral-vector vaccines in which DNA encoding the SARS-CoV-2 spike protein is introduced into the person when they are vaccinated using a modified adenovirus vector. The adenovirus vector has been modified so that it cannot replicate, and the spike protein is not expressed on the adenovirus itself.

Rather, the adenovirus vector serves only to deliver the spike DNA into the host cell. The host cell then produces the spike protein, and this elicits a protective immune response.

Compared to the delta variant, current COVID-19 vaccines offer a lesser degree of protection, with the level of protection waning more quickly in the months post vaccination. Nevertheless, vaccination will protect individuals against symptomatic coronavirus and hospitalisation.

UKHSA data demonstrates the importance of a booster vaccine for protection against the omicron variant. For example, a Pfizer-BioNTech or Moderna booster following two initial doses of the Oxford-AstraZeneca or Pfizer BioNTech vaccine boost protection against symptomatic omicron infection from 0–10% protection pre-booster dose to 50–80% within 1 week. Protection levels of about 40–70% will persist 10 weeks after booster vaccination depending on the exact vaccination regime administered.

Booster vaccination provides even greater protection against hospitalisation, with a 68% reduction in hospitalisation from omicron infection, and an 88% reduction in hospitalisation risk two weeks after a booster dose.254

2.1.2 Vaccine safety

The adverse effect profiles of the four available vaccines were similar in their phase 3 trials. Most participants in the trials had a minor local reaction (pain, redness or swelling at the injection site). Mild systemic adverse effects like fatigue, headache or myalgia were also common; these were typically short-lived (less than a few days). About 10–20% of participants had a fever after vaccination. In general, adverse events are more common after the first dose than the second dose for the Oxford-AstraZeneca vaccine and more common after the second dose than the first dose for the Pfizer-BioNTech and Moderna vaccines.

These vaccines have continued to be monitored for safety after their authorisation, and an association has emerged between the Oxford-AstraZeneca vaccine and rare cases of serious thrombosis in the context of thrombocytopenia (see 2.3.2.1 below). There have also been
very rare reports of myocarditis and pericarditis following vaccination with Pfizer-BioNTech and Moderna vaccines.\textsuperscript{197}

2.2 Eligibility for the vaccine in pregnancy

Key findings

- Vaccination against COVID-19 is strongly recommended. It should be offered to pregnant women at the same time as the rest of the population, based on age and clinical risk.

- Pregnant women should be offered the Pfizer-BioNTech or Moderna vaccines unless they have already had one dose of the Oxford-AstraZeneca vaccine, in which case they should complete the course with Oxford-AstraZeneca.

The eligibility criteria are based on recommendations from the Joint Committee on Vaccination and Immunisation (JCVI).\textsuperscript{37} The choice of vaccine is based on the recommendations from the Green Book\textsuperscript{191} and reflects the fact that most of the safety data regarding vaccination in pregnancy comes from the USA where pregnant women were usually offered the Pfizer-BioNTech or Moderna vaccines.

2.3 Potential fetal and maternal effects

More than 275 000 women in UK and US have had a COVID-19 vaccine in pregnancy with no concerning safety signals.\textsuperscript{198,229,230}

Pregnant women were not included in the large randomised controlled trials testing the safety and adverse effect profiles of the COVID-19 vaccines. However, as of November 2021, over 177 000 pregnant women from diverse ethnic backgrounds in the USA have received either a Pfizer-BioNTech or Moderna vaccine, with no evidence of harm being identified.\textsuperscript{198} In general, there are no known risks from giving inactivated or recombinant vaccines in pregnancy, or while breastfeeding,\textsuperscript{199} and there is therefore no reason to suppose that the adverse effects from these COVID-19 vaccines should be different for pregnant women compared to non-pregnant women.

2.3.1 Maternal effects

2.3.1.1 Common minor adverse effects

Minor and short-lived adverse effects such as soreness at the injection site, headache and fatigue are common in the general population after a COVID-19 vaccine. A report\textsuperscript{200} on the first 35 000 pregnant women to receive a COVID-19 vaccine in the USA showed similar patterns of reporting for common minor adverse effects. Systemic features such as fever appeared more commonly in non-pregnant women, but pregnant women did report nausea and vomiting more frequently after the second dose of the Pfizer-BioNTech and Moderna
vaccines. Smaller observational studies have also reached similar conclusions showing no significant difference between pregnant and non-pregnant women in their symptoms post-vaccination, and a reduced incidence of systemic features such as fever in pregnant women.

2.3.1.2 Vaccine-induced thrombosis and thrombocytopenia (VITT)

The rare syndrome of vaccine-induced thrombosis and thrombocytopenia (VITT) has been reported after the Oxford-AstraZeneca vaccine; it has also been reported after the Janssen vaccine. VITT is an unpredictable idiosyncratic vaccine reaction (not dissimilar to heparin-induced thrombocytopenia and thrombosis associated with heparin therapy) and it is not associated with any of the usual venous thromboembolism (VTE) risk factors. It has been described as presenting 5–28 days after the first dose, particularly in adults younger than 50 years old. Although pregnancy increases the risk of coagulopathy there is no evidence that pregnant or postpartum women are at higher risk of VITT than non-pregnant women. The risk of VITT is therefore extremely low with a first dose of the Oxford-AstraZeneca vaccine (approximately 1:100 000), and even lower with a second dose for those who were well after the first dose. The UK government has advised that individuals younger than 40 years old should be offered an alternative vaccine to the Oxford-AstraZeneca vaccine based on the risk/benefit ratio for this age group. There is no known risk of VITT with the Pfizer-BioNTech and Moderna vaccines.

2.3.2 Fetal effects

Pregnancy outcomes following mRNA vaccination (Pfizer-BioNTech and Moderna) appear similar to comparator groups prior to the onset of COVID-19. The most common adverse outcomes among 724 livebirths in the study by Shimabukuro et al. were preterm birth (9.4%), small-for-gestational-age (3.2%) and major congenital anomalies (2.2%) – all consistent with published rates. None of the mothers whose babies were born with congenital anomalies had received the COVID-19 vaccine in the first trimester or the periconception period.

Preliminary findings from the USA have not identified any safety problems with regards to maternal and neonatal risks. Spontaneous miscarriage occurred at similar rate in women who received a COVID-19 vaccine as those who are unvaccinated (104/827, 12.6%), with 92.3% of these miscarriages occurring in the first trimester.

2.3.2.1 Antibody transfer

Key findings

- SARS-CoV-2 antibodies in neonatal cord blood and in breast milk have been found following COVID-19 infection in pregnancy, and it may therefore be that passive immunity is conferred.
Studies\textsuperscript{188,205} have demonstrated the presence of SARS-CoV-2 antibodies in neonatal cord blood and in breast milk produced in response to COVID-19 infection in pregnancy. These findings suggest the development of passive immunity in the neonate. In one of these studies\textsuperscript{188} 87\% of neonates (n = 83) had IgG conferred in cord blood following COVID-19 infection in pregnancy. Furthermore, the other cohort study\textsuperscript{205} of 2312 lactating women in the Netherlands reported that 23.1\% of women had IgA antibodies in their breast milk, which remain present for 10 months following infection in pregnancy.

Similar findings have been reported following the administration of the COVID-19 vaccine. Two cohort studies\textsuperscript{199,200} of over 100 women established the presence of vaccine-elicited antibodies in infant cord blood and breast milk. Both studies were conducted in the USA and utilised Pfizer-BioNTech or Moderna vaccines. There is some suggestion that timing of vaccination in pregnancy or during lactation may have an effect on the level of passive immunity conferred to the neonate, and two studies\textsuperscript{200,205} found that production of IgG antibodies and their subsequent transfer were improved following a second dose of either vaccine. Similar to natural infection, IgA titres appear to remain stable for several weeks following vaccination, with mRNA vaccines suggesting continual transference of antibodies during lactation.\textsuperscript{206} The degree of protection these antibodies confer to the neonate, however, is not yet known.

### 2.4 Recommended vaccine timing in relation to stage of pregnancy or breastfeeding

#### 2.4.1 Timing of vaccination in pregnancy

**Key findings**

- COVID-19 vaccines can be given at any time in pregnancy.
- Breastfeeding women can receive a COVID-19 vaccine; there is no need to stop breastfeeding to have the vaccine.
- There is no evidence to suggest that COVID-19 vaccines affect fertility. Women planning a pregnancy or fertility treatment can also receive a COVID-19 vaccine and do not need to delay conception.

There is no robust evidence to guide the timing of vaccination in pregnancy; the advice above is based on expert opinion rather than experimental data.
The COVID-19 vaccines are considered to be safe and effective. Pregnant women are more likely to become seriously unwell when compared to non-pregnant women and have a higher risk of their baby being born prematurely if they develop COVID-19 in their third trimester (after 28 weeks of gestation). As far as possible, women should be offered both doses and a booster before giving birth, if time allows, or before entering the third trimester; bearing in mind that it takes time for immunity to develop and protection is higher after the second dose and booster of the vaccine.\(^{191}\)

### 2.4.2 Timing in the postpartum period

Women in the immediate postpartum period should be offered vaccination in line with the general (non-pregnant) population.\(^{191}\)

There has been a suggestion by the RCS that it might be wise to avoid vaccination for seven days after significant surgery. This advice is theoretical and based on caution around the possibility of any concomitant illness after surgery. It seems entirely reasonable, however, to offer vaccination after an uncomplicated instrumental birth or cesarean section, and indeed this may be a very useful opportunity to ensure vaccination coverage. As with all vaccinations, it would of course be appropriate to defer if a mother was unwell.

It seems entirely reasonable to offer vaccination after an uncomplicated instrumental birth or uncomplicated cesarean section, and indeed this may be a very useful opportunity to ensure vaccination coverage. As with all vaccinations, it would be advisable to defer if a mother was unwell.

### 2.4.3 Timing with breastfeeding

The JCVI advice\(^{37}\) published on 30 December 2020 stated there is no known risk in giving available COVID-19 vaccines to breastfeeding women. Breastfeeding women should be offered vaccination at the time when they become eligible (as for the general non-pregnant population). Although there are a lack of safety data for the available vaccines relating to breastfeeding, there is no plausible mechanism by which any vaccine ingredient could pass to a breastfed baby through breast milk. Women should, therefore, not stop breastfeeding in order to be vaccinated against COVID-19.

### 2.4.4 Timing for women who are planning a pregnancy/undergoing fertility treatment

There is no evidence to suggest that COVID-19 vaccines affect fertility, and there is no biologically plausible mechanism by which current vaccines could cause any impact on women’s fertility. The JCVI advises that women do not need a pregnancy test before vaccination, and that women planning a pregnancy do not need to delay pregnancy after vaccination.\(^{37}\) Animal studies\(^{207,208}\) of the Pfizer-BioNTech and Moderna vaccines showed that administering these vaccines in rats had no effect on fertility. Preliminary animal studies also showed no effect on fertility from the Oxford-AstraZeneca vaccine. The theory that immunity to the spike protein could lead to fertility problems is not supported by evidence. Most people who contract COVID-19 will develop antibody to the spike protein and there
is no evidence of fertility problems in people who have already had COVID-19. The British Fertility Society and Association of Reproductive and Clinical Scientists\textsuperscript{210} advise people of reproductive age to have a COVID-19 vaccine, including those individuals who are trying to get pregnant or planning a pregnancy in the future. Furthermore, they advise that women can have the COVID-19 vaccine during fertility treatment, and that there is no need to delay fertility treatment after receiving a COVID-19 vaccine.

### 2.5 How should women be counselled

#### Key findings

- Pregnant women should be supported to come to an informed decision about vaccination.
- There is excellent real-world evidence of vaccine efficacy, with 98% of women admitted to hospital and developing severe infection having not had the vaccine.
- An informed decision-making process should cover the options for timing of vaccination, the benefits and risks of vaccination, and the risks of declining vaccination.
- The RCOG Information sheet and decision aid can be used to aid counselling.

It is a pregnant woman’s choice to have a vaccination against COVID-19. If a pregnant woman is undecided whether to get the COVID-19 vaccine, the role of the healthcare provider is to enable the pregnant woman to make her decision through an informed shared decision-making process. It is not necessary to show evidence of this discussion prior to the pregnant women receiving their vaccination (as is the case for the general population presenting for COVID-19 vaccination).

A pregnant woman should have the opportunity to read or view reliable information about COVID-19 vaccine in pregnancy, for example from the NHS, PHE or the RCOG. An informed decision-making process involves supporting a pregnant woman to understand the options available (including the risks and benefits of those options) and to make a decision based on the evidence and her personal preference.\textsuperscript{211,212}

**Counselling may cover the following points:**

1. **The options available to the pregnant woman:**
   - To receive vaccination against COVID-19 now.
   - To decline the vaccine, with the option of having it in future (either later in her pregnancy, or after the birth of her baby).
   - To decline to have the vaccine altogether; this is a woman’s individual choice.

2. **The benefits of vaccination:**
• Reduction in severe disease for a pregnant woman.
• Potential reduction in the risk of preterm birth associated with COVID-19.
• Potential reduction in transmission of COVID-19 to vulnerable household members.
• Potential reduction in the risk of stillbirth associated with COVID-19.
• Potential protection of the newborn from COVID-19 by passive antibody transfer.

3. The risks of vaccination (see section 2.3 for further detail):

• Minor local reaction (pain, redness or swelling at the injection site). There is excellent real-world evidence of vaccine efficacy, with 98% of women admitted to hospital and getting severe infection having not had the vaccine.\textsuperscript{228}
• Mild systemic adverse effects like fatigue, headache or myalgia, typically short-lived (less than a few days).
• Thrombotic adverse events following use of the Oxford-AstraZeneca or Janssen vaccines are extremely rare.
• There has been no evidence to suggest fetal harm following vaccination against COVID-19, and fetal harm is considered to be extremely unlikely based on evidence from other non-live vaccines. Risk of fetal harm cannot be precisely estimated until large scale studies of vaccination in pregnancy have been completed.

4. The risks from COVID-19 if the pregnant woman declines vaccination:

• The risks from COVID-19 to mother and fetus are covered in detail in section 1 of this guideline, and are summarised below:
  
  o Maternal risks:
    
    - Most women with COVID-19 in pregnancy will have no symptoms. However, some women will develop critical illness from COVID-19.
    - The risk of severe illness from COVID-19 is higher for pregnant women than for non-pregnant women, particularly in the third trimester.
    - There is consistent evidence that pregnant women are more likely to be admitted to an intensive care unit than non-pregnant women with COVID-19.

  o Fetal risks:
    
    - Symptomatic maternal COVID-19 is associated with a two to three times greater risk of preterm birth.
    - Although the overall risk of stillbirth is small, the risk is approximately doubled with SARS-CoV-2 infection.\textsuperscript{149,170}
These risks should be personalised to each individual pregnant woman:

- Risk of exposure because of occupation: for example (and not limited to) healthcare and social workers, public-facing roles and education settings.
- Risk of severe illness: medical conditions (hypertension, diabetes), body mass index above 30 kg/m².

### 2.6 Research on COVID-19 vaccines in pregnant women

There is ongoing research on COVID-19 vaccines in pregnant women, addressing aspects of immunity, safety, different vaccines and optimal schedules for protecting women. More information can be found on the RCOG website. These include a randomised controlled trial funded by Pfizer being conducted worldwide, including several UK National Institute for Health Research sites, in which pregnant women are being randomly assigned to receive either the Pfizer-BioNTech vaccine or a placebo. Those who receive the placebo during the trial will then be offered the vaccine once they give birth to ensure all participants have the opportunity of being vaccinated. The HORIZON study is also being planned by Janssen, in which all participants will receive the Janssen vaccine (no one will receive a placebo). Finally, there is the PregCOV-19LSR pragmatic trial in which pregnant women are receiving different vaccines on different schedules, depending on their gestational age at enrolment. The aim is to identify the most effective schedule in order to protect pregnant women, as well as other aspects such as whether or not vaccines improve immunity conferred by breast milk.
3. Antenatal care during the COVID-19 pandemic
3. Antenatal care during the COVID-19 pandemic

3.1 What are the considerations for organisation of antenatal care?

- Women should be advised to continue their routine antenatal care, although it may be modified, unless they meet self-isolation criteria for individuals or households (including social bubbles) with suspected or confirmed COVID-19.

- Service modifications are required to enable social distancing measures and where possible good ventilation, to reduce the risk of transmission between women, staff and other clinic/hospital visitors, and to provide care to women who are self-isolating for suspected or confirmed COVID-19 for whom a hospital attendance is essential.

- The National Institute for Health and Care Excellence (NICE) recommended schedule of antenatal care should be offered in full wherever possible. Ideally and where safe, these appointments should be offered in-person, particularly to those from Black, Asian and other minority ethnic communities, those with communication difficulties or those living with medical, social or psychological conditions that put them at higher risk of complications, or adverse outcomes, during pregnancy.

- Maternity staff should be aware that for some women with hearing or communication difficulties, mask wearing may prevent lip reading.

- Basic assessments such as blood pressure and urine testing, and assessment of fundal height in women not receiving serial fetal growth ultrasound scans, are still required. Trusts and health boards should plan local strategies to ensure women are able to receive this monitoring, even where antenatal care is provided remotely.

  - If it is considered more appropriate for appointments to be conducted remotely, for example during periods of ‘local lockdown’, units should employ teleconferencing or videoconferencing consultations. The limitations of remote consultation methods should be recognised, including being aware that some women will not have sufficient internet access on their mobile devices or other computer hardware.

  - It should be acknowledged that remote appointments, particularly by telephone, may cause new challenges in relationship-building between women and healthcare professionals, especially among socially vulnerable groups, women for whom English is not their first language or women who are hearing impaired.

  - Healthcare professionals should be aware that the women may have unvoiced concerns regarding their care if they have less contact in person.

  - Healthcare professionals should be aware that women may not have the privacy within their home to disclose private, personal and sensitive information. Efforts should be made at in-person appointments, such as ultrasound scans, to discuss sensitive issues such as domestic violence,
sexual and psychological abuse, psychiatric illness and recreational drug use.

- When in-person appointments are required (e.g. for blood tests, maternal examination or ultrasound scans) these should be arranged alongside other in-person maternity appointments to limit repeated clinic attendance.

- Appropriate screening for diabetes in pregnancy should still be provided, following NICE guidance as far as possible, with awareness that modifications to screening protocols are associated with a reduction in the detection of cases of gestational diabetes.

- Particular consideration should be given to pregnant women who have comorbidities which make them clinically vulnerable to the effects of COVID-19. Shared waiting areas should be avoided.

- If women who are in this group attend hospital, where possible, they should be cared for in single rooms.

- Women should be able to notify the unit regarding non-attendance owing to self isolation for COVID-19 using standard telephone numbers already available to them.
  - There should be a system in place to effectively identify, support and follow up women who have missed appointments.
  - Units should appoint a named midwife or consultant to coordinate care for women unable to attend appointments owing to self-isolation or a positive test. Missed appointments should be reviewed and either rescheduled if an in-person review is necessary or converted to a virtual appointment.

- For women receiving antenatal care across different sites, units must ensure that there are clear pathways for communication via handheld notes, electronic records and correspondence to general practitioners.

- Open access to day assessment and maternity triage services should be maintained. Women should be actively encouraged to attend if they have concerns about their or their baby’s wellbeing.

- Continuity of care should be maintained wherever possible, particularly for women from vulnerable groups who may also be at greater risk from COVID-19.

- Healthcare providers should be aware of specific changes to services which have been suggested through regularly updated subspecialty service guidance available via the RCOG website.
Summary of evidence and rationale for guidance

Antenatal and postnatal care should be regarded as essential and women encouraged to attend, while observing social distancing and infection prevention measures, as recommended by the UK Government. Studies in the UK and internationally have shown that women who do not attend antenatal services are at increased risk of maternal death, stillbirth and other adverse perinatal outcomes. NICE guidance on antenatal care, including the schedule of antenatal appointments recommended for women with uncomplicated pregnancies, is well established in the UK.

The UK Government has published a list of conditions that make an individual extremely vulnerable to the severe effects of COVID-19, along with guidance on how best to protect these individuals.

A small study in Massachusetts, USA, conducted in spring 2020 (early in the pandemic) showed that there was no relationship between the number of in-person antenatal visits and the risk of developing COVID-19 for pregnant women, suggesting that nosocomial transmission could be minimised. No similar evidence exists for the UK.

Another small survey study from the USA found that the offer of remote appointments to pregnant women at high risk of obstetric complications reduced the rate at which women 'did not attend' their appointments, and that 86.9% of women were satisfied with the care received. As discussed earlier, the majority of pregnant or recently pregnant women who participated in an online questionnaire survey felt there were barriers to accessing maternity care while anxieties were expressed about changes to antenatal services including remote consultations.

NHS England and NHS Scotland/Scottish Perinatal Network have issued guidance on the adoption of remote consultations in secondary care in order to minimise hospital visits. Data directly comparing telephone/video appointments with in-person appointments are not available; until these are, healthcare providers should follow locally agreed guidelines for antenatal care provision.

During the pandemic, modifications to the NICE recommendation to screen for gestational diabetes were suggested to reduce the risk of pregnant women being infected with SARS-CoV-2 during hospital visits. While the number of cases of COVID-19 avoided using this strategy is unknown, evidence has quantified the reduction in diagnoses of gestational diabetes. The rationale for the modified testing strategy is described in the Appendix of the RCOG document Guidance for maternal medicine services in the coronavirus (COVID-19) pandemic.

The use of personal protective equipment (PPE) and facemasks in particular can lead to difficulties in communication, especially for women with hearing loss. Masks block lip movements and facial expressions and muffle the high frequency portions of sound. Various strategies to improve communication with women of the deaf community have been suggested and can be found on the Royal National Institute for Deaf People website.
The care of pregnant women with complex healthcare needs is challenging during a pandemic. To support healthcare providers caring for these women, the following guidance documents to assist maternity units with changes to antenatal and postnatal care were developed and can be found on the RCOG and RCM websites.

- **Guidance for antenatal and postnatal services in the evolving coronavirus (COVID-19) pandemic.**
- **Guidance for antenatal screening and ultrasound in pregnancy during the coronavirus (COVID-19) pandemic.**
- **Guidance for maternal medicine in the coronavirus (COVID-19) pandemic (Version 2.5).**
- RCM professional clinical briefings:
  - RCM Professional briefing on providing safe and effective virtual consultations.
  - RCM Professional briefing on domestic abuse during the pandemic.
  - RCM Professional briefing on public health care during the pandemic, including smoking cessation support.
  - RCM Professional briefing on antenatal care for women with and without COVID-19.

### 3.2 What are the considerations for antenatal appointments and advice for pregnant women?

#### Advice

- Evidence suggests that individuals from a Black, Asian or minority ethnic background, including pregnant women from these groups, are at higher risk of developing severe complications of COVID-19. Therefore, it is advised that:
  - Healthcare providers should discuss these risks with women of Black, Asian or minority ethnic background in a sensitive manner.
  - Women of Black, Asian or minority ethnic background are encouraged to seek advice without delay if they are concerned about their health.
  - Healthcare providers should be aware of this increased risk, and have a lower threshold to review, admit and consider multidisciplinary escalation of symptoms in women of BAME background.
  - When reorganising services, maternity units should be particularly cognisant of evidence that individuals from a Black, Asian or minority ethnic background are at particular risk of developing severe and life-threatening COVID-19 disease.
• Healthcare professionals should proactively advise all pregnant women to contact emergency antenatal services if they have any concern about their or their baby’s wellbeing.

• Carbon monoxide (CO) testing of all pregnant women should be undertaken, where it is safe to do so.

• Women should continue to take folic acid and vitamin D supplements in line with national recommendations.

• Women should be advised that influenza vaccination is still safe at all gestations of pregnancy and is recommended to protect both the woman and baby from the adverse effects of becoming seriously ill with flu during pregnancy.

• Pregnant women will continue to need at least as much support, advice, care and guidance in relation to pregnancy, childbirth and early parenthood as before the pandemic, especially socially vulnerable women (with risk factors including poverty, homelessness, substance misuse, being an asylum seeker, experiencing domestic abuse and mental health problems).
  
  o Midwifery, obstetric and support staff should remain aware of the support needs for all women, acknowledging local and national restrictions on visitors and accompanying persons may affect the amount of support women require.

• Healthcare providers should be aware of the increased risk of domestic abuse in pregnancy, which has escalated during the pandemic. Women should be encouraged to share any concerns at every opportunity and be provided with advice and support on how to access the appropriate services if required.

• Healthcare providers should maintain in-person appointments with women when there are safeguarding concerns, in order to provide extra support.

• There is evidence the pandemic has resulted in a greater level of anxiety and other mental health problems in pregnant women than in the overall population. Women should be asked about their mental health at every contact. Women who require further support should be signposted to resources and local services, which may be provided by virtual means. These include:
  
  o **Sources of self-help for anxiety and stress.**
  
  o Self-referral to local IAPT (Improving Access to Psychological Therapies) services in England. In Scotland, advice is available from Parentclub and NHS Inform. Further information is available from the RCM and Royal College of Psychiatrists websites.
Summary of evidence and rationale for guidance

The appropriate use of PPE is to protect healthcare workers, women and their families by functioning as a physical barrier to the transmission of infectious particles present in bodily fluids. Units should follow the regularly updated public health guidance issued jointly by the DHSC, Public Health Wales, Public Health Agency (PHA) Northern Ireland, Health Protection Scotland/National Services Scotland, PHE and NHS England (published by PHE on their behalf), and review this in collaboration with their local guidance and infection control teams. There are also clear guidelines on PPE from the RCM.

The UK Government has issued guidelines on the use of face coverings within enclosed spaces in England; these are applicable to women attending outpatient maternity appointments (including scans) and to hospital visitors. Scotland, Northern Ireland and Wales have issued similar guidance.

Before this pandemic, there was already extensive evidence of the inequality of experience and outcomes for women from Black, Asian or minority ethnic backgrounds giving birth in the UK. The increased risks of COVID-19 among individuals of Black, Asian or minority ethnic background are likely to result from a number of factors such as socioeconomic disadvantage, and the fact that they are more likely to work in key worker roles, including health and social care. Women of Black, Asian or minority ethnic background who are living with socioeconomic deprivation and/or in crowded conditions, those who were born outside the UK and whose first language is not English, and those with a high BMI and/or underlying medical conditions appear to be at particularly high risk.

The RCOG Race Equality Taskforce has launched a joint campaign with FiveXMore that aims to help communication with women of Black, Asian or minority ethnic background, with five easy to remember steps.

There is currently an absence of accurate information about the additional risk of smoking and severe COVID-19 infection. A scientific brief from the WHO on smoking and COVID-19, concludes that smoking is associated with increased severity of disease and death in hospitalised COVID-19 patients. The UK National Centre for Smoking Cessation and Training have advised maternity units to resume carbon monoxide testing on all pregnant women, where it is safe to do so. A risk assessment must be undertaken prior to CO testing including a well ventilated room and being able to maintain a 2 metre distance between the woman and healthcare professionals. Recommendations on smoking screening and cessation support are based on previous evidence on the effectiveness of these interventions.
Pregnancy is a risk factor for hospital admission with influenza. Influenza vaccination is safe and effective for pregnant women, who are always included in the annual NHS flu campaign. It is possible to be co-infected with influenza and SARS-CoV-2. The impact of co-infection is not known. In addition, influenza symptoms are difficult to distinguish from COVID-19 symptoms.

Isolation, bereavement, financial difficulties, insecurity and inability to access support systems are all widely recognised risk factors for mental ill health and are expected to affect individuals more than usual during the pandemic. Access to mental health services has also been constrained and delays to accessing care were evident in two maternal deaths by suicide that occurred during the spring of 2020.

This pandemic has resulted in an increased level of anxiety and other mental health problems in the general population. This has had a larger impact on women than on men. There is increasing evidence that this is likely to be even greater for pregnant women, as pregnancy represents a period of additional uncertainty. Specifically, these anxieties are likely to revolve around: a) COVID-19 itself, b) the impact of social isolation resulting in reduced support from wider family and friends, c) the potential of reduced household finances and d) major changes in antenatal and other NHS care, including some appointments being changed from in person to telephone contact. Meta-analyses and systematic reviews have found higher rates of perinatal mental health disorders during the pandemic, including anxiety and depression.

The Royal College of Psychiatrists, in collaboration with NHS England and NHS Improvement, have developed recommendations on mental wellbeing during the COVID-19 pandemic.

The coronavirus pandemic has increased the incidence of domestic abuse. Additional advice regarding support for victims of domestic abuse during the pandemic is available from the UK government. In addition, Women’s Aid, Save Lives and Refuge have updated guidance for people experiencing domestic abuse during the COVID-19 outbreak.

### 3.3 How should women with suspected or confirmed COVID-19 needing hospital attendance or advice be cared for?

**Advice**

For women who telephone maternity services:

- If women report symptoms attributed to COVID-19 on the phone to maternity services, consider differential diagnoses for fever, cough or shortness of breath. This includes, but is not limited to urinary tract infection, chorioamnionitis and pulmonary embolism.
• If women have symptoms suggestive of COVID-19, they should be advised to self-refer to national services for SARS-CoV-2 testing.

• Maternity units should develop triage tools to assess the severity of illness for women who telephone with suspected or confirmed COVID-19. This should include an assessment of symptoms, clinical and social risk factors and escalation pathways. This should include ‘safety netting advice’ about the risks of deterioration and when to seek urgent medical attention.

For women with possible or confirmed COVID-19, for whom hospital attendance is required or who self-present (this includes women who live with an individual who has possible or confirmed COVID-19):

These women should be advised to attend via private transport where possible.

• If an ambulance is required, the call handler should be alerted if the woman, or a member of her household, is symptomatic of COVID-19.

• Women should be advised to alert a member of maternity staff by mobile telephone on arrival at the hospital entrance prior to entering any of the buildings.

• Women should be met at the maternity unit or hospital entrance by staff wearing appropriate PPE to provide the woman with a fluid-resistant surgical mask.

• Staff providing care should wear appropriate PPE as per UK health protection guidance.

• Women should be cared for within isolation rooms from which all non-essential items have be removed prior to the woman’s arrival (this includes other rooms in which the woman spends time during her hospital attendance [e.g. scan rooms when bedside scans are not appropriate]).

• Women should immediately be escorted to an isolation room or cohort bay/ward, suitable for the majority of care during their hospital visit or stay.

  • Isolation rooms or ward bays should ideally have a defined area for staff to put on and remove PPE, and suitable bathroom facilities.

• The woman’s facemask should not be removed until she is isolated in a suitable room or cohort bay.

• Only essential staff should enter the isolation room or bay.

• Visitors to isolation rooms or cohort bays/ward should be kept to a minimum and follow local hospital visitor policies.

• All clinical areas must be cleaned following use, according to specific COVID-19 UK wide public health guidance.
Summary of evidence and rationale for guidance

Maternity units should develop triage tools to assess the severity of illness for women who telephone with suspected or confirmed COVID-19. An example developed by clinicians in Guy’s and St Thomas’ NHS Foundation Trust is provided in Appendix V. Triage tools should include an assessment of symptoms, clinical and social risk factors and escalation pathways. This should include ‘safety netting advice’ about the risks of deterioration and when to seek urgent medical attention.

Availability of resources, provision of services, building/unit configuration and local prevalence of COVID-19 will vary across geographical regions, and will determine how women requiring hospital admission with confirmed or suspected COVID-19 are cared for. Advice on care in isolation rooms and COVID-19 cohort bays is available from PHE, having been issued on behalf of the four nations of the UK.68 This advice may change frequently and it is vital that healthcare providers stay abreast of the latest developments.

As above, units should follow the regularly updated advice on PPE, in conjunction with guidance from the RCM and their local guidance and infection control teams.68,69 Guidance on cleaning clinical areas used to provide care to women with suspected or confirmed COVID-19 is available from PHE.68

3.4 What are the considerations for antenatal care for women who have recovered from COVID-19?

Advice

- For women who have recovered from COVID-19 with mild, moderate or no symptoms, without requiring admission to hospital, antenatal care should remain unchanged following a period of self-isolation.

- Services should ensure that women who have missed antenatal appointments because of self-isolation are seen as early as is practical after the period of self-isolation ends.

- For women who have recovered from a period of serious or critical illness with COVID-19 requiring admission to hospital for supportive therapy, ongoing antenatal care should be planned together with a consultant obstetrician prior to hospital discharge.

- Women who have been seriously or critically unwell from COVID-19 should be offered an ultrasound scan to assess the fetal biometry approximately 14 days following recovery from their illness, unless there is a pre-existing clinical reason for an earlier scan.
Summary of evidence and rationale for guidance

To date, there is an absence of evidence to guide the care for women recovering from mild or moderate symptoms of COVID-19. Women who have recovered should be encouraged to attend antenatal appointments in line with advice statements outlined above.

New studies from different nations have suggested an association between COVID-19 infection and stillbirth (see section 1.6). While substantial evidence of causality for an association between stillbirth and COVID-19 infection is lacking, there is a growing body of evidence describing the effect of COVID-19 infection on the placenta and possible associated mechanisms for poor pregnancy outcomes.

Placental histopathology studies have found that abnormalities, including fetal vascular malperfusion and villitis of unknown aetiology, are more frequent among COVID-19 cases than controls. One study found evidence of an increased immunological response for women infected with SARS-CoV-2 at term without evidence of active infection at the placental site. Placental inflammation is associated with poor pregnancy and fetal outcomes, and therefore these findings provide a hypothesis to explain the associated poorer fetal outcomes experienced by women with COVID-19 infection. Studies that have reported increased risk of developing hypertension in pregnancy following COVID-19 infection adds to the narrative of placental involvement, and therefore confirm that women recovering from severe infection with COVID-19 should be monitored accordingly.

A systematic review concluded that in comparison to mild COVID-19 infection, severe COVID-19 infection is associated with a significant increase in risk of having a baby of low birth weight (OR 1.89). However, a histopathology study which examined placentas of women with asymptomatic or mild COVID-19 infection reported no differences in outcomes (including birthweight) compared to COVID-19 negative controls. This is suggestive that as severity of COVID-19 infection increases the risk for compromised fetal growth and wellbeing are impaired. In addition it is known that two-thirds of pregnancies with SARS were affected by FGR. Ultrasound to assess fetal biometry and placental function for women who have been seriously or critically unwell from COVID-19 should be undertaken and this approach has been adopted internationally.

Guidance on fetal growth surveillance following COVID-19 was developed along with NHS England and NHS Improvement. This recommends a single fetal growth ultrasound scan a minimum of 14 days following resolution of acute COVID-19 illness that required hospitalisation.
4. Venous thromboembolism prevention
4. Venous thromboembolism prevention

Advice

• Women who are self-isolating at home should stay hydrated and mobile.

• Women should have a VTE risk assessment performed during their pregnancy in line with RCOG Green-top Guideline No. 37a. Infection with SARS-CoV-2 should be considered a transient risk factor and trigger reassessment.

• Where normally indicated, thromboprophylaxis should still be offered and administered as prescribed during the COVID-19 pandemic.

• If healthcare professionals are concerned about the risk of VTE during a period of self-isolation, a clinical VTE risk assessment (in person or by virtual means) should be performed, and thromboprophylaxis considered and prescribed on an individual basis.

• Local procedures should be followed to ensure women are supplied with low molecular weight heparin (LMWH), particularly where they cannot attend hospital during periods of self-isolation.

• Thromboprophylaxis initiated for pregnant women who are self-isolating should be continued until they have recovered from the acute illness (between 7 and 14 days). Advice should be sought from a clinician with expertise in VTE for women with ongoing morbidity and limited mobility.

• All pregnant women admitted with confirmed or suspected COVID-19 should be offered prophylactic LMWH, unless birth is expected within 12 hours or there is significant risk of haemorrhage.

• For women with severe complications of COVID-19, the appropriate dosing regimen of LMWH should be discussed with a multidisciplinary team (MDT), including a senior obstetrician or clinician with expertise in managing VTE in pregnancy.

• All pregnant women who have been hospitalised and have had confirmed COVID-19 should be offered thromboprophylaxis for 10 days following hospital discharge. A longer duration of thromboprophylaxis should be considered for women with persistent morbidity.

• If women are admitted with confirmed or suspected COVID-19 within 6 weeks postpartum, they should be offered thromboprophylaxis for the duration of their admission and for at least 10 days after discharge. Consideration should be given to extending this until 6 weeks postpartum for women with significant ongoing morbidity.
Pregnancy is a hypercoagulable state. The existing RCOG Green-top Guidelines No. 37a and 37b on VTE prevention and management should continue to support decision making during the COVID-19 pandemic. VTE risk assessment in the context of the COVID-19 pandemic should consider both the hypercoagulable state associated with the infection, as well as the increased risk that may come from self-isolation.

Evidence indicates that individuals admitted to hospital with moderate and severe COVID-19 are also hypercoagulable. Infection with SARS-CoV-2 is likely to be associated with an increased risk of maternal VTE. This is likely to be multifactorial, including the reduced mobility resulting from self-isolation at home or hospital admission, and other associated obstetric or maternal morbidities. Consequently, the cumulative risk is difficult to quantify. In the MBRRACE rapid report one women died from a confirmed thromboembolic event and a second woman experienced a sudden deterioration that may be attributed to a thromboembolic event.

Pregnant women, and women who have recently given birth, who have tested positive for SARS-CoV-2 are recommended to self-isolate at home even if they are asymptomatic – this may impact on their mobility which will alter further their VTE risk assessment.

The statements above were developed following expert consensus discussion to determine what increased risk COVID-19 may pose to pregnant women. VTE prevention for an unwell woman with COVID-19 is considered in section 6.2.
5. Labour and birth during the COVID-19 pandemic
5. Labour and birth during the COVID-19 pandemic

Women admitted to hospital, including maternity units, should be offered testing for SARS-CoV-2 on admission. This includes women admitted for intrapartum care.

5.1 What are the considerations for labour and birth in asymptomatic women who test or have tested positive for SARS-CoV-2?

Advice

- Low risk women who test positive for SARS-CoV-2 within 10 days prior to birth who are asymptomatic and wish to give birth at home or in a midwifery-led unit, should have an informed discussion around place of birth with their clinician.

- For asymptomatic women who test positive for SARS-CoV-2 on admission, continuous electronic fetal monitoring (CEFM) during labour using cardiotocography (CTG) is not recommended solely because of a positive test.
  - Fetal monitoring options should be discussed with the woman, acknowledging the current uncertainties in women who are asymptomatic with a positive test for SARS-CoV-2.
  - Women who test positive for SARS-CoV-2 should be offered delayed cord clamping and skin-to-skin contact with their baby in line with usual practice.

Summary of evidence and rationale for guidance

NHS England and NHS Scotland have recommended that women (and their support partners in NHS England) should be offered testing for SARS-CoV-2 when they are admitted to maternity units to give birth.

While fetal compromise in women who are symptomatic of COVID-19 has been reported by some case series,\(^79,80\) it is reassuring that measures of fetal compromise at birth for asymptomatic women who test positive for SARS-CoV-2 are not reported to differ from women who test negative.

The need for CEFM for asymptomatic women who test positive for SARS-CoV-2 but who are otherwise low risk for labour (e.g. CEFM would not otherwise be indicated by NICE Clinical Guideline [CG190] on *Intrapartum care for healthy women and babies*\(^82\)) is an area of clinical uncertainty because of the lack of robust evidence. It is, therefore, important that asymptomatic women of low obstetric risk should continue to have the risks and benefits of CEFM discussed with them on a holistic basis.
There is no evidence\textsuperscript{83,84} that the practice of delayed cord clamping and skin-to-skin contact between mother and baby increases the transmission of SARS-CoV-2 to the neonate. The well documented benefits of these practices should be discussed with the woman to make an informed choice and implemented in line with pre-pandemic practice. In the absence of other evidence, NICE CG190 should be followed.\textsuperscript{82}

5.2 How should a woman with suspected or confirmed COVID-19 be cared for in labour if they are symptomatic?

Advice

- Women with mild COVID-19 symptoms can be encouraged to remain at home (self-isolating) in early (latent phase) labour consistent with routine care.

- If there are no concerns regarding the health of either the woman or baby, women who attend the maternity unit and would usually be advised to return home until labour is more established can still be advised to do so, unless private transport is not available.
  - Women should be provided with the usual advice regarding signs and symptoms of labour; but also be informed about symptoms that might suggest deterioration related to COVID-19 and be advised to call back if concerned.

- Advice on PPE is available in section 5.8.

- Women with symptomatic suspected or confirmed COVID-19 should be advised to labour and give birth in an obstetric unit.

- On admission, a full maternal and fetal assessment should be undertaken, including:
  - Assessment of the severity of COVID-19 symptoms by the most senior available clinician.
  - Maternal observations including temperature, respiratory rate and oxygen saturation.
  - Confirmation of the onset of labour, as per standard care.
  - CEFM using CTG.

- The following members of the MDT should be informed of the woman’s admission: consultant obstetrician, consultant anaesthetist, midwife-in-charge, consultant neonatologist, neonatal nurse-in-charge and the infection control team. Other members of the team may include an obstetric physician or respiratory physician.

- Standard hourly maternal observations and assessment should be performed (as per the recommendations in NICE CG190, \textit{Intrapartum care for healthy women and babies}), with the addition of hourly oxygen saturation monitoring. Oxygen therapy should be titrated to aim for saturation above 94%.
• CEFM should be offered to women with symptomatic suspected or confirmed COVID-19 during labour and vaginal birth.

• Maternal infection with SARS-CoV-2 is in itself not a contraindication to performing a fetal blood sample or using fetal scalp electrodes.

• The number of staff members entering the room should be minimised, and units should develop a local policy specifying essential personnel for emergency scenarios.

• Women with symptomatic suspected or confirmed COVID-19 should be offered delayed cord clamping and skin-to-skin contact with their baby, if the condition of the woman and infant allows.

Summary of evidence and rationale for guidance

NHS England has produced clinical guidance on the temporary reorganisation of intrapartum maternity care during the coronavirus pandemic and a framework has been published in Scotland.

COVID-19 infection and control guidance issued by PHE, on behalf of the four nations of the UK, gives advice about avoiding disease transmission. WHO has produced guidance on clinical management of COVID-19.

In women with symptomatic COVID-19, there may be an increased risk of fetal compromise in active labour. In addition, it is reported that women with symptomatic COVID-19 have an increased risk of caesarean birth, which further supports the guidance to give birth in an obstetric unit where timely access to emergency care is available.

While further data is required in women with symptomatic confirmed or suspected COVID-19, it appears prudent to use CEFM, as would usually be recommended for maternal systemic infection.

There is no evidence that the practice of delayed cord clamping and skin-to-skin contact between woman and baby increases the transmission of SARS-CoV-2 to the neonate.

5.3 What are the considerations for labour and birth for women who have recovered from COVID-19?

Advice

• For women who have recovered from antenatal COVID-19 without requiring admission to hospital, and who have completed self-isolation in line with public health guidance, there should be no change to planned care during labour and birth.
• For women who have recovered following a hospital admission for serious or critical COVID-19 illness needing supportive therapy, healthcare professionals should discuss and plan place of birth with the woman. While making a personalised assessment, consideration should be given to both the growth of the fetus and the woman’s choices.

• Healthcare professionals should ensure that any growth ultrasound scan undertaken following a period of severe illness has been reviewed. If the interval between resolution of illness and presentation for birth has been insufficient to allow for a growth scan, the implications of this should be considered in the assessment and care plan.

• When participating in informed discussions with women about fetal monitoring, healthcare professionals should acknowledge evidence of fetal distress is based on small numbers of babies born to women symptomatic of COVID-19, and theoretical risks extrapolated from pregnancies affected by FGR in women with other coronaviruses.

Summary of evidence and rationale for guidance

There is an absence of evidence for this situation. The above is based on expert consensus.

5.4 What are the considerations for birth partners during the COVID-19 pandemic?

Advice

• Women should be supported and encouraged to have a birth partner present with them during active labour and birth if they wish to do so.

• Birth partners who are symptomatic, or in a period of self-isolation for confirmed SARS-CoV-2 infection, should remain in self-isolation at home and not attend the hospital.

• NHS England recommends efforts should be made to utilise the available testing capacity to test both the woman and her birth partner to mitigate infection risk where resources allow.

• Local level risk assessments should be made for each maternity service space (for example shared wards) to identify if there are elevated risks of SARS-CoV-2 transmission from the presence of a birth partner.

• On attendance at the maternity unit, all birth partners should be asked whether they have experienced any symptoms suggestive of COVID-19 in the preceding 10 days, e.g. fever, acute persistent cough, changes in or loss of sense of smell (anosmia) or taste.
Summary of evidence and rationale for guidance

Having a trusted birth partner present throughout labour is known to make a significant difference to the safety and wellbeing of women in childbirth. The pandemic has affected the levels of perinatal stress experienced by pregnant women, as well as feelings of fear and loneliness in relation to their birth experience. A supportive birth partner is a recognised protective factor for the emotional wellbeing and birth experiences of women. UK-wide PHE guidance, local hospital infection control and visitor policies should be adhered to. The NHS has produced guidance to support the access of birth partners and other supportive adults to maternity services in England and Scotland.

5.5 What informed discussions should take place with women regarding timing and mode of birth during the COVID-19 pandemic?

Advice

- Clinicians should discuss mode of birth during the COVID-19 pandemic with the woman and her family. Consideration should be given to her preferences and any obstetric or fetal indications for intervention.
Summary of evidence and rationale for guidance

There is no evidence to favour one mode of birth over another in women with COVID-19. In the earlier UKOSS study, 98 12 (5%) babies tested positive for SARS-CoV-2 infection; six within the first 12 hours (two were born by unassisted vaginal birth and four by caesarean birth) and six after 12 hours (two born vaginally and four by caesarean birth). The rate of neonatal COVID-19 infection is no greater when babies are born vaginally, breastfed or stay with their mother after birth. 99–101

Donning PPE is expected to lengthen the decision to birth interval because of the additional action required before commencing surgery, however, there is no evidence of this within the UK setting. A single centre cohort study 102 demonstrated a possible longer time to birth in urgent caesarean births for women with suspected or confirmed COVID-19 (25.5 minutes [95% CI 17.5–31.75] versus 18.0 minutes [95% CI 10.0–26.25]; P = 0.113). This did not reach statistical significance, which may be explained by the study sample size which was not chosen to power for the outcome. Simulation training has been proposed as a way of improving the response to obstetric emergencies during the COVID-19 pandemic, including donning and doffing of PPE. 103

• A personalised assessment should take place to determine whether it is beneficial overall to delay a planned caesarean birth or induction of labour (IOL), and any associated appointments, for women who are self-isolating because of suspected COVID-19 in themselves or in a household contact.
  o Consider the urgency of the birth and the risk of infectious transmission to other women, healthcare workers and, postnatally, to her baby.
  o If a planned caesarean birth or IOL cannot be delayed, follow the advice for services providing care to women admitted with suspected or confirmed COVID-19.

• Women with worsening symptoms, or who are becoming exhausted, should be offered personalised information so they can make an informed decision about expediting birth.

• Senior obstetric and medical input for a woman with severe or critical COVID-19 should be sought, particularly for decision making about birth. Consider whether the benefits of an urgent caesarean birth outweigh any risks to the woman.

• The advice in section 5.8 on PPE for caesarean birth should be followed.

• Women and their families should be informed that donning PPE for emergency caesarean births is time-consuming but essential, and this may impact on the time it takes to assist in the birth of the baby. Consider this during decision making and, where possible, discuss during birth planning.

56
5.6 What are the considerations for water birth?

**Advice**

- Water birth is not contraindicated for women who are asymptomatic of COVID-19 and presumed or confirmed SARS-CoV-2 swab negative, providing adequate PPE can be worn by those providing care.

- Women with symptomatic COVID-19 who have a cough, fever or feel unwell, should not labour and birth in water.

- Asymptomatic women who have tested positive for SARS-CoV-2 should be advised there is inadequate evidence about the risk of transmission of the virus in water.

- Healthcare providers should be aware that the integrity of PPE, such as a facemask, could be compromised when it becomes wet.

**Summary of evidence and rationale for guidance**

Labour and birth in water may confer benefits to women at low risk of complications during birth. Women report\(^{104}\) that restrictions to access water birth are a concern during the pandemic, and therefore in the absence of contraindication to water birth, this option should be available. Care providers should discuss with women the lack of evidence on this topic in the context of the COVID-19 pandemic in order to facilitate informed decision making.

The RCM\(^{227}\) notes that in relation to women who are asymptomatic of COVID-19, but test positive for SARS-CoV-2, there is inadequate evidence about the risk of transmission of the virus in water. There is evidence that SARS-CoV-2 RNA may be present in faeces, but no evidence to support that this has resulted in faecal–oral spread.\(^{105,106}\) There is, therefore, insufficient evidence for or against the use of water in labour or birth for asymptomatic women and staff caring for them. The RCM does note that healthcare providers should be aware that the integrity of PPE, such as a face mask, could be compromised when it becomes wet.

It is recommended that women with pyrexia should not labour or birth in water.\(^{82}\) Women with a cough or breathing difficulties, or those who feel unwell, should be closely monitored for their oxygen saturations and other vital signs and may require oxygen support. This care is better provided out of water to enable more effective monitoring and rapid access to emergency care.

5.7 What are the specific considerations for labour analgesia or anaesthesia

**Advice**

- Entonox (50% nitrous oxide and 50% oxygen) can be safely offered with a standard single-patient microbiological filter.
Summary of evidence and rationale for guidance

Advice published on the considerations for labour analgesia or anaesthesia is based on expert opinion following consultation with the Obstetric Anaesthetists Association (OAA).

There is no evidence that the use of Entonox is an aerosol-generating procedure (AGP). There is no evidence that epidural or spinal analgesia or anaesthesia is contraindicated in the presence of coronaviruses.\textsuperscript{107}

Intubation, required for GA, is an AGP. This significantly increases the risk of transmission of SARS-CoV-2 to attending staff.\textsuperscript{108}

UK case studies\textsuperscript{109} reported significantly lower rates of GA for caesarean births (down from 7.7\% to 3.7\%), as well as lower rates of conversion from neuraxial to GA during the initial wave of the SARS-CoV-2 infection in 2020. Recommendations for anaesthetic decision making made by the OAA are thought to have been influential in the decline in GA rate. This supports the guidance that clinicians should facilitate fully informed discussions regarding choice of analgesia early in labour for women with suspected or confirmed COVID-19.

5.8 What personal protective equipment is recommended when caring for women during labour and birth?

Advice

- Healthcare professionals should follow national recommendations on the use of PPE in clinical settings.

- Owing to the differing levels of PPE required for caesarean birth, a multidisciplinary discussion should be held about the likelihood of a woman requiring a GA.

- For caesarean births where GA is planned from the outset all staff in theatre should wear PPE, including an FFP3 mask and visor. PPE should be donned prior to commencing the GA.

- Local standard operating procedures should be developed to determine the type of PPE required in cases where GA is not planned from the outset, but neuraxial anaesthesia for caesarean birth either cannot be sited or is ineffective.
Summary of evidence and rationale for guidance

The appropriate use of PPE is to protect healthcare workers, women and their families by functioning as a physical barrier to the transmission of infectious particles present in bodily fluids. General advice from PHE, issued on behalf of the four nations of the UK, on type and specification of PPE is available. The RCM and the OAA have provided specific advice on the type and specification of PPE for maternity care and obstetric anaesthesia.

The level of PPE required by healthcare professionals caring for a woman with COVID-19 who is undergoing a caesarean birth should be determined on the basis of the risk of her requiring a GA, which would require intubation and is, therefore, an AGP.

The provision of neuraxial anaesthesia (spinal, epidural or combined spinal epidural [CSE]) is not an AGP.

The chance of requiring conversion to a GA during a caesarean birth commenced under neuraxial anaesthesia is small, but this chance increases with the urgency of caesarean birth. In situations where there are risk factors that make conversion to a GA more likely, the decision on what type of PPE to wear should be based on the individual circumstances. If the risk of requiring conversion to a GA is considered significant (e.g. in a category 1 caesarean birth), the theatre team should wear PPE appropriate to a GA in readiness.

A retrospective analysis of anaesthetic practices for caesarean births in maternity units in the north-west of England during the initial wave of the COVID-19 pandemic, found a reduction in GA rates (from 7.7% before the pandemic to 3.7% during). Further there was a reduction in conversion rates from neuraxial to GA (from 1.7% to 0.8%). The key factors identified for these reductions included anaesthetic decision-making, recommendations from anaesthetic guidelines and the increased presence of on-site anaesthetic consultants. This is encouraging but should be interpreted with some caution as the authors did not report neonatal outcomes.

5.9 How should obstetric theatres be managed during the COVID-19 pandemic?

Advice

• Elective obstetric procedures, such as caesarean birth or cervical cerclage, for women with suspected or confirmed COVID-19, should ideally be scheduled at the end of the operating list.

• Emergency procedures for women with suspected or confirmed COVID-19 should be conducted in a second obstetric theatre where available, allowing time for a full postoperative theatre clean as per national health protection guidance.

• The number of staff in the operating theatre should be kept to a minimum and all colleagues should wear appropriate PPE.
- Anaesthetic care for women with suspected or confirmed COVID-19 should be provided with reference to guidance from the Royal College of Anaesthetists (RCoA)/OAA/Faculty of Intensive Care Medicine/Intensive Care Society/Association of Anaesthetists.

- Operating theatre checklists should be used to aid closed loop communication as the wearing of PPE compromises communication.

The advice above is based on UK government advice on infection prevention and control, and guidance from the RCoA, OAA, Faculty of Intensive Care Medicine, the Intensive Care Society and the Association of Anaesthetists.

The use of PPE causes communication difficulties in operating theatre settings, including obstetric theatres. It is proposed that operating theatre checklists should be employed to improve communication in operating theatres.

5.10 What are the considerations for bereavement care during the COVID-19 pandemic?

Summary of evidence and rationale for guidance

Advice

- Maternity services should ensure that bereavement care remains of a high standard during the COVID-19 pandemic, with continued provision of appropriate intrapartum and postnatal care, including all appropriate investigations and postnatal appointments.

- Women should be supported and encouraged to have a support person accompany them to all care episodes related to a pregnancy loss if they wish.

Sands and the RCM have provided further guidance on bereavement care during the pandemic in their briefing Bereavement Care in Maternity Services During COVID-19 pandemic. Sands has also produced information for bereaved families about care during the pandemic.

6.1 How should a pregnant woman requiring hospital admission with symptoms suggestive of COVID-19 be investigated?

**Advice**

- Pregnant and postpartum women presenting with COVID-19 should be investigated and treated the same as non-pregnant women unless there is a clear reason not to do so.

- The decision for admission or for self-directed care at home depends on the overall clinical picture. Care at home should include clear ‘safety netting advice’ and in some instances this may involve home monitoring of oxygen saturation levels.

- Women presenting with a fever should be cared for in line with RCOG Green-top Guideline No. 64a *Bacterial Sepsis in Pregnancy*. Testing for SARS-CoV-2 should be offered in addition to blood cultures.

- While pyrexia may suggest COVID-19, clinicians should not assume that all pyrexia is because of COVID-19. The possibility of bacterial infection should be considered and a full sepsis screen performed in line with the [UK Sepsis Trust Sepsis Screening and Action Tool](https://www.uksepsistrust.org/) and IV antibiotics administered when appropriate.

- Bacterial (rather than viral) infection should be considered if the white blood cell count is raised (lymphocytes are usually low with COVID-19) and antibiotics should be commenced.

- Radiographic investigations should be performed as for the non-pregnant adult; this includes chest X-ray and computerised tomography (CT) of the chest. Chest imaging is essential for the evaluation of an unwell woman with COVID-19 and should be performed when indicated, and not delayed because of concerns of possible maternal and fetal exposure to radiation, as maternal wellbeing is paramount.

- A diagnosis of pulmonary embolism or heart failure should be considered for women presenting with chest pain, worsening hypoxia or a respiratory rate above 20 breaths/minute (particularly if there is a sudden increase in oxygen requirements), or in women whose breathlessness persists or worsens after expected recovery from COVID-19. Additional tests to investigate for possible differential diagnoses, including electrocardiogram, echocardiogram, CT pulmonary angiogram, ventilation perfusion lung scan, should be considered.

- Ferritin and C-reactive protein are usually raised in COVID-19. D-Dimer is also usually raised and is therefore not useful to assess VTE.

- Disseminated intravascular coagulation can also occur, with prolonged prothrombin time and activated partial thromboplastin time, and low fibrinogen levels.
Summary of evidence and rationale for guidance

The clinical symptoms of COVID-19 overlap with those of a variety of other clinical conditions. Healthcare providers should consider all differential diagnoses for women who present with a fever in pregnancy and follow the advice and guidance of the RCOG Green-top Guideline No. 64a.\textsuperscript{112}

Several studies\textsuperscript{113} have shown decreased lymphocyte counts in the general population affected by COVID-19. One systematic review\textsuperscript{114} noted decreased lymphocyte counts in pregnant women.

‘Safety netting’ describes what symptom deterioration to look out for and the specific actions to take if this occurs. Pulse oximetry may be offered as part of this process, or used in some situations, for home monitoring of oxygen saturation. An example of safety netting might include the points below, and further advice is available from the NHS.\textsuperscript{231,232,233}

- Ring your GP/local out-of-hours service/labour ward (the advice should be clear and specific to each local service) as soon as possible if you slowly start feeling more unwell or more breathless, or are having difficulty breathing when getting up to go to the toilet or similar, or you sense that something is wrong (e.g. general weakness, extreme tiredness, loss of appetite, reduced urine output, unable to care for yourself), or if you use a pulse oximeter and your blood oxygen level is 94% or 93%.

- Attend your nearest A&E or call 999 immediately, if you are unable to complete short sentences when at rest because of breathlessness, or your breathing suddenly worsens within an hour, or you have blue lips or a blue face, or you feel cold sweaty and pale, or collapse or faint, or become agitated, confused or very drowsy, or you use a pulse oximeter and it measures 92% or less.

- If using a pulse oximeter, caution should be observed for women with darker skin tones as pulse oximeters may overestimate the oxygen saturation.\textsuperscript{234}

6.2 How should a pregnant, or recently pregnant, woman with suspected or confirmed COVID-19 who is clinically deteriorating be cared for?

**Advice**

**Organisation and principles of care**

- Obstetricians should be familiar with and follow local guidelines for the initial investigation and care of women presenting with possible COVID-19.

- Women with suspected COVID-19 should be treated as if positive until test results are available.
• The priority for medical care should be to stabilise the woman’s condition with standard therapies.

• An urgent MDT meeting should be arranged for any unwell woman with suspected or confirmed COVID-19. This includes women who are requiring oxygen to maintain saturations between 94% and 98%, women with a respiratory rate above 20 breaths/minute and women with a heart rate greater than 110 beats/minute. This should ideally involve senior decision makers and may include: a consultant obstetrician, consultant anaesthetist, midwife-in-charge, consultant neonatologist, neonatal nurse-in-charge, intensivist responsible for obstetric care, an obstetric physician, a respiratory physician and the infection control team. The discussion should be shared with the woman, and her family if she chooses. The following should be considered:

  o Key priorities for medical care of the woman and her baby, and her birth preferences.

  o The most appropriate location of care (e.g. intensive care unit, ‘COVID bays’, specific COVID-19 wards, isolation room in infectious disease ward or other suitable isolation room) and lead specialty.

  o Concerns among the team regarding special considerations in pregnancy, including the health of the baby.

• A consultant in obstetrics and gynaecology should review all pregnant and recently pregnant women with suspected or confirmed COVID-19 who are in hospital at least daily, particularly if they are admitted to a bed outside of the maternity unit.

• If appropriate, a designated team member should be responsible for regularly updating the woman’s family about her health, and that of the baby.

Observations and investigations

• Clinicians should monitor both the absolute values and trends of the hourly observations, including heart rate, respiratory rate and oxygen saturation.

• Clinicians should be aware that young, fit women can compensate for deterioration in respiratory function and are able to maintain normal oxygen saturations until sudden decompensation.

• Units should have an escalation plan for the care of pregnant and postnatal women with COVID-19.

• A woman’s care should be escalated urgently if any of the following signs of decompensation develop:

  o increasing oxygen requirements or fraction of inspired oxygen (FiO₂) above 35%,
Summary of evidence and rationale for guidance

A useful summary on supportive care for adults diagnosed with COVID-19 has been published by the WHO.\textsuperscript{115} Specific guidance on the care of patients with COVID-19 who are admitted to critical care has been published by NICE and SIGN.\textsuperscript{116,117}

Hospitals should have escalation guidelines for the care of pregnant and postnatal women with COVID-19. An example of a maternity escalation plan from Guy's and St Thomas' NHS Foundation Trust is given in Appendix VI.

- increasing respiratory rate despite oxygen therapy of, or above, 25 breaths/minutes or a rapidly rising respiratory rate,
- reduction in urine output when this is being monitored,
- acute kidney injury (serum creatinine levels above 77 μmol/l in women with no pre-existing renal disease),
- drowsiness, even if the oxygen saturations are normal.

- The possibility of myocardial injury should be considered, as the symptoms are similar to those of respiratory complications of COVID-19.
- The appropriateness and frequency of fetal heart rate monitoring should be considered on an individual basis, accounting for the gestational age and the maternal condition.

Planning for the birth of the baby

- For pregnant women in the third trimester who are unwell, an individualised assessment should be undertaken by the MDT to decide whether emergency caesarean birth or IOL should be performed, either to facilitate maternal resuscitation (including the need for prone positioning) or because of concerns regarding fetal health.
- If maternal stabilisation is required before delivery can be undertaken safely, this is the priority, as it is in other maternity emergencies.
- If urgent intervention for birth is indicated for fetal reasons, then birth should be expedited as for usual obstetric indications, as long as the maternal condition is stable.
- When iatrogenic preterm birth is required, the administration of antenatal corticosteroids to promote fetal lung maturation and magnesium sulfate for fetal neuroprotection, should be considered by the MDT. Urgent intervention for birth should not be delayed for their administration.
As discussed in section 4, infection with SARS-CoV-2 requiring admission to hospital is associated with an increased risk of VTE. All pregnant and recently pregnant women should be assessed for risk of VTE and prescribed thromboprophylaxis with LMWH unless there is a contraindication. The dose of LMWH should be considered on an individual basis and discussed with the MDT. There is currently not enough evidence of the benefits and risks of therapeutic dose anticoagulation applicable to pregnant women who may require imminent operative birth, to recommend therapeutic anticoagulation routinely in the absence of suspected or proven VTE.

While most patients with severe COVID-19 infection will have normal or even high platelet counts, COVID-19 can be associated with thrombocytopenia. When aspirin has been prescribed as prophylaxis for pre-eclampsia or previous small-for-gestational-age baby, it should be discontinued for the duration of the infection as this may increase the bleeding risk in women with thrombocytopenia. Women who take LMWH thromboprophylaxis during pregnancy should discontinue this if their platelet count falls below 50 x 10^9/L and their care should be discussed with a haematologist.

Myocardial injury and its complications were observed in 11% of all patients who died in Italy up to 4 June 2020, and studies of cardiac biomarkers also support evidence of myocardial injury. Early involvement of multidisciplinary colleagues to investigate for potential myocardial injury is essential if this is suspected. Further details of investigation and management is available in the NICE rapid guideline on diagnosing myocardial injury in patients with suspected or confirmed COVID-19.

Increased rates of iatrogenic preterm birth are associated with severe COVID-19 infection in pregnancy (sections 1.4.3 and 1.6). Antenatal corticosteroids are well established as being beneficial in preterm labour, or if iatrogenic preterm birth is anticipated. Magnesium sulfate therapy is recommended for neuroprotection of the neonate, and should be offered to women up to 29+6 weeks of gestation and considered up to 33+6 weeks of gestation. The administration of steroids and magnesium sulfate to women who are severely unwell with COVID-19 should be considered by an MDT.

For non-specialist anaesthetists and physicians involved in the care of pregnant women with COVID-19 and other medical conditions, useful information is available from the RCoA guideline Care of the critically ill woman in childbirth; enhanced maternal care and the Royal College of Physicians’ Acute care toolkit 15: Managing acute medical problems in pregnancy.

Prone positioning of patients with moderate to severe acute respiratory distress syndrome (ARDS) can improve respiratory function and has been recommended for the care of patients with COVID-19. There is little evidence on the use of prone positioning in pregnancy, and guidance from the Intensive Care Society in the UK advises that it is relatively contraindicated in the second and third trimesters of pregnancy. However, a review article on prone positioning for pregnant women who are unwell with COVID-19 provides advice, guidance and an algorithm on how this can be undertaken successfully in the second and early third trimesters.
6.3 What therapies should be offered to pregnant, or recently pregnant, women with COVID-19?

Advice

- If there is clinical uncertainty about whether to offer a therapy to a pregnant woman, advice should be sought through maternal medicine networks.

- Oxygen should be titrated to target saturations to 94–98%. Using escalation through nasal cannula, face mask, venturi mask, non-rebreather mask, non-invasive positive airway pressure (e.g. CPAP), intubation and IPPV, and ECMO as appropriate. Referrals to the NHS ECMO service should be made for pregnant women or women postpregnancy using the same criteria as for other adult patients i.e. if worsening severe respiratory failure despite appropriate conventional ventilatory support, or for women in whom lung-protective ventilation cannot be achieved because of the severity of hypoxaemia or hypercapnia, or significant air-leak (e.g. barotrauma or bronchopleural fistula).

- Proning should be strongly considered. Although evidence is limited there are reports that this is feasible (with appropriate padding) up to at least 28 weeks of gestation.

- Caution should be applied to IV fluid management:
  - Hourly fluid input/output charts should be used to monitor fluid balance in women with moderate to severe symptoms of COVID-19.
  - The aim should be to maintain a neutral fluid balance in labour.
  - When required, boluses in volumes of 250–500 ml should be employed and an assessment for fluid overload made before proceeding with further fluid resuscitation.

- Antibiotics should be commenced at presentation if there is clinical suspicion of bacterial infection or sepsis, with an early review and rationalisation of antibiotics if COVID-19 is confirmed. Even when COVID-19 is confirmed, clinicians should remain open to the possibility of another coexisting condition. There should be no delay in the administration of therapy that would usually be given in maternity care (e.g. IV antibiotics in woman with fever and prolonged rupture of membranes).

- All pregnant women should be assessed for risk of VTE and prescribed thromboprophylaxis with LMWH unless there is a contraindication (see section 4). The dose of LMWH should be considered on an individual basis and discussed with the MDT. Therapeutic doses of LMWH should be employed when VTE is suspected until objective testing can be undertaken.
• Thrombocytopenia may be associated with severe COVID-19. For women with thrombocytopenia (platelets less than $50 \times 10^9/L$) aspirin and LMWH thromboprophylaxis should be discontinued and haematology advice sought. The use of mechanical aids (such as intermittent pneumatic compression) should be used if LMWH therapy is contraindicated or paused secondary to thrombocytopenia.

• Corticosteroid therapy should be given for 10 days or up to discharge, whichever is sooner, for women who are unwell with COVID-19 and requiring oxygen supplementation or ventilatory support. Suggested steroid regimens:
  - If steroids are not indicated for fetal lung maturity, oral prednisolone 40 mg daily (or oral methylprednisolone 32 mg daily), or IV hydrocortisone 80 mg twice daily, for 10 days or until discharge, whichever is sooner. IV methylprednisolone is an alternative especially for intensive care units more familiar with this preparation (e.g. 1 mg/kg twice daily for 5–7 days, weaned to 1 mg/kg once daily for 5–7 days).
  - If steroids are indicated for fetal lung maturity, intramuscular dexamethasone 12 mg twice (24 hours apart), immediately followed by oral prednisolone 40 mg once a day, or IV hydrocortisone 80 mg twice daily, to complete a total of 10 days or until discharge, whichever is sooner.
  - Those who are postpartum and who choose not to breastfeed, or who are unable to breastfeed, would be suitable for dexamethasone in line with the RECOVERY trial (6 mg once a day for up to 10 days).

• The interleukin-6 receptor antagonist (anti-IL6) Tocilizumab has been shown to improve outcomes, including survival, in hospitalised patients with hypoxia (oxygen saturation below 92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein at or above 75 mg/l). Although data for the use of tocilizumab in pregnancy in this situation are limited, there is currently no evidence that tocilizumab is teratogenic or fetotoxic. For women meeting the criteria above (hypoxic with systemic inflammation), the use of tocilizumab should be strongly considered. It is recommended that any decision to treat with anti-IL6 agents should be taken by an MDT, including obstetric and infection specialists, and given if the benefits outweigh the risks. When tocilizumab is unavailable it is reasonable to consider sarilumab though, again, the evidence in pregnancy is limited.

• Strongly consider treatment with monoclonal antibodies in pregnant and breastfeeding women if they are symptomatic, hospitalised with COVID-19 infection, and have no SARS-CoV-2 antibodies. The decision about which preparation to offer may depend on the variant; the most up-to-date information can be found at the MHRA Central Alerting System.

• Sotrovimab, also a neutralising monoclonal antibody, is recommended for pregnant women in the community who have recent-onset PCR-confirmed SARS-CoV-2 infection and are at very high risk (e.g. those with active malignancy, primary immune
Adequate early oxygen therapy is essential. There is evidence that ECMO is either not being considered or being inappropriately discounted and there is now a UK NHS consensus statement for COVID-19 patients on the criteria for considering, and referring to, an ECMO centre.

There is no evidence to guide prophylactic LMWH dosing in obstetric patients, i.e. whether to prescribe the usual prophylactic dose, a higher prophylactic dose or a therapeutic dose. There is some evidence to guide dosing in other groups of patients, which may not translate to an obstetric population, and this is also summarised in the NICE COVID-19 rapid guideline: managing COVID-19.

The interim results of the RECOVERY trial demonstrated a significant reduction in 28-day mortality for individuals with COVID-19 requiring oxygen who were given corticosteroid therapy (age-adjusted rate ratio 0.83, 95% CI 0.75–0.93; \( P < 0.001 \)). The RECOVERY trial protocol for pregnancy recommends oral prednisolone 40 mg once daily, and, in women unable to take oral medicine, IV hydrocortisone 80 mg twice daily instead of dexamethasone treatment.

Unlike dexamethasone, prednisolone and hydrocortisone are extensively metabolised in the placenta with minimal transfer to the fetus.

While the neonatal benefits of antenatal corticosteroids (betamethasone and dexamethasone) are well-established when administered to women at risk of imminent preterm birth (NICE NG25), exposure to repetitive doses of steroids is associated with adverse neonatal outcomes. It is, therefore, recommended that if corticosteroids are not indicated for fetal lung maturity, oral prednisolone 40 mg once a day, or IV hydrocortisone 80 mg twice daily, should be administered for 10 days or up to discharge, whichever is sooner.
If steroids are indicated for fetal lung maturity, intramuscular dexamethasone 12mg x2 (24 hours apart), then oral prednisolone 40 mg once a day, or IV hydrocortisone 80 mg twice daily, should be given for 10 days or up to discharge, whichever is sooner. Methylprednisolone is commonly used in the intensive care setting and may be used for those more familiar with its administration. A reasonable dose would be oral methylprednisolone 32 mg daily, or it may be given IV (e.g. 1 mg/Kg twice daily IV for 5–7 days, weaned to 1 mg/Kg once a day for 5–7 days).

Anti-IL6 agents, tocilizumab and sarilumab, have been investigated on adult patients with COVID-19, administered within 24 hours of commencing organ support in an intensive care unit. It was reported that anti-IL6 agents decreased hospital mortality and reduced progression to intubation, extracorporeal membrane oxygenation, or death. Another study investigating tocilizumab in unwell patients with COVID-19 did not show these favourable outcomes and a need for caution in the use of tocilizumab in unwell patients with COVID-19 has been proposed. Encouragingly, results from the RECOVERY trial investigating the use of tocilizumab in patients admitted to hospital with COVID-19 have shown that tocilizumab improved survival and other clinical outcomes in patients with hypoxia and systemic inflammation (C-reactive protein at or above 75 mg/l). These benefits were seen regardless of the level of respiratory support. Drug registries on the use of tocilizumab in pregnancy have limited numbers but show no evidence of harm. Tocilizumab is excreted in very low levels in breast milk. Any decision to treat pregnant or postnatal women with anti-IL6 agents should be taken by an MDT and, when feasible, in discussion with the woman.

When tocilizumab is unavailable or cannot be used, it is reasonable to consider using sarilumab in severe cases of COVID-19. Comparable efficacy between tocilizumab and sarilumab has been demonstrated in an international clinical trial, exploring overall support and organ free survival in severe COVID-19. The evidence base for sarilumab compared to placebo in COVID-19 is less robust than that for tocilizumab. In patients with severe COVID-19 requiring supplemental oxygen or mechanical ventilation two studies administering either 200mg or 400mg sarilumab showed non-significant decreases in duration of organ support or mortality rates. A pre-publication meta-analysis of these studies by NICE, highlights a dose of 400mg sarilumab is associated with a reduction in mortality at day 60 compared to placebo (Risk Ratio: 0.78 95% CI 0.64 – 0.94 [pre-publication]) but at no other timepoints. These results were derived from a predominantly male and middle-aged population, with low levels of corticosteroid co-administration in the largest of the two studies. This uncertain transferability of sarilumab to a pregnant population, does not consider its safety profile. There has been no research examining the safety of sarilumab in pregnancy or during breastfeeding. Decisions to use sarilumab should be made with multi-disciplinary input, and ideally within the context of a well conducted clinical trial.

There is a question around the timing of BCG vaccination for the babies of mothers who have received tocilizumab. In general, mothers who have been taking biologics throughout pregnancy are advised to defer BCG vaccination until the baby is aged 6 months because of a theoretical possibility of neonatal or infant immunosuppression. There is limited evidence for this recommendation, however, and there are data to suggest that babies born to these mothers are in fact able to mount a good immune response. Tocilizumab is only used as
a short dose, is extremely unlikely to affect the baby, and delay in BCG immunisation may
cause more harm than good. It therefore seems reasonable, after an informed discussion, to
offer BCG immunisation at the usual time, particularly if the tocilizumab was given early in
pregnancy. Note that casirivimab plus imdevimab (Ronapreve®) is not an immunosuppressant
and maternal administration does not require any changes to the vaccine schedule.

Neutralising monoclonal antibodies are synthetic antibodies that bind to the spike protein of
SARS-CoV-2, preventing subsequent entry of the virus into the host cell and its replication.
This effectively ‘neutralises’ the virus particle. Data on the safety of monoclonal antibodies in
pregnancy has been evaluated in earlier cohort and registry studies, indicating that exposure
in pregnancy is not associated with an increased risk for adverse pregnancy outcomes
when compared to unexposed pregnancies with the same underlying medical diseases. This
is supported by a consensus report on 69 immunosuppressives and biologics during
pregnancy and lactation, with no evidence of elevated adverse pregnancy outcomes or
malformation risks, and in a small observational series’ of tocilizumab in pregnant women
with COVID-19.

There are two neutralising monoclonal antibodies with conditional marketing authorisation
for use in the UK in the treatment of COVID-19. These are casirivimab plus imdevimab
(Ronapreve®) and sotrovimab (Xevudy).

Results from the RECOVERY trial indicate that casirivimab plus imdevimab reduced the
relative risk of mortality by 20% (24% in the treatment group versus 30% in those who
received standard care alone) in hospitalised patients with COVID-19 who had not mounted
an antibody response of their own to the virus (were seronegative/anti-S antibody negative)
at the time of treatment. The RECOVERY trial included women who were pregnant or
breastfeeding, with no serious adverse events reported. There are no data for sotrovimab in
pregnant women. The recommendation for sotrovimab and casirivimab plus imdevimab states
they may be used during pregnancy where the expected benefit to the mother justifies the
risk to the fetus.

Emerging evidence indicates that casirivimab plus imdevimab has significantly decreased
efficacy against the omicron variant.

Data published have shown IV sotrovimab administered to non-hospitalised patients with
mild-to-moderate disease with at least one risk factor for disease progression resulted in a
relative risk reduction in hospitalisation or death by 85%.

Eligibility criteria have been published by the MHRA for advice on the use of neutralising
monoclonal antibodies in hospital/community settings and can be found in detail by accessing
the Central Alerting System, which is regularly updated. Dose scheduling and exemptions can
also be accessed using this link.
Since the safety of remdesivir in pregnancy is largely unknown, consider these two criteria when making decisions about its use in pregnant women with COVID-19:

- consider on an individual basis for those who are stable but not improving,
- consider more strongly in those who are deteriorating.

In breastfeeding women with COVID-19, the use of remdesivir should be restricted to women where benefit has been reported (hospitalised patients requiring oxygen therapy, especially early in disease course, and not in patients who are mechanically ventilated). Any decision to treat with remdesivir should be taken by an MDT and, when feasible, in discussion with the woman.

Molnupiravir is an oral antiviral medicine which has been shown to significantly reduce the chance of hospitalization or death at a planned interim analysis of the Phase 3 MOVe-OUT trial in at risk, non-hospitalized adult patients with mild-to-moderate COVID-19. Eligibility criteria required that all patients had laboratory-confirmed mild-to-moderate COVID-19, with symptom onset within 5 days of study randomization, and to have a significant risk factor (e.g. obesity, diabetes or heart disease). Molnupiravir is not recommended in pregnancy, however, until further studies have established its effectiveness and safety. Pregnant women who have received molnupiravir at any stage in pregnancy should be discussed with UKTIS for further advice (www.uktis.org, 0344 892 0909 Mon-Fri 9am-5pm) and follow up as per MHRA advice.

A review of the literature on Ivermectin does not show benefit for Ivermectin in either hospital or community settings, and it should only be considered as part of a well conducted clinical trial.

Pregnant women can be enrolled in the RECOVERY trial. Where therapies or participation in trials are offered, they should also be considered for and offered to pregnant women.
7. Postnatal care
7. Postnatal care

Routine postnatal care for women in accordance with national guidelines and the RCOG guidance for maternity service organisation in areas of high-risk prevalence/local lockdown during the COVID-19 pandemic should be followed. As prevalence subsides, strategies will be needed to ensure that previous evidence-based services put on hold or amended are reinstated.

7.1 How should neonatal care for the baby be provided during the COVID-19 pandemic?

Advice

- Women and their healthy babies should remain together in the immediate postpartum period, if they do not otherwise require maternal critical care or additional neonatal care.

- Women with suspected or confirmed COVID-19 should remain with their baby and be supported to practise skin-to-skin/kangaroo care, if the newborn does not require additional medical care at this time.

- Adopt a precautionary approach for a woman who has suspected or confirmed COVID-19 and whose baby needs to be cared for in the neonatal unit, to minimise any risk of women-to-infant or women-to-staff transmission; at the same time, involve parents in decisions, mitigating potential problems for the baby’s health and wellbeing and for breastfeeding, bonding and attachment.

- If an asymptomatic mother who has tested SARS-CoV-2 positive on admission requires to remain in hospital for more than 10 days for a non-COVID related condition, national advice is that they should remain in isolation for 14 days. This advice is in regard to potential increased vulnerability of other adult patients; individual neonatal units must consider the risks and benefits of allowing the mother to visit the neonatal unit between 11 and 14 days.

- Women should be supported to make an informed decision about how they feed their baby. Women who choose to breastfeed should be supported to do so, even if they have probable or confirmed COVID-19.

- Babies born to SARS-CoV-2 positive women should be cared for as per guidance from the British Association of Perinatal Medicine (BAPM).

- Specific guidance on neonatal resuscitation during the COVID-19 pandemic is available from the Resuscitation Council.
Summary of evidence and rationale for recommendation

There are limited data to guide the neonatal care of babies of women who tested positive for SARS-CoV-2 in the third trimester. A prospective cohort study in the UK investigating SARS-CoV-2 infection in the first 28 days of life found neonatal infection is uncommon (66 babies with confirmed SARS-CoV-2 infection [incidence 5.6/10 000 livebirths, 95% CI 4.3–7.1], of whom 28 [42%] had severe neonatal SARS-CoV-2 infection [incidence 2.4/10 000 livebirths, 95% CI 1.6–3.4]), and infection with neonatal admission following birth to a woman with perinatal SARS-CoV-2 infection was unlikely; consequently, this study supported guidance to avoid separation of woman and baby.

The RCPCH/BAPM and the RCM have provided separate guidance on this topic, with accompanying FAQs produced by BAPM, as well as various COVID-19 resources on newborn life support from the Resuscitation Council.

7.2 What should women and families be advised regarding infant feeding during the COVID-19 pandemic?

Advice

• Breastfeeding should be recommended to all women in line with usual guidance.

• Individualised support, advice and guidance on breastfeeding should be offered to all women who wish to breastfeed. Remote support for breastfeeding should be signposted to all women.

• Women and their families should be informed that infection with COVID-19 is not a contraindication to breastfeeding.

• Women and their families should be supported to make a fully informed choice on how to feed their baby. The potential risks and benefits of feeding the baby in close proximity to individuals with suspected or confirmed COVID-19 should be discussed.

• When a woman is not well enough to care for her own infant or where direct breastfeeding is not possible, the woman should be supported to express her breast milk by hand or using a breast pump, and/or offer access to donor breast milk. Formula feeding is entirely acceptable if this is the mother’s choice.

• The following RCPCH/BAPM precautions should be taken to limit viral spread to the baby:
  - Wash hands before touching the baby, breast pump or bottles.
  - Avoid coughing or sneezing on the baby while feeding.
  - Consider wearing a face covering or fluid-resistant facemask while feeding or caring for the baby.
Summary of evidence and rationale for guidance

The long term well-established benefits of breastfeeding are highly likely to outweigh any potential risks of transmission of the virus through breast milk.\textsuperscript{145} A systematic review\textsuperscript{146} found that in 24 cases breast milk tested negative for COVID-19; however, given the small number of cases, this evidence should be interpreted with caution. A cohort study\textsuperscript{84} demonstrated both skin-to-skin and breastfeeding are not associated with increased neonatal infection with SARS-CoV-2. Similar findings exist in smaller studies which supports the guidance. More recently, studies have reported presence of antibodies in breast milk from previous COVID-19 infection as well as COVID vaccination.\textsuperscript{206,223–225} This suggests a mechanism of passive immunity from breastfeeding mothers to their babies.

In light of the evidence to date,\textsuperscript{143} the benefits of breastfeeding outweigh any potential risks of transmission of the virus through breast milk, and this is a view supported by the UNICEF UK Baby Friendly Initiative, which has been widely implemented in the UK.\textsuperscript{144}

The main risk of breastfeeding is the close contact between the baby and the woman, who is likely to share infective respiratory droplets.

Specific recommendations on minimising the risk of COVID-19 transmission when feeding babies has been developed by the BAPM and RCM.\textsuperscript{141,142} The NHS has general guidance on sterilising bottles in order to protect babies against infections.

Face coverings are not appropriate for babies. The UK government advice for using face coverings is directed towards adults and children aged 11 and over.\textsuperscript{147}

7.3 What are the considerations for postnatal care for women and babies following admission with COVID-19?

General advice

- Postnatal care should be provided as per NICE NG194 Postnatal care.
- Following childbirth, effective contraception should be discussed with and offered to all women prior to discharge from maternity services.
Advice

- When a woman with COVID-19 has given birth, all members of her household are recommended to self-isolate at home for 10 days.

- Women and their families should be advised about safe sleeping and a smoke-free environment, along with provision of clear advice about careful hand hygiene and infection control measures when caring for and feeding the baby.

- Families should be guided on how to identify signs of illness in their newborn or worsening of the woman’s symptoms, and should be provided with appropriate contact details if they have concerns or questions about their baby’s wellbeing. NHS leaflets, providing this information, are also available.

- Women should be advised that if they or their babies require readmission for postnatal obstetric or neonatal care during a period of self-isolation for suspected or confirmed COVID-19 they should telephone their local unit ahead of arrival.

- Women who have recently given birth and test positive for COVID-19 should receive all recommended advice, guidance and support in relation to their postnatal physical and mental health and wellbeing and care of their newborn baby. This includes necessary in-person assessments using appropriate PPE.

- In-person home or clinic appointments should be offered to allow an overall assessment of the physical and psychological health and wellbeing of the woman and her baby.

- In some areas, and where appropriate, some postnatal care will need to be via telephone or video link because of local infection rates and staff absence, but considerations should be made upon individual circumstances. This should be discussed with women and families.

- All pregnant women who have been hospitalised and have had confirmed COVID-19 should be offered thromboprophylaxis for 10 days following hospital discharge. A longer duration of thromboprophylaxis should be considered for women with persistent morbidity.

- For advice about neonatal BCG vaccination following maternal tocilizumab and Ronapreve, see section 6.3.

Summary of evidence and rationale for guidance

The BAPM has published guidelines on the neonatal care of babies born to women with COVID-19. The advice is for households to isolate for 10 days after the birth of a baby born to a woman who is infected with SARS-CoV-2 is to ensure a full period of isolation in case of incubation of the virus in the baby. This advice stands for women who are discharged home with their
baby following an uncomplicated delivery but who have tested positive for COVID-19 in the previous 14 days.

Mother’s who are symptomatic with confirmed COVID-19, and whose baby is on NNU, should not be permitted on the unit for 14 days following the onset of symptoms. They should also be symptom free before being allowed access. Mothers who are symptomatic and awaiting PCR test results should not be permitted access to NNU whilst awaiting their results. If their PCR is negative, they may be permitted access as normal according to their local hospital guidelines.

Mothers who have tested positive for COVID-19 through routine screening, but remain asymptomatic, should complete a period of 10 days isolation if discharged home and be permitted access to NNU after this time. If an asymptomatic mother who has tested SARS-CoV-2 positive on admission requires to remain in hospital for more than 10 days for a non-COVID related condition, national advice is that they should remain in isolation for 14 days. This advice is in regard to potential increased vulnerability of other adult patients; individual neonatal units must consider the risks and benefits of allowing the mother to visit the neonatal unit between 11 and 14 days.

**Guidance on the provision of contraception by maternity services after childbirth during the COVID-19 pandemic** has been produced jointly by the Faculty of Sexual and Reproductive Health, the RCOG and the RCM.

Recommendations on postnatal care should be maintained as per the NICE NG194 *Postnatal care*.148
Acknowledgements

RCOG COVID-19 guidance cell is comprised of:

Dr Edward Morris (President, RCOG), Professor Tim Draycott (Vice President for Clinical Quality, RCOG), Dr Pat O’Brien (Vice President for Membership, RCOG), Dr Brian Magowan (COVID Guidance Development Lead), Dr Mary Ross-Davie (Director for Scotland, RCM), Dr Corinne Love (Senior Medical Officer, Obstetrics, the Scottish Government), Dr Elizabeth Layden (COVID Clinical Fellow), Dr Maria Crouch (COVID Clinical Fellow), Dr Hannah Ribbons (RCOG COVID Clinical Fellow), Dr Michael Rimmer (COVID Clinical Fellow), Dr Amar Karia (Clinical Obstetric Fellow, RCOG), Louise Thomas (Heads of Quality Improvement, RCOG), Emma Gilgynn-Jones (Director of Media and PR, RCOG), Hannah Gurney (RCOG COVID Clinical Fellow), Dr Ayisha Ashmore, Professor Lucy Chappell, Dr Edward Morris, Dr Ayisha Ashmore, Professor Adam Balen, Dr Helen Campbell, Sophie Cooper, Dr Catherine Coyle, Dr Christine Ekechi, Emma Gilgynn-Jones, Hannah Gurney, Professor Paul Heath, Dr Ken Hodson, Miss Fatima Husain, Sarah James, Karen Jewell, Dr Jennifer Jardine, Professor Chrissie Jones, Dr Amar Karia, Professor Marian Knight, Dr Alison Little, Clare Livingstone, Dr Corinne Love, Dr Sarah Mee, Dr Janet Nooney, Dr Heather Payne, Jenny Priest, Charlie Podschie, Dr Luke Richardson, Dr Mike Shea, Mr Nigel Simpson, Dr Judith Standing, Dr Victoria Tzortziou-Brown.

We also wish to acknowledge the contributions of colleagues from the RCOG Digital, External Affairs and Clinical Quality teams.

We wish to acknowledge the contributions of the following current and previous members of the RCOG/RCM vaccination subgroup:

Dr Pat O’Brien, Dr Mary Ross Davie, Professor Lucy Chappell, Dr Edward Morris, Dr Ayisha Ashmore, Professor Adam Balen, Dr Helen Campbell, Sophie Cooper, Dr Catherine Coyle, Dr Christine Ekechi, Emma Gilgynn-Jones, Hannah Gurney, Professor Paul Heath, Dr Ken Hodson, Miss Fatima Husain, Sarah James, Karen Jewell, Dr Jennifer Jardine, Professor Chrissie Jones, Dr Amar Karia, Professor Marian Knight, Dr Alison Little, Clare Livingstone, Dr Corinne Love, Dr Sarah Mee, Dr Janet Nooney, Dr Heather Payne, Jenny Priest, Charlie Podschie, Dr Luke Richardson, Dr Mike Shea, Mr Nigel Simpson, Dr Judith Standing, Dr Victoria Tzortziou-Brown.

The following external experts contributed to the guidance:

Dr Matthew Jolly and Dr Misha Moore at NHS England, Professor Beverley Hunt, Professor Catherine Nelson-Piercy, Professor Rezan Abdulkadir, Dr Peter MacCallum, Dr Louise Bowles and Dr Shohreh Beski, Dr Margaret Blott, Dr Arlene Wise, Professor Lucy Chappell, Dr Anita Banerjee, Dr Guy Glover and staff at Guy’s and St Thomas’ NHS Foundation Trust, Professor Marian Knight at the University of Oxford, Dr Alison Wright and Rebeca Wilson-Crelin at NHS England and Improvement, Katie De Freitas-Merchant at the Maternal and Neonatal Safety Improvement Programme, Professor Russell Viner and Dr David Evans on behalf of the Royal College of Paediatrics and Child Health, Dr Fiona Donald and Dr Nuala Lucas on behalf of the Obstetric Anaesthetists Association and Royal College of Anaesthetists, Dr Giles Berrisford on behalf of the Royal College of Psychiatrists, Professor Asma Khalil, Dr Lucy Mackillop, Dr Charlotte Frise, Dr Toni Hazell, Dr Ed Mullins, Emma Crookes and Shaiata Gohir on behalf of the RCOG Women’s Network, Dr Benjamin Black, Zeenath Uddin, Mr Kim Hinshaw from the British Maternal & Fetal Medicine Society, Professor Donald Peebles from University College Hospitals NHS Foundation Trust, Professor Justin Clarke from the British Society for Gynaecological Endoscopy, Jaki Lambert at the Scottish Government, Dr Fiona Donald on behalf of the Royal College of Anaesthetists and Dr Nuala Lucas from the Obstetric Anaesthetists Association, Louise Page from the British Intrapartum Care Society, Dr Jennifer Jardine, Dr Chrissie Jones at the University of Southampton, Dr Peter MacCallum at Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Dr Helen Mactier, on behalf of the British Association of Perinatal Medicine, Dr Sarah Stock and Professor James Boardman, Edinburgh, Dr Victoria Male, Imperial College London, Dr Katie Cranfield, Newcastle, Dr Stephen Webb, President Intensive Care Society, Dr Deborah Horner, Bradford NHS Trust, Dr Tony Kelly National Clinical Advisor for Maternal and Neonatal Safety Improvement Programme at NHS England and Improvement and members of the RCOG Guidelines Committee.
These individuals were, but are not currently, members of the guidance cell and have contributed to earlier versions of this document:

Dr Jennifer Jardine (Clinical Fellow, RCOG), Dr Sophie Relph (Clinical Fellow, RCOG), Dr Andrew Thomson (COVID Guidance Development Lead, RCOG), Dr Jahnvi Daru (Honorary Clinical Fellow, RCOG), Dr Christine Ekechi (Honorary Clinical Fellow, RCOG), Dr Gemma Goodyear (Clinical Fellow, RCOG), Dr Anushka Tirlapur (Honorary Clinical Fellow, RCOG), Dr Sayaka Okano (Honorary Clinical Fellow, RCOG), Dr Michal Shea (Honorary Clinical Fellow, RCOG), Lara Waite (Clinical Midwivery Fellow, RCOG), Dr Aiysha Ashmore (Clinical Fellow, RCOG), Anita Powell (Senior Director for Clinical Quality, RCOG), Gemma Thurston (Business Manager, RCOG), Stephen Hall (Political Advisor to the President, RCOG), Gozde Zorlu (Media and PR Manager, RCOG) and Sophie Cooper (Business Coordinator, RCOG).
## Appendix I: Summary of previous updates

<table>
<thead>
<tr>
<th>Version</th>
<th>Date</th>
<th>Summary of changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>13/03/2020</td>
<td>1.2: At the time of writing, Public Health Wales are aligning with Public Health England on case definitions, assessment, infection prevention and control and testing. We will update this guidance if these changes</td>
</tr>
<tr>
<td>2</td>
<td>13/03/2020</td>
<td>2.2: Updated to reflect PHE and health protection advice as per 13.03.20, in particular to use online symptom checkers and to treat all individuals with symptoms as possibly having COVID-19.</td>
</tr>
<tr>
<td>2</td>
<td>13/03/2020</td>
<td>3.2: Sentence on who to test updated to reflect advice to test women with symptoms suggestive of COVID-19 who require admission.</td>
</tr>
<tr>
<td>2</td>
<td>13/03/2020</td>
<td>3.6.4 and 3.6.5: Updated to suggest considering delay of elective caesarean birth or induction for women with symptoms suggestive of COVID-19 as well as those with confirmed COVID-19.</td>
</tr>
<tr>
<td>2</td>
<td>13/03/2020</td>
<td>3.8: Infant feeding modified from recommendation to wear a face mask to try and avoid coughing or sneezing on the baby, and consider wearing face mask where available.</td>
</tr>
<tr>
<td>2</td>
<td>13/03/2020</td>
<td>5 (new). New section - Advice for pregnant healthcare professionals.</td>
</tr>
<tr>
<td>2</td>
<td>13/03/2020</td>
<td>Appendix 1: Flow chart amended to reflect modified PHE guidance.</td>
</tr>
<tr>
<td>3</td>
<td>17/03/2020</td>
<td>2: Advice for Health Professionals to share with Pregnant Women updated to reflect current guidelines.</td>
</tr>
<tr>
<td>3</td>
<td>17/03/2020</td>
<td>3: New section added on Advice for all midwifery and obstetric services.</td>
</tr>
<tr>
<td>3</td>
<td>17/03/2020</td>
<td>4.1: General advice to services providing care to pregnant women updated to reflect advice from chief medical officer on 16/3/20.</td>
</tr>
<tr>
<td>3</td>
<td>17/03/2020</td>
<td>4.1: Advice on cleaning ultrasound equipment added, and reference added.</td>
</tr>
<tr>
<td>3</td>
<td>17/03/2020</td>
<td>4.5: Linked to new national guidance on the actions required when a COVID-19 case was not diagnosed on admission</td>
</tr>
<tr>
<td>3</td>
<td>17/03/2020</td>
<td>4.6.2: Recommendations added: There is evidence of household clustering and household co-infection. Asymptomatic birth partners should be treated as possibly infected and asked to wear a mask and wash their hands frequently. If symptomatic, birth partners should remain in isolation and not attend the unit. The use of birthing pools in hospital should be avoided in suspected or confirmed cases, given evidence of transmission in faeces and the inability to use adequate protection equipment for healthcare staff during water birth.</td>
</tr>
<tr>
<td>3</td>
<td>17/03/2020</td>
<td>4.6.2: Advice about Entonox changed to There is no evidence that the use of Entonox is an aerosol-prone procedure Entonox should be used with a single-patient microbiological filter. This is standard issue throughout maternity units in the UK.</td>
</tr>
<tr>
<td>3</td>
<td>17/03/2020</td>
<td>4.6.4: Anaesthetic management for women with symptoms or confirmed COVID-19, which was previously in this guidance, has been removed and external links provided</td>
</tr>
<tr>
<td>Date</td>
<td>Section</td>
<td>Changes</td>
</tr>
<tr>
<td>------------</td>
<td>---------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>17/03/2020</td>
<td>4.7.1</td>
<td>Statement inserted ‘Chest imaging, especially CT chest, is essential for the evaluation of the unwell patient with COVID-19 and should be performed when indicated and not delayed due to fetal concerns.’</td>
</tr>
<tr>
<td>17/03/2020</td>
<td>Updated</td>
<td>to reflect current public health guidance on self-isolation and social distancing.</td>
</tr>
<tr>
<td>17/03/2020</td>
<td>4.7.1</td>
<td>Advice on neonatal management and testing has been removed. Please refer to RCPCH guidance.</td>
</tr>
<tr>
<td>17/03/2020</td>
<td>6</td>
<td>Advice for healthcare professionals updated in line with Chief Medical Officer statement on Monday 16 March.</td>
</tr>
<tr>
<td>21/03/2020</td>
<td>6</td>
<td>Section on ‘Occupational health advice for employers and pregnant women during the COVID-19 pandemic’ added, replacing the previous section 6 on ‘Information for Healthcare Professionals’. Section includes specific recommendations for healthcare professionals.</td>
</tr>
<tr>
<td>21/03/2020</td>
<td>1.3-1.4</td>
<td>Additional information added on the susceptibility of pregnant women to COVID-19 infection.</td>
</tr>
<tr>
<td>21/03/2020</td>
<td>2</td>
<td>Additional information on social distancing for pregnant women added, particularly specifying stringent adherence to recommendations for women &gt;28 weeks gestation</td>
</tr>
<tr>
<td>21/03/2020</td>
<td>4.7</td>
<td>New section added on specific recommendations for PPE during labour and birth.</td>
</tr>
<tr>
<td>21/03/2020</td>
<td>1</td>
<td>Addition of information and links for the UKOSS reporting system.</td>
</tr>
<tr>
<td>21/03/2020</td>
<td>All</td>
<td>General proofread and editorial changes</td>
</tr>
<tr>
<td>21/03/2020</td>
<td>6</td>
<td>Page 36 title changed to ‘Occupational health advice for employers and pregnant women during the COVID-19 pandemic’</td>
</tr>
<tr>
<td>26/03/2020</td>
<td>4.1</td>
<td>Chapter 6: ‘Occupational health advice for employees and pregnant women during the COVID-19 pandemic’ has been removed from this general guidance on pregnancy and COVID-19 infection, and published as a separate document given the distinct audience for the occupational health advice.</td>
</tr>
<tr>
<td>26/03/2020</td>
<td>4.7.3</td>
<td>On Personal Protective Equipment updated in line with NHS England guidance</td>
</tr>
<tr>
<td>28/03/2020</td>
<td>1.3</td>
<td>Section updated to include new evidence on possible vertical transmission</td>
</tr>
<tr>
<td>28/03/2020</td>
<td>2.2</td>
<td>Sentence added on the major new measures announced by government for pregnant women with co-existing significant congenital or acquired heart disease.</td>
</tr>
<tr>
<td>28/03/2020</td>
<td>2.3</td>
<td>Section updated to emphasise the need to attend maternity care.</td>
</tr>
<tr>
<td>28/03/2020</td>
<td>3</td>
<td>General advice for antenatal care extended to include considerations for vulnerable women. Section also added on general advice regarding intrapartum services.</td>
</tr>
<tr>
<td>28/03/2020</td>
<td>3.1</td>
<td>Specific advice added regarding the cessation of carbon monoxide monitoring in pregnancy, following advice from the National Centre for Smoking Cessation and Training.</td>
</tr>
<tr>
<td>28/03/2020</td>
<td>4</td>
<td>Scotland specific links to Health Protection Scotland removed after confirmation from the Scottish government that National links from gov.uk should be used.</td>
</tr>
<tr>
<td>28/03/2020</td>
<td>4.3.6</td>
<td>Scotland specific links to Health Protection Scotland removed after confirmation from the Scottish government that National links from gov.uk should be used.</td>
</tr>
<tr>
<td>28/03/2020</td>
<td>4.7.3</td>
<td>Scotland specific links to Health Protection Scotland removed after confirmation from the Scottish government that National links from gov.uk should be used.</td>
</tr>
<tr>
<td>28/03/2020</td>
<td>4.7.6</td>
<td>Advice on PPE considerations for caesarean birth and general advice for obstetric theatres moved to new section ‘Specific peri-operative advice for pregnant women with suspected/confirmed COVID-19 requiring surgical intervention’</td>
</tr>
<tr>
<td>Date</td>
<td>Page</td>
<td>Section</td>
</tr>
<tr>
<td>------------</td>
<td>------</td>
<td>---------</td>
</tr>
<tr>
<td>28/03/2020</td>
<td>5</td>
<td>4.8.1</td>
</tr>
<tr>
<td>28/03/2020</td>
<td>5</td>
<td>4.8.1</td>
</tr>
<tr>
<td>28/03/2020</td>
<td>5</td>
<td>4.9.2</td>
</tr>
<tr>
<td>28/03/2020</td>
<td>5</td>
<td>4.10</td>
</tr>
<tr>
<td>28/03/2020</td>
<td>5</td>
<td>5.1</td>
</tr>
<tr>
<td>03/04/2020</td>
<td>6</td>
<td>Throughout</td>
</tr>
<tr>
<td>03/04/2020</td>
<td>6</td>
<td>1.2</td>
</tr>
<tr>
<td>03/04/2020</td>
<td>6</td>
<td>1.4</td>
</tr>
<tr>
<td>03/04/2020</td>
<td>6</td>
<td>3.2</td>
</tr>
<tr>
<td>03/04/2020</td>
<td>6</td>
<td>3.4</td>
</tr>
<tr>
<td>03/04/2020</td>
<td>6</td>
<td>3.5</td>
</tr>
<tr>
<td>03/04/2020</td>
<td>6</td>
<td>4.1</td>
</tr>
<tr>
<td>03/04/2020</td>
<td>6</td>
<td>4.3</td>
</tr>
<tr>
<td>03/04/2020</td>
<td>6</td>
<td>4.9</td>
</tr>
<tr>
<td>09/04/2020</td>
<td>7</td>
<td>1.4</td>
</tr>
<tr>
<td>09/04/2020</td>
<td>7</td>
<td>1.4</td>
</tr>
<tr>
<td>09/04/2020</td>
<td>7</td>
<td>2.3</td>
</tr>
<tr>
<td>09/04/2020</td>
<td>7</td>
<td>3.1</td>
</tr>
<tr>
<td>09/04/2020</td>
<td>7</td>
<td>3.2</td>
</tr>
<tr>
<td>09/04/2020</td>
<td>7</td>
<td>3.2</td>
</tr>
<tr>
<td>09/04/2020</td>
<td>7</td>
<td>3.3</td>
</tr>
</tbody>
</table>
Section 4.2 renamed ‘Women with unconfirmed COVID-19 but symptoms suggestive of possible infection’ to allow for inclusion of new recommendations on women who call the maternity unit with possible COVID-19 infection (not just attend in person).

Additional recommendations made to consider usual differential diagnoses in women who call the maternity unit to report a new fever/cough/respiratory symptoms.

New subsection added on the care of pregnant women who are self-isolating at home with suspected COVID-19.

Changed to subsection 4.3.3 (subsequent subsections re-numbered).

New recommendations re. prophylactic low molecular weight heparin to reduce risk of venous thromboembolism with COVID-19 infection in pregnancy, and to consider pulmonary embolism if women with COVID-19 suddenly deteriorate.

Statement on calling neonatal team early to inform them of imminent birth of a baby to a woman with COVID-19 moved to section 4.5, because it applies to all cases of COVID-19, not just in women with severe disease.

New paragraph on the quality of the available evidence and resultant classification of the advice.

New evidence included on the risk of COVID-19 in the woman, including a case series of pregnant women attending two maternity units in New York, who were screened for COVID-19 on arrival, the inclusion of the first report of maternal death directly attributed to COVID-19 in scientific literature and an update to the ICNARC data.

Restructured, including some new subtitles to organise and break up the text.

Renamed ‘risk of venous thromboembolism’.

Section restructured for clarity.

Re-ordered the two sections within the text so that considerations for birth are written before considerations for neonatal and postnatal care.

Section re-structured. Also includes clarification that the recommendation for 10 days postnatal LMWH is regardless of mode of birth.

Table of previous updates moved to appendix 3.

Aims updated to include: The provision of safe, woman-centred care to women who are pregnant, give birth or are in the early postnatal period during the COVID-19 pandemic.

Findings of UKOSS data included in the summaries on viral transmission, effects on the woman and effects on the fetus/neonate. Where this supersedes existing references because of higher quality research or larger numbers, it has been used to replace it.

Updated information on possibility of vertical transmission to state that there are serious limitations to the available evidence.

Updated with emerging evidence on increased risk from COVID-19 to individuals with black, Asian and minority ethnic (BAME) background.

Information to share with pregnant women and their families has been removed from the guidance. All this information is also available in the RCOG information for pregnant women and their families in the COVID-19 hub. All subsequent sections have been renumbered.

Added paragraph about reducing transmission between staff.
<table>
<thead>
<tr>
<th>Date</th>
<th>Page</th>
<th>New Content</th>
</tr>
</thead>
<tbody>
<tr>
<td>13/05/2020</td>
<td>3.2</td>
<td>Statement and recommendations added: Emerging evidence suggests that individuals of black and minority ethnic (BAME) background may be at higher risk of developing severe complications of COVID-19. This may equally apply to pregnant women. We therefore advise: Women of BAME background should be opportunistically advised that they may be at higher risk of complications of COVID-19, and advised to seek help early if they are concerned about their health. Clinicians should be aware of this increased risk, and have a lower threshold to review, admit and consider multidisciplinary escalation in women of BAME background.</td>
</tr>
<tr>
<td>13/05/2020</td>
<td>2.2</td>
<td>Removed statement that further guidance on remote consultations will be published soon, and provided reference to RCM/RCOG guidance on antenatal and postnatal care.</td>
</tr>
<tr>
<td>13/05/2020</td>
<td>2.3</td>
<td>Changed the statement that units should consider reducing provision of induction of labour for indications that are not ‘strictly necessary’, to units should consider reducing induction of labour where this is not ‘medically indicated’.</td>
</tr>
<tr>
<td>13/05/2020</td>
<td>3.3</td>
<td>Reference to NHS England ‘Clinical guide for the temporary reorganisation of intrapartum maternity care during the coronavirus pandemic’ added.</td>
</tr>
<tr>
<td>13/05/2020</td>
<td>3.3</td>
<td>Statement added: ‘Care should be taken to maintain safe services which continue to offer women support and choice as far as possible at this time. In particular, women should continue to be encouraged to contact their maternity unit with concerns about their or their baby’s wellbeing. Justification should be provided for any service rationalisation required.’</td>
</tr>
<tr>
<td>13/05/2020</td>
<td>3.3</td>
<td>Statement added: ‘When reorganising services, maternity units should be particularly cognisant of emerging evidence that black, Asian and minority ethnic group (BAME) individuals are at particular risk of developing severe and life-threatening COVID-19. There is already extensive evidence on the inequality of experience and outcomes for BAME women during pregnancy and birth in the UK. Particular consideration should be given to the experience of women of BAME background and of lower socioeconomic status, when evaluating the potential or actual impact of any service change.’</td>
</tr>
<tr>
<td>13/05/2020</td>
<td>4.6</td>
<td>Recommendation to be aware that myocardial injury is common among individuals with COVID-19, and reference added to NICE Guidance on diagnosis of myocardial injury in patients with suspected or confirmed COVID-19.</td>
</tr>
<tr>
<td>13/05/2020</td>
<td>4.6</td>
<td>Title change from ‘Additional considerations in women with moderate/severe symptoms’ to ‘Women with suspected or confirmed COVID-19 and moderate/severe symptoms’, to reflect that this includes information relevant to pregnant women admitted with COVID-19 outside of obstetric services.</td>
</tr>
</tbody>
</table>
### 4.6 (Now 3.6): Recommendation added: ‘Prophylaxis for venous thromboembolism should be prescribed during admission unless contraindicated. At the time of discharge from hospital following a period of care for confirmed COVID-19 infection, all women should be prescribed at least 10 days of prophylactic LMWH.’ This is consistent with recommendations already made elsewhere in previous versions of this document.

### 4.6 (Now 3.6): Changed statement ‘Consider bacterial infection if the white blood cell count is raised (lymphocytes usually normal or low with COVID-19) and commence antibiotics’ to ‘Bacterial infection is an important differential diagnosis to COVID-19 infection. We advise blood cultures and a low threshold for antibiotics at presentation, with early review and rationalisation of antibiotics if COVID-19 is confirmed.’
# Version 10

The following Version 10 summary of changes includes an additional column to reflect significant restructure changes between version 9 and 10 of this guidance.

<table>
<thead>
<tr>
<th>Date</th>
<th>Subject</th>
<th>Summary of changes from version 9 to version 10</th>
<th>Location in v10</th>
</tr>
</thead>
<tbody>
<tr>
<td>04/06/2020</td>
<td>Introduction</td>
<td>Now incorporates the following sections from v9:</td>
<td>• Purpose and scope&lt;br&gt; • Identification and assessment of evidence&lt;br&gt; • Epidemiology&lt;br&gt; • Transmission&lt;br&gt; • Effect of COVID-19 on pregnant women&lt;br&gt; • Risk factors for hospital admission with COVID-19&lt;br&gt; • Effect of COVID-19 on the fetus</td>
</tr>
<tr>
<td>04/06/2020</td>
<td>Antenatal care during the COVID-19 pandemic</td>
<td>2.2 General advice regarding the continued provision of antenatal and postnatal services</td>
<td>2.1 What are the considerations for organisation of antenatal care during the COVID-19 pandemic?</td>
</tr>
<tr>
<td>04/06/2020</td>
<td>Antenatal care during the COVID-19 pandemic</td>
<td>2.3 General advice regarding possible service modifications during COVID-19</td>
<td>2.2 What are the considerations for antenatal appointments?</td>
</tr>
<tr>
<td>04/06/2020</td>
<td>Antenatal care during the COVID-19 pandemic</td>
<td>2.6 Smoking cessation and carbon monoxide monitoring in pregnancy</td>
<td>2.3 What are the considerations for antenatal appointments?</td>
</tr>
<tr>
<td>04/06/2020</td>
<td>Antenatal care during the COVID-19 pandemic</td>
<td>2.5 Maternal mental wellbeing</td>
<td>2.2 What are the considerations for antenatal appointments?</td>
</tr>
<tr>
<td>04/06/2020</td>
<td>Antenatal care during the COVID-19 pandemic</td>
<td>3.1 General advice for services providing care to pregnant women with suspected or confirmed COVID-19, where hospital attendance is necessary</td>
<td>2.3 How should women with suspected or confirmed COVID-19 needing hospital attendance or advice be cared for?</td>
</tr>
<tr>
<td>Date</td>
<td>Section</td>
<td>Paragraph</td>
<td>Reference</td>
</tr>
<tr>
<td>------------</td>
<td>----------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
</tr>
<tr>
<td>04/06/2020</td>
<td>Antenatal care during the COVID-19 pandemic</td>
<td>3.2 Women with unconfirmed COVID-19 but symptoms suggestive of possible infection</td>
<td>2.3 How should women with suspected or confirmed COVID-19 needing hospital attendance or advice be cared for?</td>
</tr>
<tr>
<td>04/06/2020</td>
<td>Antenatal care during the COVID-19 pandemic</td>
<td>3.3.3 Attendance for unscheduled/urgent antenatal care in women with suspected or confirmed COVID-19</td>
<td>2.3 How should women with suspected or confirmed COVID-19 needing hospital attendance or advice be cared for?</td>
</tr>
<tr>
<td>04/06/2020</td>
<td>Antenatal care during the COVID-19 pandemic</td>
<td>4.1 Antenatal care for pregnant women following self-isolation for symptoms suggestive of COVID-19</td>
<td>2.4 What are the considerations for antenatal care for women who have recovered from COVID-19?</td>
</tr>
<tr>
<td>04/06/2020</td>
<td>Antenatal care during the COVID-19 pandemic</td>
<td>4.2 Antenatal care for pregnant women following hospitalisation for confirmed COVID-19 illness</td>
<td>2.4 What are the considerations for antenatal care for women who have recovered from COVID-19?</td>
</tr>
<tr>
<td>04/06/2020</td>
<td>Venous thromboembolism prevention</td>
<td>3.3.1 Risk of venous thromboembolism</td>
<td>3.1 How should prevention of venous thromboembolism during the COVID-19 pandemic be addressed?</td>
</tr>
<tr>
<td>04/06/2020</td>
<td>Venous thromboembolism prevention</td>
<td>3.4 Women who develop new symptoms of COVID-19 during admission (antenatal, intrapartum or postnatal) Sentence on thromboprophylaxis</td>
<td>3.1 How should prevention of venous thromboembolism during the COVID-19 pandemic be addressed?</td>
</tr>
<tr>
<td>04/06/2020</td>
<td>Labour and birth</td>
<td>2.4 General advice regarding intrapartum services</td>
<td>4.4 What about birth partners during the COVID-19 pandemic?</td>
</tr>
<tr>
<td>04/06/2020</td>
<td>Labour and birth</td>
<td>Not in version 9</td>
<td>New section in version 10: 4.1 What are the considerations for labour and birth in asymptomatic women who test or have tested positive for SARS-CoV-2?</td>
</tr>
<tr>
<td>04/06/2020</td>
<td>Labour and birth</td>
<td>3.5 Women attending for intrapartum care with suspected or confirmed COVID-19</td>
<td>4.2 How should a woman with suspected/confirmed COVID-19 be looked after in labour if they are symptomatic?</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>4.5 What informed discussions should take place with women regarding timing and mode of birth during the COVID-19 pandemic?</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>4.6 What are the specific considerations for labour analgesia or anaesthesia?</td>
</tr>
<tr>
<td>04/06/2020</td>
<td>Labour and birth</td>
<td>3.7 Specific perioperative advice for healthcare professionals caring for pregnant women with suspected/confirmed COVID-19 who require surgical intervention</td>
<td>4.8 How should obstetric theatres be managed during the COVID-19 pandemic?</td>
</tr>
<tr>
<td>04/06/2020</td>
<td>Postnatal</td>
<td>3.8 Neonatal care</td>
<td>4.7 What personal protective equipment is recommended when caring for women during labour and birth?</td>
</tr>
<tr>
<td>04/06/2020</td>
<td>Postnatal</td>
<td>4.3 Postnatal care for pregnant women immediately following hospitalisation for confirmed COVID-19 illness</td>
<td>4.6 How should neonatal care for the baby be provided during the COVID-19 pandemic?</td>
</tr>
<tr>
<td>04/06/2020</td>
<td>Postnatal</td>
<td>4.3 Postnatal care for pregnant women immediately following hospitalisation for confirmed COVID-19 illness</td>
<td>6.2 What should parents/carers be advised regarding infant feeding during the COVID-19 pandemic?</td>
</tr>
<tr>
<td>04/06/2020</td>
<td>Postnatal</td>
<td>4.3 Postnatal care for pregnant women immediately following hospitalisation for confirmed COVID-19 illness</td>
<td>6.3 What are the considerations for postnatal care for women and babies following admission with COVID-19?</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Version</th>
<th>Date</th>
<th>Summary of changes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>10.1</strong></td>
<td>19/06/2020</td>
<td>1.1: Removal of ‘MERS, Middle East Respiratory Syndrome’ from the literature search strategy since it has not resulted in any new references since the first search.</td>
</tr>
<tr>
<td><strong>10.1</strong></td>
<td>19/06/2020</td>
<td>1.4: UKOSS reference changed to the published article in The BMJ.</td>
</tr>
<tr>
<td><strong>10.1</strong></td>
<td>19/06/2020</td>
<td>2.2: Advice on face masks changed to reflect national guidance from NHS England.</td>
</tr>
<tr>
<td><strong>10.1</strong></td>
<td>19/06/2020</td>
<td>4.4: Advice on number of visitors and/or birth partners for hospital inpatients changed to reflect national guidance from NHS England.</td>
</tr>
<tr>
<td><strong>10.1</strong></td>
<td>19/06/2020</td>
<td>5.2: Advice for women who are clinically deteriorating modified to include government recommendations based on the interim results of the RECOVERY trial.</td>
</tr>
<tr>
<td><strong>10.1</strong></td>
<td>19/06/2020</td>
<td>6.2: Specified that babies should not be advised to wear face masks because of the risk of suffocation.</td>
</tr>
<tr>
<td><strong>II</strong></td>
<td>24/07/2020</td>
<td>1.1: Updated methodology about search strategies and the review process.</td>
</tr>
<tr>
<td><strong>II</strong></td>
<td>24/07/2020</td>
<td>1.3: Updated evidence that there is a low rate of vertical transmission and possible transplacental transmission.</td>
</tr>
<tr>
<td><strong>II</strong></td>
<td>24/07/2020</td>
<td>1.4: Updated evidence that pregnant women are not necessarily more susceptible to SARS-CoV-2 than the general population.</td>
</tr>
<tr>
<td><strong>II</strong></td>
<td>24/07/2020</td>
<td>1.5: Updated evidence identifying the risk factors of Black, Asian and minority ethnicity (BAME), obesity and comorbidities in pregnant women admitted with COVID-19.</td>
</tr>
<tr>
<td><strong>II</strong></td>
<td>24/07/2020</td>
<td>1.6: Updated evidence on possible fetal growth restriction associated with COVID-19.</td>
</tr>
<tr>
<td>Date</td>
<td>Section</td>
<td>Advice</td>
</tr>
<tr>
<td>------------</td>
<td>-----------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>24/07/2020</td>
<td>2.1:</td>
<td>Updated advice:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Units should employ teleconferencing and videoconferencing where possible and consider which appointments can be most appropriately conducted remotely, especially in areas of local lockdown to minimise hospital attendance.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Particular consideration should be given to pregnant women who are 'shielding' or have been 'shielding'. Shared waiting areas should be avoided.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Units should appoint a named midwife or consultant to coordinate care for women forced to miss appointments due to self-isolation or a positive test.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Missed appointments should be reviewed and either rescheduled if a face-to-face review is necessary or converted to a remote appointment.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Evidence added on the possible increased incidence of stillbirths in women without symptoms suggestive of COVID-19 in the pandemic compared to pre-pandemic periods.</td>
</tr>
<tr>
<td>24/07/2020</td>
<td>2.2:</td>
<td>Updated advice:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Evidence suggests that individuals of BAME background are at higher risk of developing severe complications of COVID-19. This also applies for pregnant women. We therefore advise that:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>o Women of BAME background should be advised that they may be at higher risk of complications of COVID-19; and encouraged to seek advice without delay if they are concerned about their health.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>o Clinicians should maintain face-to-face appointments with women when there are safeguarding concerns in order to provide extra support.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>o It is recommended that women should continue to take folic acid and vitamin D supplements as per national recommendations.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>o If women or their families express concerns about their mental health or 'red flag' symptoms such as suicidal thoughts or sudden mood changes they should be supported to access urgent care by healthcare providers signposting or referring appropriately.</td>
</tr>
<tr>
<td>24/07/2020</td>
<td>2.3:</td>
<td>Amended advice:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Visitors to isolation rooms or ward cohort bays should be kept to a minimum and follow local hospital visitor policies.</td>
</tr>
<tr>
<td>24/07/2020</td>
<td>4.1:</td>
<td>Amended advice:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• For asymptomatic women who test positive for SARS-CoV-2 on admission, continuous electronic fetal monitoring (CEFM) during labour using cardiotocography (CTG) is not recommended solely for this reason, and should only be used if it is required for another reason (e.g. previous caesarean birth).</td>
</tr>
<tr>
<td></td>
<td></td>
<td>o Fetal monitoring options should be discussed with the woman, acknowledging the current uncertainties in the care of women who are asymptomatic with a positive test for SARS-CoV-2.</td>
</tr>
<tr>
<td>Date</td>
<td>Section</td>
<td>Advice</td>
</tr>
<tr>
<td>------------</td>
<td>---------</td>
<td>-------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>24/07/2020</td>
<td>4.2</td>
<td>Additional advice:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• There are no contraindications to performing a fetal blood sample or using fetal scalp electrodes.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Advice on waterbirths has been revised and moved to (new) section 4.6.</td>
</tr>
<tr>
<td>24/07/2020</td>
<td>4.3</td>
<td>Amended advice:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Informed discussions with women about fetal monitoring should acknowledge that evidence of fetal distress is based on small numbers of babies born to women symptomatic of COVID-19 and theoretical risks extrapolated from pregnancies affected by fetal growth restriction in women with other coronaviruses.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Advice removed: on birth partners being asked to remain by the woman’s bedside and not to walk around the ward/hospital.</td>
</tr>
<tr>
<td>24/07/2020</td>
<td>4.4</td>
<td>Amended advice:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• If birth partners are symptomatic or in a period of self-isolation for confirmed SARS-CoV-2 infection, they should remain in self-isolation at home and not attend the unit.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Advice removed: on birth partners being asked to remain by the woman’s bedside and not to walk around the ward/hospital.</td>
</tr>
<tr>
<td>24/07/2020</td>
<td>4.5</td>
<td>Amended advice:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Women and their families should be aware that donning PPE for emergency caesarean births is time-consuming but essential, and that this may impact on the time it takes to assist in the birth of the baby and potentially result in an adverse outcome. This should be taken into account during decision-making and ideally discussed during birth planning.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Removed advice on the use of birthing pools in hospital for women with suspected or confirmed cases of COVID-19.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Updated evidence about vertical transmission and data about donning PPE.</td>
</tr>
<tr>
<td>24/07/2020</td>
<td>4.6</td>
<td>New section ‘What are the considerations regarding waterbirth?’</td>
</tr>
<tr>
<td>24/07/2020</td>
<td>4.8</td>
<td>Amended advice:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Healthcare professionals are advised to follow national recommendations on the use of personal protective equipment in clinical settings.</td>
</tr>
<tr>
<td>24/07/2020</td>
<td>4.10</td>
<td>New section ‘What are the considerations for bereavement care during the COVID-19 pandemic?’</td>
</tr>
<tr>
<td>24/07/2020</td>
<td>5.1</td>
<td>Amended advice:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Women should be offered testing for COVID-19 if they meet the inpatient or community PHE criteria.</td>
</tr>
</tbody>
</table>
24/07/2020 5.2: Updated advice:

- A designated team member should be responsible for regularly updating the woman’s family about her progress, utilising interpreting services where necessary.
- Thrombocytopenia is associated with severe COVID-19. For women with thrombocytopenia (platelets <50 x 10^9/L) stop aspirin prophylaxis and thromboprophylaxis and seek haematology advice.
- Consider using mechanical aids (such as intermittent calf compressors) if thromboprophylaxis is paused secondary to thrombocytopenia
- Consider the use of antiviral medications, such as remdesivir, that have been shown to be potentially beneficial in COVID-19.
- If there is clinical uncertainty in whether to offer a therapy to a pregnant woman, seek advice through maternal medicine networks.

24/07/2020 6.1: Added advice:

- Women with suspected or confirmed COVID-19 should be supported and enabled to remain together with their babies when the woman is well enough, and to practice skin-to-skin/kangaroo care, if the newborn baby does not require additional medical care at this time.
- For a woman who has suspected or confirmed COVID-19 and whose baby needs to be cared for on the neonatal unit, a precautionary approach should be adopted to minimise any risk of women-to-infant transmission; at the same time, steps should be taken to involve parents in decisions, mitigating potential problems for the baby’s health and well-being and for breastfeeding and attachment.
- Women who have suspected, probable or confirmed COVID-19 should be enabled and supported to breastfeed, if this is what they choose.

24/07/2020 6.2: Title amended to: What should women and families be advised regarding infant feeding during the COVID-19 pandemic?

Added advice

- Breastfeeding is recommended for all women and newborn infants.
- Support, advice and guidance on breastfeeding should be provided to all women who choose to breastfeed
- When a woman is not well enough to care for her own infant or where direct breastfeeding is not possible, she should be supported to express her breastmilk by hand expression or by pump, and/or be offered access to donor breast milk.
### 6.3: Added advice:

- New mothers with COVID-19 still require all recommended advice, guidance and support in relation to their postnatal physical and mental health and wellbeing and care of their newborn.
- Postnatal care should be provided as per national guidance. Face-to-face home or clinic appointments are required to provide physical checks and the offer of screening, including any wound examinations from caesarean births/assisted births, the newborn blood spot test and checking the weight of the baby. In some areas, and where appropriate, some postnatal care will need to be via virtual appointments using telephone or video link due to local infection rates and staff absence but considerations need to be made upon individual circumstances. This needs to be communicated to women and families.

### Throughout:

**Comprehensive editorial review resulting in rewording and minor changes which do not affect meaning.** Any changes to meaning and recommendations are detailed elsewhere in this table of changes.

### 1.2-1.7 Summary of evidence:

Comprehensively updated and rewritten to incorporate changes to evidence base, in particular the MBRRACE Rapid Report and recent systematic reviews.

### 2.1 Antenatal care

**Recommendations added:**

- The NICE recommended schedule of antenatal care should be offered in full wherever possible. These appointments should be offered in-person as far as possible, with particular attention to those from BAME communities or those living with medical, social or psychological conditions that make them higher risk.
- Appropriate screening for diabetes in pregnancy should be provided, following NICE guidance as far as possible, with awareness that changes in screening provision may be associated with a reduction in the detection of milder cases of gestational diabetes.
- Open access for pregnant women to day assessment and triage services should be maintained. Women should be actively encouraged to attend if they have concerns about their or their baby’s wellbeing.
- Continuity of carer should be maintained wherever possible, particularly where this is offered to women from vulnerable groups who may also be at greater risk from COVID-19.

### 2.2 Title changed for ‘what are the considerations for antenatal appointments?’ to ‘what are the considerations for antenatal appointments and advice for pregnant women?’
### 2.2 Recommendations added

- Women should be advised that vaccination against influenza is safe at all gestations of pregnancy and is recommended to protect both the woman and baby from the adverse effects of becoming seriously ill with flu during pregnancy. During the COVID-19 pandemic, it is particularly important that pregnant women take up the influenza vaccine to reduce their risk of contracting flu.

- Appointments where physical examination is not required and where there are no additional risk factors are most appropriate to be conducted by virtual means.

- Services should establish triage processes to ensure that women with mental health concerns can be appropriately assessed.

### Recommendations removed

- Virtual consultations should be encouraged where appropriate to minimise contact in person, however traditional in-person appointments may be more effective, especially when interpreters are required.

Supporting statement updated with evidence from MBRRACE UK Rapid Report and survey studies regarding modifications to care during the pandemic.

### 3.1 Thromboembolism

Supporting statement updated with reference to MBRRACE rapid report.

### 4.1 Labour and birth

Recommendations updated to reflect national policy change to 10 days isolation following a positive test for COVID-19.
4.4 Birth partners. Recommendations revised to:

- On attendance at the maternity unit, all birth partners should be asked whether they have experienced any symptoms suggestive of COVID-19 in the preceding 14 days, e.g. fever, acute persistent cough, changes in or loss of sense of smell (anosmia) or taste.
  - If they have had symptoms within the last 10 days, they should be asked to leave the maternity unit immediately and self-isolate at home, unless they have had a negative test result for coronavirus since symptom onset.
  - If they have had a fever within the last 48 hours, they should be asked to leave the maternity unit immediately and self-isolate at home, regardless of their test result.
  - Guidance about testing of women and their birth partners is discussed in the RCOG document *Principles for the testing and triage of women seeking maternity care in hospital settings, during the COVID-19 pandemic*.

Asymptomatic birth partners, not otherwise advised to be self-isolating, should be permitted to stay with the woman throughout labour and birth, unless the birth occurs under general anaesthetic. Further guidance about access to maternity services for birth partners and other supportive adults has been published by the NHS, and should be followed as far as possible.

4.6 Water birth. Supporting statement updated to reflect evidence review by the UK Infection Prevention and Control Cell.

6.3 Postnatal care. Recommendation revised to clarify that postnatal women who have tested positive for COVID-19, while required to isolate along with their households for 14 days, should still receive necessary in-person postnatal care.

Throughout:

- Comprehensive editorial review resulting in rewording and minor changes.
- New evidence added to most sections to support or update existing conclusions or advice.
- New section added: Vaccination against COVID-19.
- Comprehensively updated including new evidence, key findings, new sections on the frequency of severe illness in pregnant women, data from the UK comparing pregnant and non-pregnant women, data from international studies comparing pregnant and non-pregnant women and insertion of tables in appendix summarising studies.
- Sections 2 and 6 updated: to signpost to guidance documents to assist maternity units with changes to antenatal and postnatal care.
- New appendices added and updated to reflect changes to document.
Appendix II: Development method of this guidance

The development methods have evolved over the lifetime of this guidance. This version of the guidance was developed by a multidisciplinary group of authors listed in acknowledgments. Specific sections of the guidance were contributed by subject experts also listed in Acknowledgments.

Weekly literature reviews are generated using the following search terms, MESH headings and associated synonyms: pregnancy, coronavirus, SARS, severe acute respiratory syndrome, infant, newborn and breastfeeding. The search results are published weekly on the RCOG website. Populations of interest include pregnant women, those recently given birth, partners, neonates. Studies of other populations are included where necessary, in order to understand population risk, asymptomatic carriage of coronavirus and antibody results where we believe these findings can be extrapolated to pregnant women. The retrieved evidence is reviewed by clinically trained members of the guidance team for inclusion. The criteria for including evidence has evolved as the evidence base has matured. For each section of the guidance, the best available evidence is included. The guidance also includes reference to ‘grey’ literature such as registry studies, reports from national organisations and non-peer reviewed content. Where there is a need to change practice and where published alternatives are not available, ‘preprints’ are discussed within the core guidance team and considered for inclusion.

For this guidance, good practice points are based on expert consensus of the multidisciplinary guidance group comprising healthcare providers across a variety of disciplines reviewing the available evidence and from their own expertise and experience within clinical practice. Appreciating the paucity of high-quality evidence in this area, this guidance is reviewed regularly to ensure the advice remains up-to-date and relevant.

While this document has not been subject to an open peer review or formal stakeholder consultation process, specific individuals and groups were asked to review its content prior to publication. These are listed in Acknowledgments and include a wide range of external stakeholders including lay representatives, other Royal Colleges and professional associations and representatives from the governments across England and the devolved nations. Feedback on this guidance sent to the dedicated COVID-19 inbox is also considered.

No external funding was received in order to develop this guidance.
**Appendix III: Summary of key studies on maternal and pregnancy outcomes**

**Key studies summary on the effect of COVID-19 on pregnancy and maternal outcomes**

Tables 1 and 2 give details of the key studies on which sections 1.5.2 and 1.5.3 are based. The largest study is the PregCOV-19 systematic review. Thirteen publications already included in that systematic review are not listed individually; only the PregCOV-19 systematic review and studies that were published since that review are shown in these tables. Forest plots from an unpublished meta-analysis of the publications listed in tables 1 and 2 are included below. Updated June 2021. Case series with less than 20 cases have been excluded.

Table 1: Summary of key studies relevant for the effect of COVID-19 on pregnancy outcomes

<table>
<thead>
<tr>
<th>Study</th>
<th>Country</th>
<th>Population</th>
<th>Effect of COVID-19 on pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allotey et al 2020</td>
<td>30 countries</td>
<td>COVID-19 Approx 1000 pregnant women with COVID-19 Control Approx 5000 pregnant women without COVID-19</td>
<td>COVID-19 12.4% Preterm (147/1184) Control 7.8% Preterm (572/7365) aOR 1.47 (1.14–1.91)</td>
</tr>
<tr>
<td>PregCOV-19 Systematic Review (updated 29/11/20)</td>
<td>30 countries</td>
<td>COVID-19 Approx 1000 pregnant women with COVID-19 Control Approx 5000 pregnant women without COVID-19</td>
<td>COVID-19 12.4% Preterm (147/1184) Control 7.8% Preterm (572/7365) aOR 1.47 (1.14–1.91)</td>
</tr>
<tr>
<td>Vousden et al 2021</td>
<td>UK</td>
<td>COVID-19 1148 pregnant women with COVID-19 hospitalised for any reason (722 symptomatic) Control Historical control of 694 pregnant women from 2018</td>
<td>Overall 15.6% preterm (156/1003) 1.1% stillbirth (11/1019) Symptomatic COVID 19% preterm birth (76% iatrogenic) (120/623) 49% caesarean section Asymptomatic COVID 9% preterm birth (36/380) 40% caesarean section</td>
</tr>
<tr>
<td>Study</td>
<td>Location</td>
<td>Case Population</td>
<td>Control Population</td>
</tr>
<tr>
<td>-------</td>
<td>----------</td>
<td>----------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>Study 1</td>
<td>USA</td>
<td>6380 pregnant women with COVID</td>
<td>400,066 pregnant women without COVID</td>
</tr>
<tr>
<td>Study 2</td>
<td>Barcelona, Spain</td>
<td>317 pregnant women with COVID-19 (detected by antibody or PCR)</td>
<td>1908 pregnant women without COVID-19</td>
</tr>
<tr>
<td>Study 3</td>
<td>NY, USA</td>
<td>105 women who were seropositive for SARS-CoV-2 but PCR negative at delivery</td>
<td>591 women who were seronegative for SARS-CoV-2 and PCR negative at delivery</td>
</tr>
<tr>
<td>Study</td>
<td>Country</td>
<td>Details</td>
<td>Controls</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-----------</td>
<td>-------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Metz et al 2021</td>
<td>USA</td>
<td>1219 pregnant women with COVID-19, split by severity:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 47% asymptomatic</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 27% mild</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 14% moderate</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 8% severe</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 4% critical</td>
<td></td>
</tr>
<tr>
<td>Savirón-Comudella et al 2021</td>
<td>Spain</td>
<td>65 pregnant with COVID (by Ab or PCR), all asymptomatic or mild infection</td>
<td>1146 pregnant women without COVID-19</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abedzadeh-Kalahroudi 2021</td>
<td>Iran</td>
<td>56 women with COVID-19</td>
<td>94 pregnant women with COVID-19</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trahan 2021</td>
<td>Canada</td>
<td>45 pregnant women with COVID-19</td>
<td>225 pregnant women without COVID-19</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zgutka 2021</td>
<td>NY, USA</td>
<td>62 pregnant women with COVID-19</td>
<td>124 pregnant women without COVID-19</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Country</td>
<td>COVID-19 Description</td>
<td>Control Description</td>
</tr>
<tr>
<td>------------------</td>
<td>---------------</td>
<td>--------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------</td>
</tr>
<tr>
<td>Katz 2021</td>
<td>USA</td>
<td>490 pregnant women with COVID-19 (176 (35.95) symptomatic)</td>
<td>Control 964 pregnant women without COVID-19</td>
</tr>
<tr>
<td>Martinez-Perez 2021</td>
<td>Spain</td>
<td>246 pregnant women with COVID-19</td>
<td>Control 763 pregnant women without COVID-19</td>
</tr>
<tr>
<td>Hcini 2021</td>
<td>French Guiana</td>
<td>137 pregnant women with COVID-19</td>
<td>Control 370 pregnant women without COVID-19</td>
</tr>
<tr>
<td>Villar 2021</td>
<td>18 countries</td>
<td>706 pregnant women with COVID-19</td>
<td>Control 1424 pregnant women without COVID-19</td>
</tr>
<tr>
<td>Adhikari 2020</td>
<td>USA</td>
<td>252 pregnant women with COVID-19</td>
<td>Control 3122 pregnant women without COVID-19</td>
</tr>
</tbody>
</table>

Note: RR = Relative Risk
<table>
<thead>
<tr>
<th>Study</th>
<th>Country</th>
<th>Population</th>
<th>Effect of COVID-19 on pregnant women</th>
</tr>
</thead>
<tbody>
<tr>
<td>Soto-Torres 2021[178]</td>
<td></td>
<td>COVID-19</td>
<td>Control</td>
</tr>
<tr>
<td></td>
<td></td>
<td>106 pregnant women with COVID-19</td>
<td>103 pregnant women without COVID-19</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>COVID-19</td>
</tr>
<tr>
<td></td>
<td></td>
<td>20.8% preterm (35/40) (22/106)</td>
<td>Control</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8.8% preterm (35/40) (9/103)</td>
<td>OR</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2.37 (1.14–4.91)</td>
<td></td>
</tr>
<tr>
<td>Gurol-Urganci 2021[170]</td>
<td>UK</td>
<td>COVID-19</td>
<td>Control</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3527 pregnant women with COVID-19</td>
<td>338 553 pregnant women without COVID-19</td>
</tr>
<tr>
<td></td>
<td></td>
<td>12.1% preterm</td>
<td>COVID-19</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.85% stillbirth</td>
<td>Control</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5.8% preterm</td>
<td>OR</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2.17 (1.96–2.42)</td>
<td></td>
</tr>
<tr>
<td>Zambrano et al. 2020[58]</td>
<td>USA</td>
<td>Pregnant</td>
<td>Not pregnant</td>
</tr>
<tr>
<td>CDC Report</td>
<td></td>
<td>23 434 pregnant women with symptomatic COVID-19</td>
<td>386 028 non-pregnant women aged 15-44 with symptomatic COVID-19</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Pregnant</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 1.05% ICU</td>
<td>Not pregnant</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 0.29% invasive ventilation</td>
<td>• 1.05% ICU</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 0.07% ECMO</td>
<td>• 0.11% invasive ventilation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 0.15% death</td>
<td>• 0.07% ECMO</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• 0.15% death</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Adjusted OR</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 1.84 (1.30–2.61)</td>
<td>• 0.39% ICU</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• 1.5% death</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• 1.5% death</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• 0.8% death</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>OR (95% CI)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>OR (95% CI)</td>
</tr>
</tbody>
</table>

Table 2: Summary of key studies relevant for the effect of COVID-19 on maternal outcomes

<table>
<thead>
<tr>
<th>Study</th>
<th>Country</th>
<th>Population</th>
<th>Effect of COVID-19 on pregnant women</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allotey et al. 2020[49]</td>
<td>30 countries</td>
<td>Pregnant</td>
<td>Not pregnant</td>
</tr>
<tr>
<td>PregCOV-19 Systematic Review</td>
<td></td>
<td>34 047 pregnant women with COVID-19</td>
<td>567 075 non-pregnant women with COVID-19</td>
</tr>
<tr>
<td>(updated 29/11/20)</td>
<td></td>
<td></td>
<td>Pregnant</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 1.8% ICU (616)</td>
<td>Not pregnant</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 0.6% ventilation (270)</td>
<td>• 1.7% ICU (9568)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• 0.6% ventilation (3280)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• 2.13 (1.54–2.95)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• 2.59 (2.28–2.94)</td>
</tr>
<tr>
<td>Martinez-Portilla et al 2020</td>
<td>Mexico</td>
<td>Pregnant</td>
<td>Not pregnant</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5183 pregnant women with symptomatic COVID-19</td>
<td>5183 matched non-pregnant women aged 15-49 with symptomatic COVID-19</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Pregnant</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 1.5% death</td>
<td>Not pregnant</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 13% ICU</td>
<td>• 0.8% death</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 8.1% intubated</td>
<td>• 7.4% ICU</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• 8.6% intubated</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• OR 1.84 (1.30–2.61)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• 2.25 (1.86–2.71)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• 0.93 (0.70–1.25)</td>
</tr>
<tr>
<td>Study</td>
<td>Country</td>
<td>Pregnancy Status</td>
<td>ComparISON Gender</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>---------------</td>
<td>------------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>DeBolt et al 2020[51]</td>
<td>USA</td>
<td>Pregnant</td>
<td>Not pregnant</td>
</tr>
<tr>
<td>Badr et al 2020[50]</td>
<td>France</td>
<td>Pregnant</td>
<td>Not pregnant</td>
</tr>
<tr>
<td>Oakes et al 2021[57]</td>
<td>USA</td>
<td>Pregnant:</td>
<td>Not pregnant:</td>
</tr>
<tr>
<td>Lokken et al 2021[54]</td>
<td>USA</td>
<td>Pregnant</td>
<td>Not pregnant</td>
</tr>
<tr>
<td>Artymuk et al 2021[81]</td>
<td>Siberia, Russia</td>
<td>Pregnant</td>
<td>Not pregnant</td>
</tr>
<tr>
<td>Behrens 2021[82]</td>
<td>USA</td>
<td>Pregnant</td>
<td>Not pregnant</td>
</tr>
<tr>
<td>Country</td>
<td>Dataset</td>
<td>Study Design</td>
<td>Pregnant Women</td>
</tr>
<tr>
<td>-----------</td>
<td>-----------</td>
<td>------------------------------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Iran</td>
<td>Vizheh 2021(^{184})</td>
<td>110 pregnant women with COVID</td>
<td>110</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>9.1% ICU (10)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Not pregnant men</td>
<td>8.1% ICU (18)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P value</td>
<td></td>
</tr>
<tr>
<td>Iran</td>
<td>Qeaden 2021(^{183})</td>
<td>1609 pregnant women with COVID-19</td>
<td>1609</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1.6% ventilation (26)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P value</td>
<td>P = 0.48</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Not pregnant men</td>
<td>1.9% ventilation (39)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P value</td>
<td>P = 0.26</td>
</tr>
</tbody>
</table>
Meta-analysis of the effect of COVID-19 on pregnancy outcomes

Meta-analysis of the effects of COVID-19 on pregnancy outcomes (preterm birth, stillbirth) was performed using data from the studies in Table 1 (above) published since the last update of the PregCOV-19 systematic review, using the online Cochrane Revman software (Shea et al, unpublished). The results of this meta-analysis are compared with the results of the latest online update of the PregCOV-19 systematic review from 29 November 2020.

---

**Preterm birth – studies since PregCOV-19**

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Pregnant with COVID-19</th>
<th>Pregnant without COVID-19</th>
<th>Odds ratio M-H, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events</td>
<td>Total</td>
<td>Events</td>
</tr>
<tr>
<td>Abedzadeh-Kalashroudi 2021</td>
<td>19</td>
<td>56</td>
<td>12</td>
</tr>
<tr>
<td>Achikari 2020</td>
<td>27</td>
<td>252</td>
<td>328</td>
</tr>
<tr>
<td>Crovetto 2021</td>
<td>20</td>
<td>176</td>
<td>81</td>
</tr>
<tr>
<td>Jering 2021</td>
<td>322</td>
<td>6380</td>
<td>16137</td>
</tr>
<tr>
<td>Kitz 2021</td>
<td>73</td>
<td>490</td>
<td>98</td>
</tr>
<tr>
<td>Martinez-Perez 2021</td>
<td>34</td>
<td>246</td>
<td>51</td>
</tr>
<tr>
<td>Melnaasar 2021</td>
<td>8</td>
<td>105</td>
<td>37</td>
</tr>
<tr>
<td>Soto-Torres 2021</td>
<td>22</td>
<td>106</td>
<td>9</td>
</tr>
<tr>
<td>Trehon 2021</td>
<td>7</td>
<td>45</td>
<td>21</td>
</tr>
<tr>
<td>UKOSS 2021</td>
<td>156</td>
<td>1093</td>
<td>63</td>
</tr>
<tr>
<td>Villar 2021</td>
<td>159</td>
<td>706</td>
<td>194</td>
</tr>
<tr>
<td>Zupitza 2021</td>
<td>11</td>
<td>62</td>
<td>10</td>
</tr>
</tbody>
</table>

Total (95% CI): 9627 / 409306 | 100.0% | 1.46 [1.35, 1.59] |

Heterogeneity: Chi² = 27.17, df = 11 (P = 0.004); I² = 60%
Test for overall effect: Z = 8.93 (P < 0.00001)
Test for subgroup differences: Not applicable

---

**Stillbirth – studies since PregCOV-19**

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>With COVID-19</th>
<th>Without COVID-19</th>
<th>Odds ratio M-H, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events</td>
<td>Total</td>
<td>Events</td>
</tr>
<tr>
<td>Abedzadeh-Kalashroudi 2021</td>
<td>2</td>
<td>56</td>
<td>0</td>
</tr>
<tr>
<td>Achikari 2020</td>
<td>0</td>
<td>252</td>
<td>18</td>
</tr>
<tr>
<td>Crovetto 2021</td>
<td>1</td>
<td>178</td>
<td>6</td>
</tr>
<tr>
<td>Hcini 2021</td>
<td>7</td>
<td>137</td>
<td>4</td>
</tr>
<tr>
<td>Jering 2021</td>
<td>34</td>
<td>6380</td>
<td>1289</td>
</tr>
<tr>
<td>Martinez-Perez 2021</td>
<td>3</td>
<td>246</td>
<td>1</td>
</tr>
<tr>
<td>Savignon-Cornudella 2021</td>
<td>0</td>
<td>65</td>
<td>2</td>
</tr>
<tr>
<td>UKOSS 2021</td>
<td>11</td>
<td>1019</td>
<td>2</td>
</tr>
</tbody>
</table>

Total (95% CI): 8333 / 407426 | 100.0% | 1.94 [1.44, 2.60] |

Heterogeneity: Chi² = 8.48, df = 7 (P = 0.29); I² = 17%
Test for overall effect: Z = 4.41 (P < 0.0001)
Test for subgroup differences: Not applicable
Meta-analysis of the maternal effects of COVID-19 (ICU admission, mechanical ventilation, and death) was performed using data from the studies in Table 2 (above) published since the last update of the PregCOV-19 systematic review, using the online Cochrane Revman software (Shea et al, unpublished). The results of this meta-analysis are compared with the results of the latest online update of the PregCOV-19 systematic review from 29 November 2020.\(^\text{149}\)

### ICU admission – studies since PregCoV19

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Pregnant Events</th>
<th>Total</th>
<th>Not Pregnant Events</th>
<th>Total</th>
<th>Weight</th>
<th>Odds ratio M-H, Fixed, 95% CI</th>
<th>Odds ratio M-H, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Artymuk 2021</td>
<td>303</td>
<td>8485</td>
<td>1811</td>
<td>80848</td>
<td>38.8%</td>
<td>1.62 [1.43, 1.83]</td>
<td></td>
</tr>
<tr>
<td>Badr 2020</td>
<td>9</td>
<td>83</td>
<td>3</td>
<td>107</td>
<td>0.3%</td>
<td>4.22 [1.10, 16.11]</td>
<td></td>
</tr>
<tr>
<td>DeBolt 2020</td>
<td>15</td>
<td>38</td>
<td>16</td>
<td>94</td>
<td>0.7%</td>
<td>3.10 [1.37, 7.39]</td>
<td></td>
</tr>
<tr>
<td>Martinez-Portilla 2020</td>
<td>674</td>
<td>5183</td>
<td>384</td>
<td>5183</td>
<td>39.1%</td>
<td>1.87 [1.64, 2.13]</td>
<td></td>
</tr>
<tr>
<td>Vizheh 2021</td>
<td>10</td>
<td>110</td>
<td>18</td>
<td>234</td>
<td>1.2%</td>
<td>1.20 [0.53, 2.69]</td>
<td></td>
</tr>
<tr>
<td>Zambrano 2020</td>
<td>246</td>
<td>23434</td>
<td>1506</td>
<td>385958</td>
<td>20.0%</td>
<td>2.71 [2.37, 3.10]</td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>37333</strong></td>
<td><strong>472464</strong></td>
<td><strong>100.0%</strong></td>
<td><strong>1.94 [1.80, 2.10]</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total events:</td>
<td>1257</td>
<td>3738</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Chi\(^2\) = 35.86, df = 5 (P < 0.00001); \(I^2 = 86%\)
Test for overall effect: Z = 17.30 (P < 0.00001)
Test for subgroup differences: Not applicable
Mechanical ventilation – studies since PregCov19

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Pregnant Events</th>
<th>Total</th>
<th>Not Pregnant Events</th>
<th>Total</th>
<th>Weight</th>
<th>Odds ratio M-H, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Artymuk 2021</td>
<td>41</td>
<td>8485</td>
<td>845</td>
<td>80476</td>
<td>23.6%</td>
<td>0.48 [0.33, 0.63]</td>
</tr>
<tr>
<td>Badr 2020</td>
<td>10</td>
<td>38</td>
<td>10</td>
<td>94</td>
<td>0.6%</td>
<td>3.00 [1.13, 7.96]</td>
</tr>
<tr>
<td>DeBolt 2020</td>
<td>26</td>
<td>1609</td>
<td>396</td>
<td>20884</td>
<td>8.2%</td>
<td>0.65 [0.57, 1.27]</td>
</tr>
<tr>
<td>Martinez-Portila 2020</td>
<td>420</td>
<td>5183</td>
<td>446</td>
<td>5183</td>
<td>60.2%</td>
<td>0.94 [0.81, 1.08]</td>
</tr>
<tr>
<td>Qaeed 2021</td>
<td>65</td>
<td>23434</td>
<td>425</td>
<td>386028</td>
<td>7.1%</td>
<td>2.52 [1.94, 3.28]</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>38832</td>
<td>492772</td>
<td>100.0%</td>
<td></td>
<td>0.95 [0.86, 1.06]</td>
<td></td>
</tr>
<tr>
<td>Total events</td>
<td>570</td>
<td>2124</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Chi² = 84.78, df = 5 (P < 0.00001); I² = 94%
Test for overall effect: Z = 0.67 (P = 0.99)
Test for subgroup differences: Not applicable

Death – studies since PregCOV-19

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Pregnant Events</th>
<th>Total</th>
<th>Not Pregnant Events</th>
<th>Total</th>
<th>Weight</th>
<th>Odds ratio M-H, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Behrens 2021</td>
<td>0</td>
<td>43</td>
<td>39</td>
<td>1265</td>
<td>2.6%</td>
<td>0.36 [0.20, 0.60]</td>
</tr>
<tr>
<td>Lokken 2021</td>
<td>3</td>
<td>240</td>
<td>32</td>
<td>34902</td>
<td>0.4%</td>
<td>13.79 [4.19, 45.35]</td>
</tr>
<tr>
<td>Martinez-Portila 2020</td>
<td>78</td>
<td>5183</td>
<td>41</td>
<td>5183</td>
<td>39.7%</td>
<td>1.92 [1.31, 2.80]</td>
</tr>
<tr>
<td>Qadeen 2021</td>
<td>4</td>
<td>1609</td>
<td>100</td>
<td>20884</td>
<td>14.0%</td>
<td>0.52 [0.19, 1.41]</td>
</tr>
<tr>
<td>Vlameh 2021</td>
<td>6</td>
<td>110</td>
<td>12</td>
<td>234</td>
<td>7.1%</td>
<td>1.07 [0.39, 2.92]</td>
</tr>
<tr>
<td>Zambrano 2020</td>
<td>35</td>
<td>23434</td>
<td>463</td>
<td>567075</td>
<td>36.1%</td>
<td>1.83 [1.20, 2.80]</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>30619</td>
<td>620543</td>
<td>100.0%</td>
<td></td>
<td>1.64 [1.30, 2.07]</td>
<td></td>
</tr>
<tr>
<td>Total events</td>
<td>126</td>
<td>667</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Chi² = 20.27, df = 5 (P = 0.001); I² = 75%
Test for overall effect: Z = 4.18 (P < 0.00001)
Test for subgroup differences: Not applicable

Maternal Risks: pregnant vs non-pregnant women with COVID-19

<table>
<thead>
<tr>
<th></th>
<th>ICU admission</th>
<th>Mechanical ventilation</th>
<th>Death</th>
</tr>
</thead>
<tbody>
<tr>
<td>PregCOVID-19</td>
<td>OR = 2.13</td>
<td>OR = 2.59</td>
<td>OR = 0.96</td>
</tr>
<tr>
<td>Studies since</td>
<td>OR = 1.94</td>
<td>OR = 0.95</td>
<td>OR = 1.64</td>
</tr>
</tbody>
</table>

OR = 2.13 [1.54 to 2.95]  OR = 2.59 [1.28 to 2.94]  OR = 0.96 [0.79 to 1.18]  OR = 1.64 [1.30 to 2.01]
Appendix IV: Example of a telephone triage tool for symptomatic women with suspected or confirmed COVID-19
(adapted from Guy’s and St Thomas’ NHS Foundation Trust)

Assess severity of illness:
• Shortness of breath/difficulty breathing
• Difficulty completing short sentences without needing to stop/gasp for air
• Coughing blood
• Pain or pressure in chest (other than with coughing)
• Unable to keep liquids down
• Less responsive than normal or becoming confused while talking

None of these symptoms

Assess clinical and social risks:
• Age >35 years old, BMI >30 kg/m²
• Women of the Black, Asian or other minority ethnic community
• Consider VTE risk assessment and score
• Medical co-morbidities: diabetes, hypertension, asthma/respiratory disease, HIV, heart disease, immunosuppression, chronic kidney disease
• Obstetric factors: at risk of fetal growth restriction, suspected preterm labour, reduced fetal movements
• Social factors: language barriers, safeguarding concerns, mental health issues, poor social support, domestic violence

No risk factors

Advise to self-isolate and arrange a COVID-19 test (if not yet done) in line with national guidance:
• Inform named consultant and midwifery team
• Safety net to call back if symptoms worsen
## Appendix V: Example of a maternity escalation plan for women with suspected or confirmed COVID-19
(adapted from Guy’s and St Thomas’ NHS Foundation Trust)

<table>
<thead>
<tr>
<th>Category</th>
<th>Clinical criteria for oxygenation</th>
<th>Suggested actions</th>
<th>Other considerations for viable fetus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Green</td>
<td>SpO$_2$ 94%–98% Room air and RR ≤ 20</td>
<td>Ensure no obstetric or medical concerns</td>
<td>Assess fetal wellbeing</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Discharge for self-isolation in line with national guidance</td>
<td>Consider fetal monitoring</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Discuss timing of birth</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Depending on the gestational age:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Consider steroids for fetal lungs</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Consider magnesium sulfate for neuroprotection if considering birth of the baby</td>
</tr>
<tr>
<td>Yellow</td>
<td>Target SpO$_2$ 94%–98% on ≥ FiO$_2$ 28% and/or RR ≥ 21</td>
<td>Increase oxygen flow rate to maintain SaO$_2$ 94%–98%</td>
<td>Assess fetal wellbeing</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Assessment by obstetric registrar</td>
<td>Consider fetal monitoring</td>
</tr>
<tr>
<td></td>
<td></td>
<td>In-patient care</td>
<td>Discuss timing of birth</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Inform maternity escalation team:</td>
<td>Depending on the gestational age:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Obstetric consultant</td>
<td>• Consider steroids for fetal lungs</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Obstetric anaesthetist</td>
<td>• Consider magnesium sulfate for neuroprotection if considering birth of the baby</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• On-call medical team</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Give oral prednisolone 40 mg for treatment of COVID-19</td>
<td></td>
</tr>
<tr>
<td>Amber</td>
<td>Target SpO$_2$ 94%–98% on ≥ FiO$_2$ 35% and/or RR ≥ 25</td>
<td>Increase oxygen flow rate to maintain SaO$_2$ 94%–98%</td>
<td>Discuss the risks and benefits of emergency caesarean birth</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Consider 15l/min O$_2$ via non-rebreath mask</td>
<td>Depending on the gestational age:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Refer to ITU team</td>
<td>• Consider steroids for fetal lungs</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Urgent review by the maternity escalation team</td>
<td>• Consider magnesium sulfate for neuroprotection if considering birth</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Consider awake proning position when feasible/high flow oxygen in critical care setting only</td>
<td></td>
</tr>
<tr>
<td>Red</td>
<td>SpO$_2$ &lt; 94% on 15l/min O$_2$ via non-rebreath mask</td>
<td>Urgent review by ITU team</td>
<td>Discuss the risks and benefits of emergency caesarean birth</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Urgent attendance by the maternity escalation team</td>
<td>Depending on the gestational age:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Consider awake proning position when feasible/high flow oxygen in critical care setting only</td>
<td>• Consider steroids for fetal lungs</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Consider magnesium sulfate for neuroprotection if considering birth</td>
</tr>
<tr>
<td>Peri-arrest</td>
<td>Call 2222 – adult cardiac arrest team, obstetric crash team and neonatal crash team</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Peri-arrest
Appendix VI: Maternal structured checklist – for pregnant and/or postpartum women with confirmed or suspected COVID-19

(developed by North Bristol NHS Trust)

Maternal Structured Checklist – for pregnant and/or postpartum women with confirmed or suspected COVID-19

This is designed to be used during the multi-professional review of a pregnant or postpartum woman with confirmed or suspected symptoms of COVID-19. It does not replace, nor should repeat the observations and information recorded on the Maternal Critical Care chart or eObs.

Relevant notes can be made as each item is considered either directly into the woman’s notes or by annotating the work sheet which should be dated, signed and filed in the woman’s maternity notes at the end of the review.

VACCINATION STATUS:

Clinical Summary:  

Bloods to be taken on Day 1:
- SARS Spike antibody
- FBC/Renal 3/ LFTs
- Procalcitonin
- D-dimer
- LDH
- CK Troponin
- BNP
- Ferritin
- AST

<table>
<thead>
<tr>
<th>Items to be considered</th>
<th>Notes:</th>
</tr>
</thead>
</table>
| **A**  
  Airway:  
  o Respiratory deterioration requiring high flow nasal O₂, CPAP, or invasive ventilation, requires transfer to ITU  
  o Early ITU involvement – contact: xxxx  
  o Anaesthetic team to accompany for transfer  
  N.B. In peri-arrest situation staff in room to doom full AGP PPE in case of deterioration and CPR requirement |
### Breathing:
- Respiratory rate & trend (*concerning if > 30*)
- $\text{SpO}_2$ (*titrate } O_2 \text{ to maintain 94 to 96%*) – prescribe on drug chart
- Are there increasing $O_2$ requirements?
- $\text{FiO}_2$ (*concerning if >40%, or over 4 litres per min*)
- Cough, sputum
- Chest examination findings
- CXR e.g., atypical viral pneumonitis, ARDS
  - If abnormal CXR for follow-up repeat CXR in six weeks
- Consider PE if chest pain and worsening hypoxia or if deteriorates after expected recovery from COVID-19
- If requires **Oxygen, give oral prednisolone 40mg once a day or intravenous hydrocortisone 80 mg twice a day** (for 10 days or discharge home), or dexamethasone as in ‘N’ below.
- **Which medics should see COVID – 19 patients in obstetrics?**
  - Stable: Medical on call (Contact details: xxxx)
  - Acutely unwell women: ICU Consultant (Contact details: xxxx)

### Circulation & Cardio-vascular:
- Heart rate, BP, capillary refill time, vasopressors
- Presence of palpitations & chest tightness
- Consider ECG & echocardiogram
- Measure Troponin and BNP – if raised is a marker of severe disease

**N.B. In cardiac arrest chest compressions & airway management will generate aerosols, therefore full AGP PPE required before commencing CPR**

### Disability:
- Level of consciousness: AVPU (*concerning if drowsy*)
- Pain
- Epidural or spinal block

### Electrolytes:
- **Renal function** - Acute Kidney Injury (has been reported in 25% of COVID-19 cases)
- **Liver function may be deranged**
- High neutrophil-lymphocyte ratio (>3.0), low albumin, elevated Troponin, elevated D-dimers, and elevated Ferritin – are markers of severe illness

### Fluid balance:
- Input (*consider targeted fluid therapy and neutral fluid balance as under and over resuscitation may be problematic*)
- Urine output (*concerning if reduction in output*)
- Blood loss, drains
### GI & glucose control:
- Gastro-protection measures (commence Omeprazole 40mg bd until eating for 48 hours)
- Bowel function (up to 40% of cases suffer bowel symptoms N.B. stools can be potential source of infection)
- Glucose level

### Hematology & VTE prophylaxis:
**Laboratory findings:**
- FBC (lymphopenia is common and a high (>3.0) neutrophil-lymphocyte ratio concerning)
- Thrombocytopenia may occur (stop LMWH if platelets under 50)
- Lactate
- Clotting profile (pro-thrombotic state is common)

**VTE prophylaxis** for all suspected or confirmed cases of COVID-19
- non-pharmacological treatments (TEDS and Flowtrons)
- LMWH unless delivery planned/likely in next 12 hours
  - No oxygen requirement = normal prophylaxis
  - O₂ dependent = high dose LMWH prophylaxis (eg 40mg bd) – but balance with bleeding / delivery risk
- A minimum of 10 days LMWH normal dose prophylaxis on discharge
- Treatment dose if suspected or confirmed VTE (if antenatal give 1mg /kg BD)

### Infection:
- Raised temperature (*not always due to COVID-19, so check for other causes*)
- Sepsis Six screening
- CRP – if >75 and O₂ requirement consider **Tociluzimab**
- Inflammatory markers, cultures
- Give antibiotics for normal indications (e.g., GBS, prematurity, PROM)
- Consider antibiotics if bacterial superinfection suspected

Review all outstanding investigations

### Lines:
Cannula, arterial line, urinary catheter, wound drains

### Maternal Co-Morbidities:
- e.g., Diabetes, hypertension, asthma, epilepsy – continue treatment & monitor
### Neonatal Considerations:

#### Antenatal
- If steroids are indicated for fetal lung maturity, intramuscular **dexamethasone 6 mg every 12 hours for four doses**. If steroids are also required for Covid (oral prednisolone 40 mg once a day, or IV hydrocortisone 80 mg twice daily omit these for the 48 hours that fetal steroids are given.
- Administer MgSO₄, if appropriate for neonatal neuroprotection.
- Intrapartum – Neonatologist present in full PPE for AGP for neonatal resuscitation.

#### Postnatal
- Baby remaining with mother? Update on condition if on NICU. Discussion around parental visiting on NICU based on timing and availability of baby swab results.
- BCG immunisation should be offered at the usual time.

### Obstetric:

#### Antenatal
- BD CTGs whilst unwell.
- MDT decision regarding mode and timing of birth consider: maternal condition, fetal condition & gestation, and potential for maternal improvement after elective birth.
- Stabilise mother prior to birth.
- Serial Growth Scans starting two weeks post Covid.

#### Intrapartum
- Electronic fetal monitoring advised – with acute Covid or Covid during pregnancy (write on Pink notes).
- Full AGP PPE when birth imminent in case neonatal resuscitation is required.

#### Postpartum
- At least 10 days LMWH prophylaxis on discharge.
Pharmacology:
Review medications
- If requires Oxygen give oral Prednisolone 40mg once a day or intravenous hydrocortisone 80 mg twice a day (for 10 days or discharge home).
- If patient is already on oral prednisolone and need dexamethasone for fetal lungs, stop oral Prednisolone while giving IM dexamethasone. Restart oral Prednisolone after 4 doses of IM Dexamethasone given.
- Tociluzimab if CRP>75 and O₂ requirement – discuss with infectious disease/acute medicine/respiratory consultant to consider tocilizumab.
- RONAPREVE (REGEN-COV monoclonal antibodies) in those with no SARS_Cov2 antibodies (See flowchart)
  - COVID-19 POSITIVE WITH SYMPTOMS
    - Send blood for Spike antibody
    - Spike antibody positive – not for Ronapreve
- Spike antibody NEGATIVE – MDT discussion re treatment with Ronapreve 2.4g
  - COVID-19 positive on screening and no symptoms
    - Send blood for Spike antibody but can be treated with Ronapreve 1.2g regardless of antibody status if at high risk of progression to severe covid” or “covid presents material risk of destabilising an existing condition or compromising recovery from hospital procedure as determined by MDT”.

Summary and Plan

Multi-professional Review completed by:
Anaesthetist........................................... Midwife........................................... Obstetrician...........................................
Signature........................................... Print........................................... Date...........................................
References
References

2. World Health Organization. Coronavirus disease (COVID-19) situation reports. 2020; Website
3. Centers for Disease Control and Prevention. Human Coronavirus Types. 2020; Website


24. Knight M, Bunch K, Tufnell D. Saving Lives, Improving Mothers’ Care - Lessons learned to inform maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2016-18. 2020; [Website](#)


28. NHS. Vitamin D. 2017; [Website]

29. NHS. Vitamins, supplements and nutrition in pregnancy. 2020; [Website]


32. Rimmer MP, Al Wattar BH. Provision of obstetrics and gynaecology services during the COVID-19 pandemic: a survey of junior doctors in the UK National Health Service. BJOG 2020;127(9):1123-1128


37. Joint Committee on Vaccination and Immunisation. Advice on priority groups for COVID-19 vaccination. 2020; [Website]


43. NHS England and NHS Improvement: Clinical guide for the management of remote consultations and remote working in secondary care during the coronavirus pandemic. 2020; Website


46. National Institute for Health and Care Excellence. Diabetes in pregnancy: management from preconception to the postnatal period. NICE guideline 3 [NG3]. 2015; Website

47. van-de-l’Isle Y, Steer PJ, Watt Coote I, Cauldwell M. Impact of changes to national UK Guidance on testing for gestational diabetes screening during a pandemic: a single-centre observational study. BJOG 2021;128(5):917-920


50. Chodosh J, Weinstein BE, Blustein J. Face masks can be devastating for people with hearing loss. BMJ 2020;370:m2683


59. Banks J, Xu X. The mental health effects of the first two months of lockdown and social distancing during the Covid-19 pandemic in the UK. Website


65. Royal College of Midwives. Domestic Abuse. 2020; Website


69. Royal College of Midwives. Personal Protective Equipment: Know your Rights. 2020; Website


85. NHS. Clinical guide for the temporary reorganisation of intrapartum maternity care during the coronavirus pandemic. 2020; Website


87. World Health Organization. COVID-19 Clinical management: living guidance. 2021; Website


115. World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. 2020; Website


120. National Institute for Health and Care Excellence. COVID-19 rapid guideline: acute myocardial injury. NICE guideline 171 [NG171]. 2020; Website


122. Royal College of Anaesthetists. Care of the critically ill woman in childbirth; enhanced maternal care. 2018; Website


124. Intensive Care Society. Prone Positioning in Adult Critical Care. 2020; Website


142. Royal College of Midwives. Optimising mother-baby contact and infant feeding in a pandemic. Rapid review Version 2. 2020; Website

144. UNICEF Baby Friendly Initiative. Statements on supporting infant feeding during the coronavirus (Covid-19) outbreak. 2021; Website


147. UK Government Department of Health and Social Care: Public advised to cover faces in enclosed spaces. 2020; Website


162. RECOVERY Collaborative Group, Horby PW, Mafham M, Peto L. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv 2021; Journal


198. Centers for Disease Control and Prevention. V-safe COVID-19 Vaccine Pregnancy Registry. 2021; *Website*


211. NHS England and NHS Improvement. Shared Decision Making Summary Guide. February 2019; [Website]

212. National Institute for Health and Care Excellence. Shared decision making. NICE guideline 197 [NG197]. 2021; [Website]

213. ClinicalTrials.gov. Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS CoV-2 RNA Vaccine Candidate (BNT162b2) Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older: 2021; [Website]


215. St George’s Vaccine Institute: Preg-Cov-trial. 2021; [Website]


Fox A, Marino J, Amanat F, Oguntuyo K, Hahn-Holbrook J, Lee B, et al. The Spike-specific IgA in milk commonly-elicited after SARS-CoV-2 infection is concurrent with a robust secretory antibody response, exhibits neutralization potency strongly correlated with IgA binding, and is highly durable over time. medRxiv 2021; Journal

Knight M, Ramakrishnan R, Bunch K, ISARIC4C Consortium, UK Obstetric Surveillance System (UKOSS) and COVID-19 Clinical Information Network (CO-CIN). Females in hospital with SARS-CoV-2 infection, the association with pregnancy and pregnancy outcomes: A UKOSS/ISARIC/CO-CIN investigation. 2021; Website

Royal College of Midwives. RCM Clinical Briefing Sheet – Waterbirth during the COVID-19 pandemic. June 2021; Website

Vousden N, Ramakrishnan R, Bunch K : Impact of SARS-CoV-2 variant on the severity of maternal infection and perinatal outcomes: Data from the UK Obstetric Surveillance System national cohort. medRxiv 2021 Journal

UK Health Security Agency. COVID-19 vaccine surveillance report week 46. November 2021; Website

Public Health Scotland. Covid-19 statistical report (Scotland). 2021; Website

NHS. Suspected coronavirus (COVID-19): Important information to keep you safe while isolating at home. 2021; Website

NHS. How to look after yourself at home if you have coronavirus (COVID-19). 2021; Website

NHS. Pregnancy and coronavirus (COVID-19). 2021; Website


NHS Scotland, Scottish Perinatal Network. NHS Near Me. Website


DISCLAIMER: The Royal College of Obstetricians and Gynaecologists (RCOG) has produced this guidance as an aid to good clinical practice and clinical decision-making. This guidance is based on the best evidence available at the time of writing, and the guidance will be kept under regular review as new evidence emerges. This guidance is not intended to replace clinical diagnostics, procedures or treatment plans made by a clinician or other healthcare professional and RCOG accepts no liability for the use of its guidance in a clinical setting. Please be aware that the evidence base for COVID-19 and its impact on pregnancy and related healthcare services is developing rapidly and the latest data or best practice may not yet be incorporated into the current version of this document. RCOG recommends that any departures from local clinical protocols or guidelines should be fully documented in the patient’s case notes at the time the relevant decision is taken.